Joseph Ross, MD, MHS

• A. David Paltiel
• Albert Ko
• Carol Oladele
• Cary Gross
• Emily Wang
• Erica Spatz
• Gail D'Onofrio
• Gregg Gonsalves
• Harlan Krumholz
• Howard Forman
• Jason L. Schwartz
• Judith Lichtman
• Karen Wang
• Marcella Nunez-Smith
• Mayur M. Desai
• Michael B. Bracken
• Michaela Dinan
• Rohan Khera
• Rong Wang
• Xiaomei Ma

Delivery of Health Care; Health Services Research; Pharmaceutical Services; Quality of Health Care

Health Care Management; Health Policy; Pharmaceuticals and Medical Devices; Health Systems Reform

• Learning From the Success of the ACTIV PlatformRoss J, Malani P. Learning From the Success of the ACTIV Platform. JAMA 2023, 330: 2363-2364. PMID: 37976051, DOI: 10.1001/jama.2023.24087.
• Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices ProgramMoneer O, Rathi V, Johnston J, Ross J, Dhruva S. Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program. JAMA Cardiology 2023, 8: 1174-1181. PMID: 37878306, DOI: 10.1001/jamacardio.2023.3819.
• Studies Of Prescription Digital Therapeutics Often Lack Rigor And InclusivityKumar A, Ross J, Patel N, Rathi V, Redberg R, Dhruva S. Studies Of Prescription Digital Therapeutics Often Lack Rigor And Inclusivity. Health Affairs 2023, 42: 1559-1567. PMID: 37931187, DOI: 10.1377/hlthaff.2023.00384.
• Feasibility of Emulating Clinical Trials Supporting US FDA Supplemental Indication Approvals of Drugs and BiologicsJanda G, Wallach J, Dhodapkar M, Ramachandran R, Ross J. Feasibility of Emulating Clinical Trials Supporting US FDA Supplemental Indication Approvals of Drugs and Biologics. JAMA Internal Medicine 2023, 183: 1271-1273. PMID: 37782514, PMCID: PMC10546285, DOI: 10.1001/jamainternmed.2023.4073.
• A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsCiani O, Manyara A, Davies P, Stewart D, Weir C, Young A, Blazeby J, Butcher N, Bujkiewicz S, Chan A, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno V, Devane D, Faria C, Gilbert P, Harris R, Lassere M, Marinelli L, Markham S, Powers J, Rezaei Y, Richert L, Schwendicke F, Tereshchenko L, Thoma A, Turan A, Worrall A, Christensen R, Collins G, Ross J, Taylor R. A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials. EClinicalMedicine 2023, 65: 102283. PMID: 37877001, PMCID: PMC10590868, DOI: 10.1016/j.eclinm.2023.102283.
• Unique Device Identifiers—Missing in ActionRathi V, Ross J, Redberg R. Unique Device Identifiers—Missing in Action. JAMA Internal Medicine 2023, 183: 1049-1050. PMID: 37603363, DOI: 10.1001/jamainternmed.2023.3561.
• Unique Device Identifiers for Medical Devices at 10 YearsDhruva S, Ross J, Wilson N. Unique Device Identifiers for Medical Devices at 10 Years. JAMA Internal Medicine 2023, 183: 1045-1046. PMID: 37603351, DOI: 10.1001/jamainternmed.2023.3572.
• Medical Product Industry Ties to Patient Advocacy Organizations’ Executive LeadershipBhat S, Ross J, Ramachandran R. Medical Product Industry Ties to Patient Advocacy Organizations’ Executive Leadership. JAMA Internal Medicine 2023, 183: 1164-1166. PMID: 37603342, PMCID: PMC10442781, DOI: 10.1001/jamainternmed.2023.2842.
• Financial Conflicts of Interest in Public Comments on Medicare National Coverage Determinations of Medical DevicesLu A, Ji R, Ge A, Ross J, Ramachandran R, Redberg R, Dhruva S. Financial Conflicts of Interest in Public Comments on Medicare National Coverage Determinations of Medical Devices. JAMA 2023, 330: 1094-1096. PMID: 37589985, PMCID: PMC10436180, DOI: 10.1001/jama.2023.14414.
• Payer-Negotiated Prices for Cardiac Electrophysiology Procedures at 2022-2023 Top 100 US News & World Report for Cardiology and Heart Surgery HospitalsGupta K, Gupta R, Xiao R, Rathi V, Miller P, Ross J, Dhruva S. Payer-Negotiated Prices for Cardiac Electrophysiology Procedures at 2022-2023 Top 100 US News & World Report for Cardiology and Heart Surgery Hospitals. Circulation Arrhythmia And Electrophysiology 2023, 16: e012159. PMID: 37622312, DOI: 10.1161/circep.123.012159.
• Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trialsWallach J, Deng Y, Polley E, Dhruva S, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Jeffery M, Lyon T, Ross J, McCoy R. Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials. Clinical Trials 2023, 20: 689-698. PMID: 37589143, PMCID: PMC10843567, DOI: 10.1177/17407745231193137.
• Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trialDeng Y, Polley E, Wallach J, Herrin J, Ross J, McCoy R. Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial. BMJ Medicine 2023, 2: e000419. PMID: 37577025, PMCID: PMC10414064, DOI: 10.1136/bmjmed-2022-000419.
• Press Releases of Drug-Related Randomized Trial Results Prior to Publication in High-Impact Journals: an Observational StudyPurohit U, Sacks C, Raissi A, Hughes E, Boctor M, Manzoor S, Hodzic-Santor B, Zhu K, Raudanskis A, Ross J, Fralick M. Press Releases of Drug-Related Randomized Trial Results Prior to Publication in High-Impact Journals: an Observational Study. Journal Of General Internal Medicine 2023, 38: 3107-3114. PMID: 37532876, PMCID: PMC10651612, DOI: 10.1007/s11606-023-08313-1.
• Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel TherapeuticsWong A, Mooghali M, Ramachandran R, Ross J, Wallach J. Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics. JAMA Network Open 2023, 6: e2331753. PMID: 37651145, PMCID: PMC10472182, DOI: 10.1001/jamanetworkopen.2023.31753.
• Approval of Drugs With Unmet Trial End Points—In ReplyJohnston J, Ross J, Ramachandran R. Approval of Drugs With Unmet Trial End Points—In Reply. JAMA Internal Medicine 2023, 183: 889-890. PMID: 37307009, DOI: 10.1001/jamainternmed.2023.2240.
• Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort studyVokinger K, Glaus C, Kesselheim A, Serra-Burriel M, Ross J, Hwang T. Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study. The BMJ 2023, 382: e074166. PMID: 37407074, PMCID: PMC10320829, DOI: 10.1136/bmj-2022-074166.
• Association of Receipt of Paycheck Protection Program Loans With Staffing Patterns Among US Nursing HomesTravers J, McGarry B, Friedman S, Holaday L, Ross J, Lopez L, Chen K. Association of Receipt of Paycheck Protection Program Loans With Staffing Patterns Among US Nursing Homes. JAMA Network Open 2023, 6: e2326122. PMID: 37498597, PMCID: PMC10375300, DOI: 10.1001/jamanetworkopen.2023.26122.
• Availability of Unique Device Identifiers for Class I Medical Device Recalls From 2018 to 2022Mooghali M, Ross J, Kadakia K, Dhruva S. Availability of Unique Device Identifiers for Class I Medical Device Recalls From 2018 to 2022. JAMA Internal Medicine 2023, 183: 735-737. PMID: 37184854, PMCID: PMC10186206, DOI: 10.1001/jamainternmed.2023.0727.
• 785-P: Comparative Effectiveness of Second-Line Glucose-Lowering Medications—Emulation of a Target Trial Using Real-World DataDENG Y, POLLEY E, WALLACH J, HERRIN J, ROSS J, MCCOY R. 785-P: Comparative Effectiveness of Second-Line Glucose-Lowering Medications—Emulation of a Target Trial Using Real-World Data. Diabetes 2023, 72 DOI: 10.2337/db23-785-p.
• 1234-P: Derivation of a Claims-Computable Major Adverse Cardiovascular Event Estimator (ACME) in Adults with Type 2 DiabetesMCCOY R, SWARNA K, DENG Y, HERRIN J, ROSS J, KENT D, BORAH B, CROWN W, MONTORI V, UMPIERREZ G, GALINDO R, BRITO J, MICKELSON M, POLLEY E. 1234-P: Derivation of a Claims-Computable Major Adverse Cardiovascular Event Estimator (ACME) in Adults with Type 2 Diabetes. Diabetes 2023, 72 DOI: 10.2337/db23-1234-p.
• Extending the US Food and Drug Administration’s Postmarket AuthoritiesLynch H, Sachs R, Lee S, Herder M, Ross J, Ramachandran R. Extending the US Food and Drug Administration’s Postmarket Authorities. JAMA Health Forum 2023, 4: e231313. PMID: 37294583, DOI: 10.1001/jamahealthforum.2023.1313.
• US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019Dhodapkar M, Ross J, Ramachandran R. US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019. JAMA Network Open 2023, 6: e2318889. PMID: 37358857, PMCID: PMC10293905, DOI: 10.1001/jamanetworkopen.2023.18889.
• Trends in the Use of Gabapentinoids and Opioids in the Postoperative Period Among Older AdultsBongiovanni T, Gan S, Finlayson E, Ross J, Harrison J, Boscardin W, Steinman M. Trends in the Use of Gabapentinoids and Opioids in the Postoperative Period Among Older Adults. JAMA Network Open 2023, 6: e2318626. PMID: 37326989, PMCID: PMC10276300, DOI: 10.1001/jamanetworkopen.2023.18626.
• Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study.Mooghali M, Wallach J, Mitchell A, Skydel J, Ross J, Ramachandran R. Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study. Journal Of Clinical Oncology 2023, 41: 1590-1590. DOI: 10.1200/jco.2023.41.16_suppl.1590.
• Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014Sankar A, Everhart A, Jena A, Jeffery M, Ross J, Shah N, Karaca-Mandic P. Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014. The Joint Commission Journal On Quality And Patient Safety 2023, 49: 458-466. PMID: 37380503, DOI: 10.1016/j.jcjq.2023.05.003.
• Rapid, accurate publication and dissemination of clinical trial results: benefits and challengesZannad F, Crea F, Keaney J, Spencer S, Hill J, Pfeffer M, Pocock S, Raderschadt E, Ross J, Sacks C, Van Spall H, Winslow R, Jessup M. Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges. European Heart Journal 2023, 44: 4220-4229. PMID: 37165687, DOI: 10.1093/eurheartj/ehad279.
• US Orphan Drug ActRoss J. US Orphan Drug Act. The BMJ 2023, 381: p928. PMID: 37160304, DOI: 10.1136/bmj.p928.
• Characterization of US Food and Drug Administration Class I Recalls from 2018 to 2022 for Moderate- and High-Risk Medical Devices: A Cross-Sectional StudyMooghali M, Ross J, Kadakia K, Dhruva S. Characterization of US Food and Drug Administration Class I Recalls from 2018 to 2022 for Moderate- and High-Risk Medical Devices: A Cross-Sectional Study. Medical Devices Evidence And Research 2023, 16: 111-122. PMID: 37229515, PMCID: PMC10204764, DOI: 10.2147/mder.s412802.
• Pain Management in Older Adults Before and During the First Year of COVID-19 Pandemic: Prevalence, Trends, and CorrelatesManhapra A, Fortinsky R, Berg K, Ross J, Rhee T. Pain Management in Older Adults Before and During the First Year of COVID-19 Pandemic: Prevalence, Trends, and Correlates. The Journals Of Gerontology Series A 2023, 78: 1627-1640. PMID: 37096328, PMCID: PMC10460550, DOI: 10.1093/gerona/glad115.
• Physician responses to apple watch-detected irregular rhythm alertsDemkowicz P, Dhruva S, Spatz E, Beatty A, Ross J, Khera R. Physician responses to apple watch-detected irregular rhythm alerts. American Heart Journal 2023, 262: 29-37. PMID: 37084933, DOI: 10.1016/j.ahj.2023.04.008.
• Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020Essa M, Ross J, Dhruva S, Desai N, Yeh R, Faridi K. Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020. Journal Of The American Heart Association 2023, 12: e028869. PMID: 37042289, PMCID: PMC10227267, DOI: 10.1161/jaha.122.028869.
• Challenges and solutions to advancing health equity with medical devicesKadakia K, Rathi V, Ramachandran R, Johnston J, Ross J, Dhruva S. Challenges and solutions to advancing health equity with medical devices. Nature Biotechnology 2023, 41: 607-609. PMID: 37037905, DOI: 10.1038/s41587-023-01746-3.
• US Food and Drug Administration Approval of Drugs Not Meeting Pivotal Trial Primary End Points, 2018-2021Johnston J, Ross J, Ramachandran R. US Food and Drug Administration Approval of Drugs Not Meeting Pivotal Trial Primary End Points, 2018-2021. JAMA Internal Medicine 2023, 183: 376-380. PMID: 36780148, PMCID: PMC9926353, DOI: 10.1001/jamainternmed.2022.6444.
• Ensuring Public Trust in an Empowered FDARoss J, Berg K, Ramachandran R. Ensuring Public Trust in an Empowered FDA. New England Journal Of Medicine 2023, 388: 1249-1251. PMID: 37017494, DOI: 10.1056/nejmp2300438.
• Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.govRivero-de-Aguilar A, Pérez-Ríos M, Ruano-Raviña A, Candal-Pedreira C, Puente-Hernandez M, Ross J, Varela-Lema L. Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.gov. Journal Of Neurology Neurosurgery & Psychiatry 2023, 94: 597-604. PMID: 36977551, DOI: 10.1136/jnnp-2023-331132.
• US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeuticsEadie A, MacGregor A, Wallach J, Ross J, Herder M. US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics. BMJ Evidence-Based Medicine 2023, 28: 151-156. PMID: 36944478, DOI: 10.1136/bmjebm-2022-112005.
• Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning methodNgufor C, Yao X, Inselman J, Ross J, Dhruva S, Graham D, Lee J, Siontis K, Desai N, Polley E, Shah N, Noseworthy P. Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. American Heart Journal 2023, 260: 124-140. PMID: 36893934, PMCID: PMC10615250, DOI: 10.1016/j.ahj.2023.02.015.
• A MACHINE LEARNING-GUIDED APPROACH FOR ADAPTIVE TRIAL ENRICHMENT AND ACCELERATION OF CARDIOVASCULAR OUTCOME TRIALS: INSIGHTS FROM THE SPRINT AND ACCORD-BP TRIALSOikonomou E, Spatz E, Ross J, Suchard M, Krumholz H, Khera R. A MACHINE LEARNING-GUIDED APPROACH FOR ADAPTIVE TRIAL ENRICHMENT AND ACCELERATION OF CARDIOVASCULAR OUTCOME TRIALS: INSIGHTS FROM THE SPRINT AND ACCORD-BP TRIALS. Journal Of The American College Of Cardiology 2023, 81: 2314. DOI: 10.1016/s0735-1097(23)02758-4.
• Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018Rathi V, Johnston J, Dhruva S, Ross J. Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018. BMJ Surgery Interventions & Health Technologies 2023, 5: e000152. PMID: 36793371, PMCID: PMC9923248, DOI: 10.1136/bmjsit-2022-000152.
• Using real-world data from health systems to evaluate the safety and effectiveness of a catheter to treat ischemic ventricular tachycardiaDhruva S, Zhang S, Chen J, Noseworthy P, Doshi A, Agboola K, Herrin J, Jiang G, Yu Y, Cafri G, Farr K, Mbwana M, Ross J, Coplan P, Drozda J. Using real-world data from health systems to evaluate the safety and effectiveness of a catheter to treat ischemic ventricular tachycardia. Journal Of Interventional Cardiac Electrophysiology 2023, 66: 1817-1825. PMID: 36738387, DOI: 10.1007/s10840-023-01496-x.
• Implementing clinical trial data sharing requires training a new generation of biomedical researchersMansmann U, Locher C, Prasser F, Weissgerber T, Sax U, Posch M, Decullier E, Cristea I, Debray T, Held L, Moher D, Ioannidis J, Ross J, Ohmann C, Naudet F. Implementing clinical trial data sharing requires training a new generation of biomedical researchers. Nature Medicine 2023, 29: 298-301. PMID: 36732626, DOI: 10.1038/s41591-022-02080-y.
• Exploring unique device identifier implementation and use for real-world evidence: a mixed-methods study with NESTcc health system network collaboratorsDhruva S, Ridgeway J, Ross J, Drozda J, Wilson N. Exploring unique device identifier implementation and use for real-world evidence: a mixed-methods study with NESTcc health system network collaborators. BMJ Surgery Interventions & Health Technologies 2023, 5: e000167. PMID: 36704544, PMCID: PMC9872505, DOI: 10.1136/bmjsit-2022-000167.
• Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional studyMooghali M, Glick L, Ramachandran R, Ross J. Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional study. BMJ Open 2023, 13: e069115. PMID: 36690402, PMCID: PMC9872463, DOI: 10.1136/bmjopen-2022-069115.
• Adding device identifiers to claims forms—a key step to advance medical device safetyKadakia K, Dhruva S, Ross J, Krumholz H. Adding device identifiers to claims forms—a key step to advance medical device safety. The BMJ 2023, 380: p82. PMID: 36631149, DOI: 10.1136/bmj.p82.
• Use of Recalled Devices in New Device Authorizations Under the US Food and Drug Administration’s 510(k) Pathway and Risk of Subsequent RecallsKadakia K, Dhruva S, Caraballo C, Ross J, Krumholz H. Use of Recalled Devices in New Device Authorizations Under the US Food and Drug Administration’s 510(k) Pathway and Risk of Subsequent Recalls. JAMA 2023, 329: 136-143. PMID: 36625810, PMCID: PMC9857464, DOI: 10.1001/jama.2022.23279.
• Integrating real-world data to assess cardiac ablation device outcomes in a multicenter study using the OMOP common data model for regulatory decisions: implementation and evaluationYu Y, Jiang G, Brandt E, Forsyth T, Dhruva S, Zhang S, Chen J, Noseworthy P, Doshi A, Collison-Farr K, Kim D, Ross J, Coplan P, Drozda J. Integrating real-world data to assess cardiac ablation device outcomes in a multicenter study using the OMOP common data model for regulatory decisions: implementation and evaluation. JAMIA Open 2023, 6: ooac108. PMID: 36632328, PMCID: PMC9831049, DOI: 10.1093/jamiaopen/ooac108.
• Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional studyVarma T, Mello M, Ross J, Gross C, Miller J. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study. BMJ Medicine 2023, 2: e000395. PMID: 36936269, PMCID: PMC9951369, DOI: 10.1136/bmjmed-2022-000395.
• Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China PEACE-Million Persons Project and primary health-care survey: a cross-sectional studyGroup C, Zhou T, Wang Y, Zhang H, Wu C, Tian N, Cui J, Bai X, Yang Y, Zhang X, Lu Y, Spatz E, Ross J, Krumholz H, Lu J, Li X, Hu S. Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China PEACE-Million Persons Project and primary health-care survey: a cross-sectional study. The Lancet Global Health 2023, 11: e83-e94. PMID: 36521957, DOI: 10.1016/s2214-109x(22)00428-4.
• The Philips Respironics Recall of Ventilators and Positive Airway Pressure Machines—Breakdowns in Medical Device SurveillanceKadakia K, Ross J, Rathi V. The Philips Respironics Recall of Ventilators and Positive Airway Pressure Machines—Breakdowns in Medical Device Surveillance. JAMA Internal Medicine 2023, 183: 5-8. PMID: 36374487, DOI: 10.1001/jamainternmed.2022.5141.
• Differences In Debt Among Postgraduate Medical Residents By Self-Designated Race And Ethnicity, 2014–19Holaday L, Weiss J, Sow S, Perez H, Ross J, Genao I. Differences In Debt Among Postgraduate Medical Residents By Self-Designated Race And Ethnicity, 2014–19. Health Affairs 2023, 42: 63-73. PMID: 36623219, PMCID: PMC9954659, DOI: 10.1377/hlthaff.2022.00446.
• Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal ArticlesJanda G, Khetpal V, Shi X, Ross J, Wallach J. Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles. JAMA Network Open 2022, 5: e2245847. PMID: 36484989, PMCID: PMC9856222, DOI: 10.1001/jamanetworkopen.2022.45847.
• Artificial Intelligence in Breast Cancer ScreeningPotnis K, Ross J, Aneja S, Gross C, Richman I. Artificial Intelligence in Breast Cancer Screening. JAMA Internal Medicine 2022, 182: 1306-1312. PMID: 36342705, PMCID: PMC10623674, DOI: 10.1001/jamainternmed.2022.4969.
• PreScription DigitaL ThErapEutic For Patients with Insomnia (SLEEP-I): A Protocol for a Pragmatic Randomized Controlled TrialDreyer R, Berkowitz A, Yaggi H, Schneeberg L, Shah N, Emanuel L, Prakash K, Jeffery M, Thorndike F, Deeg M, Ervin K, Ross J. PreScription DigitaL ThErapEutic For Patients with Insomnia (SLEEP-I): A Protocol for a Pragmatic Randomized Controlled Trial. Sleep Medicine 2022, 100: s133-s134. DOI: 10.1016/j.sleep.2022.05.365.
• Assessment of Market-Level Information on Quality Using Hospital Care CompareOddleifson D, Xu X, Ross J, Spatz E, Desai N. Assessment of Market-Level Information on Quality Using Hospital Care Compare. Journal Of General Internal Medicine 2022, 38: 1581-1583. PMID: 36443632, PMCID: PMC10160280, DOI: 10.1007/s11606-022-07965-9.
• Retracted papers originating from paper mills: cross sectional studyCandal-Pedreira C, Ross J, Ruano-Ravina A, Egilman D, Fernández E, Pérez-Ríos M. Retracted papers originating from paper mills: cross sectional study. The BMJ 2022, 379: e071517. PMID: 36442874, PMCID: PMC9703783, DOI: 10.1136/bmj-2022-071517.
• Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness AnalysisSavinkina A, Paltiel A, Ross J, Gonsalves G. Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis. Open Forum Infectious Diseases 2022, 9: ofac637. PMID: 36589482, PMCID: PMC9792084, DOI: 10.1093/ofid/ofac637.
• Consistency between trials presented at conferences, their subsequent publications and press releasesRowhani-Farid A, Hong K, Grewal M, Reynolds J, Zhang A, Wallach J, Ross J. Consistency between trials presented at conferences, their subsequent publications and press releases. BMJ Evidence-Based Medicine 2022, 28: 95-102. PMID: 36357160, PMCID: PMC10086295, DOI: 10.1136/bmjebm-2022-111989.
• US Post-Graduate Residency Competitiveness, Trainee Diversity, and Future Salary Among 12 Clinical SpecialtiesMensah M, Ghanney Simons E, Mangurian C, Ross J. US Post-Graduate Residency Competitiveness, Trainee Diversity, and Future Salary Among 12 Clinical Specialties. Journal Of General Internal Medicine 2022, 38: 1567-1569. PMID: 36357730, PMCID: PMC10160250, DOI: 10.1007/s11606-022-07868-9.
• Abstract 13439: Trends in Spending for P2Y12 Inhibitors by Medicare and MedicaidEssa M, Ross J, Dhruva S, Desai N, Yeh R, Faridi K. Abstract 13439: Trends in Spending for P2Y12 Inhibitors by Medicare and Medicaid. Circulation 2022, 146: a13439-a13439. DOI: 10.1161/circ.146.suppl_1.13439.
• Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward?Dhruva SS, Ramachandran R, Ross JS. Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward? New England Journal Of Medicine 2022, 387: 1539-1541. PMID: 36301560, DOI: 10.1056/nejmp2210198.
• Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATEManyara AM, Davies P, Stewart D, Weir CJ, Young A, Butcher NJ, Bujkiewicz S, Chan AW, Collins GS, Dawoud D, Offringa M, Ouwens M, Ross JS, Taylor RS, Ciani O. Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE. BMJ Open 2022, 12: e064304. PMID: 36220321, PMCID: PMC9557267, DOI: 10.1136/bmjopen-2022-064304.
• Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional studyDhodapkar MM, Shi X, Ramachandran R, Chen EM, Wallach JD, Ross JS. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study. The BMJ 2022, 379: e071752. PMID: 36198428, PMCID: PMC9533298, DOI: 10.1136/bmj-2022-071752.
• Spontaneous reporting of post-market safety signals: what evidence should support regulatory action?Dhodapkar MM, Ross JS, Ramachandran R. Spontaneous reporting of post-market safety signals: what evidence should support regulatory action? The BMJ 2022, 379: o2409. PMID: 36198410, DOI: 10.1136/bmj.o2409.
• Emulating the GRADE trial using real world data: retrospective comparative effectiveness studyDeng Y, Polley EC, Wallach JD, Dhruva SS, Herrin J, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Lyon TD, Shah ND, Ross JS, McCoy RG. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. The BMJ 2022, 379: e070717. PMID: 36191949, PMCID: PMC9527635, DOI: 10.1136/bmj-2022-070717.
• Characteristics of Retracted Research Articles About COVID-19 vs Other TopicsShi X, Abritis A, Patel RP, Grewal M, Oransky I, Ross JS, Wallach JD. Characteristics of Retracted Research Articles About COVID-19 vs Other Topics. JAMA Network Open 2022, 5: e2234585. PMID: 36194415, PMCID: PMC9533180, DOI: 10.1001/jamanetworkopen.2022.34585.
• Analysis of Patient-Focused Information About Left Atrial Appendage Occlusion on US Hospital Web PagesDhruva SS, Ji RZ, Ross JS, Spatz ES, Redberg RF. Analysis of Patient-Focused Information About Left Atrial Appendage Occlusion on US Hospital Web Pages. JAMA Internal Medicine 2022, 182: 1226-1229. PMID: 36190724, PMCID: PMC9531069, DOI: 10.1001/jamainternmed.2022.4287.
• Post-submission changes to prespecified statistical analysis plansIslam N, Cole TJ, Ross JS, Feeney T, Loder E. Post-submission changes to prespecified statistical analysis plans. The BMJ 2022, 378: o2244. PMID: 36130792, DOI: 10.1136/bmj.o2244.
• Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysisGouraud H, Wallach J, Boussageon R, Ross J, Naudet F. Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis. BMJ Medicine 2022, 1: e000154. PMID: 36936564, PMCID: PMC9978683, DOI: 10.1136/bmjmed-2022-000154.
• Prolonged use of newly prescribed gabapentin after surgeryBongiovanni T, Gan S, Finlayson E, Ross J, Harrison JD, Boscardin J, Steinman MA. Prolonged use of newly prescribed gabapentin after surgery. Journal Of The American Geriatrics Society 2022, 70: 3560-3569. PMID: 36000860, PMCID: PMC9771946, DOI: 10.1111/jgs.18005.
• PreScription DigitaL ThErapEutic for Patients with Insomnia (SLEEP-I): a protocol for a pragmatic randomised controlled trialDreyer RP, Berkowitz A, Yaggi HK, Schneeberg L, Shah ND, Emanuel L, Kolla B, Jeffery MM, Deeg M, Ervin K, Thorndike F, Ross JS. PreScription DigitaL ThErapEutic for Patients with Insomnia (SLEEP-I): a protocol for a pragmatic randomised controlled trial. BMJ Open 2022, 12: e062041. PMID: 35940841, PMCID: PMC9364397, DOI: 10.1136/bmjopen-2022-062041.
• Safety and Effectiveness of a Catheter With Contact Force and 6-Hole Irrigation for Ablation of Persistent Atrial Fibrillation in Routine Clinical PracticeDhruva SS, Zhang S, Chen J, Noseworthy PA, Doshi AA, Agboola KM, Herrin J, Jiang G, Yu Y, Cafri G, Farr K, Ervin KR, Ross JS, Coplan PM, Drozda JP. Safety and Effectiveness of a Catheter With Contact Force and 6-Hole Irrigation for Ablation of Persistent Atrial Fibrillation in Routine Clinical Practice. JAMA Network Open 2022, 5: e2227134. PMID: 35976649, PMCID: PMC9386540, DOI: 10.1001/jamanetworkopen.2022.27134.
• Acute pain pathways: protocol for a prospective cohort studyJeffery MM, Ahadpour M, Allen S, Araojo R, Bellolio F, Chang N, Ciaccio L, Emanuel L, Fillmore J, Gilbert GH, Koussis P, Lee C, Lipkind H, Mallama C, Meyer T, Moncur M, Nuckols T, Pacanowski MA, Page DB, Papadopoulos E, Ritchie JD, Ross JS, Shah ND, Soukup M, St. Clair CO, Tamang S, Torbati S, Wallace DW, Zhao Y, Heckmann R. Acute pain pathways: protocol for a prospective cohort study. BMJ Open 2022, 12: e058782. PMID: 35790333, PMCID: PMC9258513, DOI: 10.1136/bmjopen-2021-058782.
• Public Misinformation and Science Communication in Times of Public Health CrisesVera MA, El-Khoury JM, Thorp H, Tofel RJ, Ross JS, Mandavilli A, Topol E. Public Misinformation and Science Communication in Times of Public Health Crises. Clinical Chemistry 2022, 68: hvac088-. PMID: 35675305, DOI: 10.1093/clinchem/hvac088.
• Medical Device User Fee Reauthorization — Back to Basics or Looking Ahead?Rathi VK, Ross JS, Redberg RF, Dhruva SS. Medical Device User Fee Reauthorization — Back to Basics or Looking Ahead? New England Journal Of Medicine 2022, 387: 196-199. PMID: 35675195, DOI: 10.1056/nejmp2204947.
• Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart FailureFaridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.
• Hospital-Administered Cancer Therapy Prices for Patients With Private Health InsuranceXiao R, Ross JS, Gross CP, Dusetzina SB, McWilliams JM, Sethi RKV, Rathi VK. Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance. JAMA Internal Medicine 2022, 182: 603-611. PMID: 35435948, PMCID: PMC9016607, DOI: 10.1001/jamainternmed.2022.1022.
• Generating evidence during a pandemic: what’s reliable?Wallach JD, Moneer O, Ross JS. Generating evidence during a pandemic: what’s reliable? The BMJ 2022, 377: o1229. PMID: 35577370, DOI: 10.1136/bmj.o1229.
• Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological studyMoneer O, Daly G, Skydel JJ, Nyhan K, Lurie P, Ross JS, Wallach JD. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study. The BMJ 2022, 377: e069400. PMID: 35537738, PMCID: PMC9086409, DOI: 10.1136/bmj-2021-069400.
• Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017Skydel JJ, Egilman AC, Wallach JD, Ramachandran R, Gupta R, Ross JS. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017. JAMA Health Forum 2022, 3: e221158. PMID: 35977252, PMCID: PMC9142876, DOI: 10.1001/jamahealthforum.2022.1158.
• Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021Gupta R, Morten CJ, Zhu AY, Ramachandran R, Shah ND, Ross JS. Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021. JAMA Health Forum 2022, 3: e221096. PMID: 35977259, PMCID: PMC9123500, DOI: 10.1001/jamahealthforum.2022.1096.
• Abstract 43: A Case-based Survey Of Physician Practice Patterns Following Asymptomatic, Wearable Device-detected Irregular RhythmDemkowicz P, Dhruva S, Spatz E, Beatty A, Ross J, Khera R. Abstract 43: A Case-based Survey Of Physician Practice Patterns Following Asymptomatic, Wearable Device-detected Irregular Rhythm. Circulation Cardiovascular Quality And Outcomes 2022, 15 DOI: 10.1161/circoutcomes.15.suppl_1.43.
• B-45 | Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale StoryGoldsweig A, Deng Y, Yao X, Aronow H, Cohen D, Desai N, Messe S, Ross J, Lansky A, Savitz S. B-45 | Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Story. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100151. DOI: 10.1016/j.jscai.2022.100151.
• In Medicaid Managed Care Networks, Care Is Highly Concentrated Among A Small Percentage Of PhysiciansLudomirsky AB, Schpero WL, Wallace J, Lollo A, Bernheim S, Ross JS, Ndumele CD. In Medicaid Managed Care Networks, Care Is Highly Concentrated Among A Small Percentage Of Physicians. Health Affairs 2022, 41: 760-768. PMID: 35500192, DOI: 10.1377/hlthaff.2021.01747.
• A Different Case of Penumbra—ReplyKadakia KT, Ross JS, Krumholz HM. A Different Case of Penumbra—Reply. JAMA Internal Medicine 2022, 182: 570-571. PMID: 35285863, DOI: 10.1001/jamainternmed.2022.0105.
• FDA Indication Extrapolations—Allowing Flexibility While Providing Greater ClarityRamachandran R, Ross JS. FDA Indication Extrapolations—Allowing Flexibility While Providing Greater Clarity. JAMA Network Open 2022, 5: e227961. PMID: 35438761, DOI: 10.1001/jamanetworkopen.2022.7961.
• Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US AdultsBrito JP, Deng Y, Ross JS, Choi NH, Graham DJ, Qiang Y, Rantou E, Wang Z, Zhao L, Shah ND, Lipska KJ. Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults. JAMA Internal Medicine 2022, 182: 418-425. PMID: 35226058, PMCID: PMC8886450, DOI: 10.1001/jamainternmed.2022.0045.
• A multicenter evaluation of computable phenotyping approaches for SARS-CoV-2 infection and COVID-19 hospitalizationsKhera R, Mortazavi BJ, Sangha V, Warner F, Patrick Young H, Ross JS, Shah ND, Theel ES, Jenkinson WG, Knepper C, Wang K, Peaper D, Martinello RA, Brandt CA, Lin Z, Ko AI, Krumholz HM, Pollock BD, Schulz WL. A multicenter evaluation of computable phenotyping approaches for SARS-CoV-2 infection and COVID-19 hospitalizations. Npj Digital Medicine 2022, 5: 27. PMID: 35260762, PMCID: PMC8904579, DOI: 10.1038/s41746-022-00570-4.
• Access to High-Volume Hospitals for High-Risk Cancer Surgery for Racial and Ethnic Minoritized GroupsSalazar MC, Canavan ME, Holaday LW, Billingsley KG, Ross J, Boffa DJ, Gross CP. Access to High-Volume Hospitals for High-Risk Cancer Surgery for Racial and Ethnic Minoritized Groups. JNCI Cancer Spectrum 2022, 6: pkac024. PMID: 35603855, PMCID: PMC8997114, DOI: 10.1093/jncics/pkac024.
• NATIONAL MEDICARE FORMULARY COVERAGE AND OUT-OF-POCKET COSTS OF QUADRUPLE THERAPY FOR HEART FAILURE WITH REDUCED EJECTION FRACTIONFaridi K, Dayoub E, Ross J, Dhruva S, Desai N. NATIONAL MEDICARE FORMULARY COVERAGE AND OUT-OF-POCKET COSTS OF QUADRUPLE THERAPY FOR HEART FAILURE WITH REDUCED EJECTION FRACTION. Journal Of The American College Of Cardiology 2022, 79: 225. DOI: 10.1016/s0735-1097(22)01216-5.
• UNDERREPRESENTATION AND EXCLUSION OF PATIENTS WITH CARDIOVASCULAR DISEASE IN INTENSIVE CARE RANDOMIZED CONTROL TRIALSAli T, Grimshaw A, Thomas A, Solomon M, Krumholz H, Ross J, Miller P. UNDERREPRESENTATION AND EXCLUSION OF PATIENTS WITH CARDIOVASCULAR DISEASE IN INTENSIVE CARE RANDOMIZED CONTROL TRIALS. Journal Of The American College Of Cardiology 2022, 79: 518. DOI: 10.1016/s0735-1097(22)01509-1.
• SAFETY AND EFFECTIVENESS OF THERMOCOOL STSF CATHETER FOR ABLATION OF ISCHEMIC VENTRICULAR TACHYCARDIADhruva S, Zhang S, Chen J, Noseworthy P, Doshi A, Agboola K, Herrin J, Jiang G, Yu Y, Cafri G, Farr K, Ervin K, Ross J, Coplan P, Drozda J. SAFETY AND EFFECTIVENESS OF THERMOCOOL STSF CATHETER FOR ABLATION OF ISCHEMIC VENTRICULAR TACHYCARDIA. Journal Of The American College Of Cardiology 2022, 79: 116. DOI: 10.1016/s0735-1097(22)01107-x.
• SAFETY AND EFFECTIVENESS OF THERMOCOOL ST CATHETER FOR ABLATION OF PERSISTENT ATRIAL FIBRILLATION USING REAL-WORLD DATADhruva S, Zhang S, Chen J, Noseworthy P, Doshi A, Agboola K, Herrin J, Jiang G, Yu Y, Cafri G, Farr K, Ervin K, Ross J, Coplan P, Drozda J. SAFETY AND EFFECTIVENESS OF THERMOCOOL ST CATHETER FOR ABLATION OF PERSISTENT ATRIAL FIBRILLATION USING REAL-WORLD DATA. Journal Of The American College Of Cardiology 2022, 79: 73. DOI: 10.1016/s0735-1097(22)01064-6.
• Sensible regulation and clinical implementation of clinical decision support software as a medical deviceMori M, Jarrin R, Lu Y, Kadakia K, Huang C, Ross JS, Krumholz HM. Sensible regulation and clinical implementation of clinical decision support software as a medical device. The BMJ 2022, 376: o525. PMID: 35228206, DOI: 10.1136/bmj.o525.
• Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adultsBrito JP, Deng Y, Ross JS, Choi NH, Graham DJ, Qiang Y, Rantou E, Wang Z, Zhao L, Shah ND, Lipska KJ. Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults. Endocrine 2022, 76: 349-358. PMID: 35107758, PMCID: PMC9210352, DOI: 10.1007/s12020-022-02987-z.
• Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019Zhou T, Liu P, Dhruva SS, Shah ND, Ramachandran R, Berg KM, Ross JS. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019. JAMA Internal Medicine 2022, 182: 185-195. PMID: 34982097, PMCID: PMC8728660, DOI: 10.1001/jamainternmed.2021.7457.
• Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in RheumatologyDuarte-García A, Crowson CS, McCoy RG, Herrin J, Lam V, Putman MS, Ross JS, Matteson EL, Shah ND. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. Mayo Clinic Proceedings 2022, 97: 250-260. PMID: 35120693, PMCID: PMC9013005, DOI: 10.1016/j.mayocp.2021.08.026.
• Association of Psychiatric Diagnoses and Medicaid Coverage with Length of Stay Among Inpatients Discharged to Skilled Nursing FacilitiesBartlett VL, Ross JS, Balasuriya L, Rhee TG. Association of Psychiatric Diagnoses and Medicaid Coverage with Length of Stay Among Inpatients Discharged to Skilled Nursing Facilities. Journal Of General Internal Medicine 2022, 37: 3070-3079. PMID: 35048298, PMCID: PMC9485316, DOI: 10.1007/s11606-021-07320-4.
• Payer-Negotiated Prices for Telemedicine ServicesWu SS, Rathi VK, Ross JS, Sethi RKV, Xiao R. Payer-Negotiated Prices for Telemedicine Services. Journal Of General Internal Medicine 2022, 37: 3495-3497. PMID: 35029785, PMCID: PMC8759432, DOI: 10.1007/s11606-022-07398-4.
• Renewing the Call for Reforms to Medical Device Safety—The Case of PenumbraKadakia KT, Beckman AL, Ross JS, Krumholz HM. Renewing the Call for Reforms to Medical Device Safety—The Case of Penumbra. JAMA Internal Medicine 2022, 182: 59-65. PMID: 34842892, DOI: 10.1001/jamainternmed.2021.6626.
• Heart Watch Study: protocol for a pragmatic randomised controlled trialDhruva SS, Shah ND, Vemulapalli S, Deshmukh A, Beatty AL, Gamble GM, Freeman JV, Hummel JP, Piccini JP, Akar JG, Ervin K, Arges KL, Emanuel L, Noseworthy PA, Hu T, Bartlett V, Ross JS. Heart Watch Study: protocol for a pragmatic randomised controlled trial. BMJ Open 2021, 11: e054550. PMID: 35234659, PMCID: PMC8719216, DOI: 10.1136/bmjopen-2021-054550.
• Loneliness, sadness, and feelings of social disconnection in older adults during the COVID‐19 pandemicHoladay LW, Oladele CR, Miller SM, Dueñas MI, Roy B, Ross JS. Loneliness, sadness, and feelings of social disconnection in older adults during the COVID‐19 pandemic. Journal Of The American Geriatrics Society 2021, 70: 329-340. PMID: 34850379, PMCID: PMC8896574, DOI: 10.1111/jgs.17599.
• Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating CenterDhruva SS, Jiang G, Doshi AA, Friedman DJ, Brandt E, Chen J, Akar JG, Ross JS, Ervin KR, Farr K, Shah ND, Coplan P, Noseworthy PA, Zhang S, Forsyth T, Schulz WL, Yu Y, Drozda JP. Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center. BMJ Surgery Interventions & Health Technologies 2021, 3: e000089. PMID: 35047806, PMCID: PMC8749235, DOI: 10.1136/bmjsit-2021-000089.
• Strengthening the FDA’s Enforcement of ClinicalTrials.gov Reporting RequirementsRamachandran R, Morten CJ, Ross JS. Strengthening the FDA’s Enforcement of ClinicalTrials.gov Reporting Requirements. JAMA 2021, 326: 2131-2132. PMID: 34766971, DOI: 10.1001/jama.2021.19773.
• Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug AdministrationSankar A, Swanson KM, Zhou J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration. JAMA Network Open 2021, 4: e2136662. PMID: 34851398, PMCID: PMC8637256, DOI: 10.1001/jamanetworkopen.2021.36662.
• Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare BeneficiariesWheelock KM, Ross JS, Murugiah K, Lin Z, Krumholz HM, Khera R. Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries. JAMA Network Open 2021, 4: e2137288. PMID: 34870678, PMCID: PMC8649845, DOI: 10.1001/jamanetworkopen.2021.37288.
• Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAASwanson MJ, Johnston JL, Ross JS. Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA. Trials 2021, 22: 817. PMID: 34789308, PMCID: PMC8597303, DOI: 10.1186/s13063-021-05790-9.
• Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical TrialsRamachandran R, Ross JS, Miller JE. Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials. JAMA Network Open 2021, 4: e2134233. PMID: 34792596, PMCID: PMC8603077, DOI: 10.1001/jamanetworkopen.2021.34233.
• Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018Wallach JD, Ramachandran R, Bruckner T, Ross JS. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018. JAMA Network Open 2021, 4: e2133601. PMID: 34751764, PMCID: PMC8579231, DOI: 10.1001/jamanetworkopen.2021.33601.
• Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated ApprovalWallach JD, Zhang AD, Skydel JJ, Bartlett VL, Dhruva SS, Shah ND, Ross JS. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval. JAMA Network Open 2021, 4: e2133667. PMID: 34751763, PMCID: PMC8579227, DOI: 10.1001/jamanetworkopen.2021.33667.
• Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration.Egilman AC, Kapczynski A, McCarthy ME, Luxkaranayagam AT, Morten CJ, Herder M, Wallach JD, Ross JS. Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration. The Journal Of Law, Medicine & Ethics 2021, 49: 456-485. PMID: 34665102, DOI: 10.1017/jme.2021.67.
• Optimiser les données accessibles dans le portail de renseignements cliniques de Santé CanadaEgilman AC, Ross JS, Herder M. Optimiser les données accessibles dans le portail de renseignements cliniques de Santé Canada. Canadian Medical Association Journal 2021, 193: e1616-1618. PMID: 34663613, PMCID: PMC8547254, DOI: 10.1503/cmaj.210877-f.
• Early experience with the FDA’s regulatory review of novel gene therapiesPuthumana J, Egilman AC, Ramachandran R, Naushad N, Shah N, Ross J. Early experience with the FDA’s regulatory review of novel gene therapies. BMJ Evidence-Based Medicine 2021, 27: 195-198. PMID: 34635478, DOI: 10.1136/bmjebm-2021-111720.
• Clinical studies sponsored by digital health companies participating in the FDA’s Precertification Pilot Program: A cross-sectional analysisBartlett VL, Dhruva SS, Shah ND, Ross JS. Clinical studies sponsored by digital health companies participating in the FDA’s Precertification Pilot Program: A cross-sectional analysis. Clinical Trials 2021, 19: 119-122. PMID: 34632824, PMCID: PMC9888320, DOI: 10.1177/17407745211048493.
• Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer TreatmentWallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Network Open 2021, 4: e2130587. PMID: 34677594, PMCID: PMC8536955, DOI: 10.1001/jamanetworkopen.2021.30587.
• Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval PathwayGyawali B, Ross JS, Kesselheim AS. Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval Pathway. JAMA Internal Medicine 2021, 181: 1275-1276. PMID: 34254981, DOI: 10.1001/jamainternmed.2021.4604.
• Levothyroxine Use in the United States, 2008-2018Brito JP, Ross JS, Kawkgi O, Maraka S, Deng Y, Shah ND, Lipska KJ. Levothyroxine Use in the United States, 2008-2018. JAMA Internal Medicine 2021, 181: 1402-1405. PMID: 34152370, PMCID: PMC8218227, DOI: 10.1001/jamainternmed.2021.2686.
• Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020Johnston JL, Dhruva SS, Ross JS, Rathi VK. Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020. JAMA Internal Medicine 2021, 181: 1409-1412. PMID: 34152383, PMCID: PMC8218229, DOI: 10.1001/jamainternmed.2021.3042.
• Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial FibrillationStecher C, Everhart A, Smith LB, Jena A, Ross JS, Desai NR, Shah N, Karaca-Mandic P. Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation. Circulation Cardiovascular Quality And Outcomes 2021, 14: e008040. PMID: 34555928, PMCID: PMC8530939, DOI: 10.1161/circoutcomes.121.008040.
• Implementation of 21st Century Cures Act Expanded Access Policies RequirementsKang S, Chang S, Ross JS, Miller JE. Implementation of 21st Century Cures Act Expanded Access Policies Requirements. Clinical Pharmacology & Therapeutics 2021, 110: 1579-1584. PMID: 34431083, DOI: 10.1002/cpt.2401.
• Distribution of Paycheck Protection Program Loans to Healthcare Organizations in 2020Chen K, Lopez L, Ross JS, Travers JL. Distribution of Paycheck Protection Program Loans to Healthcare Organizations in 2020. Journal Of General Internal Medicine 2021, 37: 2132-2133. PMID: 34505980, PMCID: PMC8432282, DOI: 10.1007/s11606-021-07108-6.
• Optimizing the data available via Health Canada’s clinical information portalEgilman AC, Ross JS, Herder M. Optimizing the data available via Health Canada’s clinical information portal. Canadian Medical Association Journal 2021, 193: e1305-e1306. PMID: 34426449, PMCID: PMC8412426, DOI: 10.1503/cmaj.210877.
• Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trialVu K, Zhou J, Everhart A, Desai N, Herrin J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. BMC Nephrology 2021, 22: 284. PMID: 34419007, PMCID: PMC8379779, DOI: 10.1186/s12882-021-02491-y.
• Characteristics of available studies and dissemination of research using major clinical data sharing platformsVazquez E, Gouraud H, Naudet F, Gross CP, Krumholz HM, Ross JS, Wallach JD. Characteristics of available studies and dissemination of research using major clinical data sharing platforms. Clinical Trials 2021, 18: 657-666. PMID: 34407656, PMCID: PMC8595516, DOI: 10.1177/17407745211038524.
• The Association Between History of Depression and Access to Care Among Medicare Beneficiaries During the COVID-19 PandemicBalasuriya L, Quinton JK, Canavan ME, Holland ML, Edelman EJ, Druss BG, Ross JS. The Association Between History of Depression and Access to Care Among Medicare Beneficiaries During the COVID-19 Pandemic. Journal Of General Internal Medicine 2021, 36: 3778-3785. PMID: 34405350, PMCID: PMC8370448, DOI: 10.1007/s11606-021-06990-4.
• Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities.McCoy RG, Van Houten HK, Karaca-Mandic P, Ross JS, Montori VM, Shah ND. Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities. Diabetes Care 2021, 44: 2302-2311. PMID: 34348996, PMCID: PMC8929191, DOI: 10.2337/dc20-2977.
• Outcomes-Driven Clinical Phenotyping in Cardiogenic Shock using a Mixture of ExpertsHurley N, Berkowitz A, Masoudi F, Ross J, Desai N, Shah N, Dhruva S, Mortazavi B. Outcomes-Driven Clinical Phenotyping in Cardiogenic Shock using a Mixture of Experts. 2021, 00: 1-4. DOI: 10.1109/bhi50953.2021.9508568.
• Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metforminSaffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS, Taddei T. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obesity And Metabolism 2021, 23: 2402-2408. PMID: 34227216, PMCID: PMC8429193, DOI: 10.1111/dom.14488.
• Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis reportJiang G, Dhruva SS, Chen J, Schulz WL, Doshi AA, Noseworthy PA, Zhang S, Yu Y, Young H, Brandt E, Ervin KR, Shah ND, Ross JS, Coplan P, Drozda JP. Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report. Journal Of The American Medical Informatics Association 2021, 28: 2241-2250. PMID: 34313748, PMCID: PMC8449615, DOI: 10.1093/jamia/ocab117.
• Unplanned hospital visits after ambulatory surgical careBongiovanni T, Parzynski C, Ranasinghe I, Steinman MA, Ross JS. Unplanned hospital visits after ambulatory surgical care. PLOS ONE 2021, 16: e0254039. PMID: 34283840, PMCID: PMC8291649, DOI: 10.1371/journal.pone.0254039.
• Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating CircumstancesOrkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, Boutron I, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan AW, Orkin A, Gill P, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg P, Weijer C, Simes J, Rombey T, Williams H, Wittes J, Moher D, Richards D, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala A, Schulz K, Calleja S, Boutron I, Ross J, Golub R, Khan K, Mulrow C, Siegfried N, Heber J, Lee N, Kearney P, Wanyenze R, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan A, Kiermer V, Corrigan-Curay J, Concato J. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances. JAMA 2021, 326: 257-265. PMID: 34152382, DOI: 10.1001/jama.2021.9941.
• Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysisAxson S, Mello MM, Lincow D, Yang C, Gross C, Ross JS, Miller J. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis. BMJ Open 2021, 11: e053248. PMID: 34281933, PMCID: PMC8291313, DOI: 10.1136/bmjopen-2021-053248.
• Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislationBenning TJ, Shah ND, Inselman JW, Van Houten HK, Ross JS, Wyatt KD. Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation. Clinical Trials 2021, 18: 732-740. PMID: 34269090, PMCID: PMC10119689, DOI: 10.1177/17407745211030683.
• Physical activity, patient-reported symptoms, and clinical events: Insights into postprocedural recovery from personal digital devicesBartlett VL, Ross JS, Shah ND, Ciaccio L, Akar JG, Noseworthy PA, Dhruva SS. Physical activity, patient-reported symptoms, and clinical events: Insights into postprocedural recovery from personal digital devices. Cardiovascular Digital Health Journal 2021, 2: 212-221. PMID: 35265911, PMCID: PMC8890038, DOI: 10.1016/j.cvdhj.2021.06.002.
• Identification of Hospitals That Care for a High Proportion of Patients With Social Risk FactorsMatty R, Heckmann R, George E, Barthel AB, Suter LG, Ross JS, Bernheim SM. Identification of Hospitals That Care for a High Proportion of Patients With Social Risk Factors. JAMA Health Forum 2021, 2: e211323. PMID: 35977204, PMCID: PMC8796989, DOI: 10.1001/jamahealthforum.2021.1323.
• Future of covid-19 vaccine pricing: lessons from influenzaRamachandran R, Dhodapkar M, Ross JS, Schwartz JL. Future of covid-19 vaccine pricing: lessons from influenza. The BMJ 2021, 373: n1467. PMID: 34158283, DOI: 10.1136/bmj.n1467.
• Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug AdministrationEgilman A, Wallach JD, Puthumana J, Zhang AD, Schwartz JL, Ross JS. Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration. Journal Of General Internal Medicine 2021, 36: 3281-3284. PMID: 34131876, PMCID: PMC8205312, DOI: 10.1007/s11606-021-06943-x.
• Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine useBrito JP, Ross JS, Deng Y, Sangaralingham L, Graham DJ, Qiang Y, Wang Z, Yao X, Zhao L, Smallridge RC, Bernet V, Shah ND, Lipska KJ. Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use. Endocrine 2021, 74: 592-602. PMID: 34089480, PMCID: PMC9210353, DOI: 10.1007/s12020-021-02779-x.
• Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021Xiao R, Rathi VK, Gross CP, Ross JS, Sethi RKV. Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021. JAMA 2021, 326: 184-185. PMID: 34086052, PMCID: PMC8278265, DOI: 10.1001/jama.2021.8535.
• Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019Dhodapkar M, Zhang AD, Puthumana J, Downing NS, Shah ND, Ross JS. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019. JAMA Network Open 2021, 4: e2113224. PMID: 34110392, PMCID: PMC8193429, DOI: 10.1001/jamanetworkopen.2021.13224.
• Medicare beneficiaries' plans for the COVID‐19 vaccine in Fall 2020, and why some planned to declineHoladay LW, Balasuriya L, Roy B, Ross JS, Oladele CR. Medicare beneficiaries' plans for the COVID‐19 vaccine in Fall 2020, and why some planned to decline. Journal Of The American Geriatrics Society 2021, 69: 2434-2437. PMID: 33990945, PMCID: PMC8242621, DOI: 10.1111/jgs.17285.
• Direct-to-consumer personal genomic tests need better regulationMoneer O, Miller JE, Shah ND, Ross JS. Direct-to-consumer personal genomic tests need better regulation. Nature Medicine 2021, 27: 940-943. PMID: 34017136, DOI: 10.1038/s41591-021-01368-9.
• Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic PrecursorsLong AS, Zhang AD, Meyer CE, Egilman AC, Ross JS, Wallach JD. Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors. JAMA Network Open 2021, 4: e215731. PMID: 33956134, PMCID: PMC8103227, DOI: 10.1001/jamanetworkopen.2021.5731.
• Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved DrugsMiller JE, Mello MM, Wallach JD, Gudbranson EM, Bohlig B, Ross JS, Gross CP, Bach PB. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. JAMA Network Open 2021, 4: e217075. PMID: 33950209, PMCID: PMC8100865, DOI: 10.1001/jamanetworkopen.2021.7075.
• OUTCOMES OF CONTEMPORARY NON-INFERIORITY VERSUS SUPERIORITY CARDIOVASCULAR TRIALSDreyfus I, Varunok N, Madhavan M, Burton J, Redfors B, Collier T, Rossello X, Owen R, Francese D, Desai N, Ross J, Kaul S, Pocock S, Stone G, Krumholz H, Bikdeli B. OUTCOMES OF CONTEMPORARY NON-INFERIORITY VERSUS SUPERIORITY CARDIOVASCULAR TRIALS. Journal Of The American College Of Cardiology 2021, 77: 1640. DOI: 10.1016/s0735-1097(21)02996-x.
• NATIONAL PATTERNS OF DIRECT ORAL ANTICOAGULANT PRESCRIBING BY UNITED STATES CLINICIANS AMONG MEDICARE BENEFICIARIESWheelock K, Ross J, Murugiah K, Lin Z, Krumholz H, Khera R. NATIONAL PATTERNS OF DIRECT ORAL ANTICOAGULANT PRESCRIBING BY UNITED STATES CLINICIANS AMONG MEDICARE BENEFICIARIES. Journal Of The American College Of Cardiology 2021, 77: 336. DOI: 10.1016/s0735-1097(21)01695-8.
• US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018Skydel JJ, Zhang AD, Dhruva SS, Ross JS, Wallach JD. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018. Clinical Trials 2021, 18: 488-499. PMID: 33863236, PMCID: PMC8292154, DOI: 10.1177/17407745211005044.
• Misreporting of Results of Research in PsychiatryBowcut J, Levi L, Livnah O, Ross JS, Knable M, Davidson M, Davis JM, Weiser M. Misreporting of Results of Research in Psychiatry. Schizophrenia Bulletin 2021, 47: 1254-1260. PMID: 33860793, PMCID: PMC8379531, DOI: 10.1093/schbul/sbab040.
• Covid-19, open science, and the CVD-COVID-UK initiativeRoss JS. Covid-19, open science, and the CVD-COVID-UK initiative. The BMJ 2021, 373: n898. PMID: 33827892, DOI: 10.1136/bmj.n898.
• Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer TherapeuticsVarma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.
• Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug AdministrationPuthumana J, Egilman AC, Zhang AD, Schwartz JL, Ross JS. Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration. JAMA Internal Medicine 2021, 181: 559-560. PMID: 33170923, PMCID: PMC7656319, DOI: 10.1001/jamainternmed.2020.7472.
• Leveraging Open Science to Accelerate ResearchKadakia KT, Beckman AL, Ross JS, Krumholz HM. Leveraging Open Science to Accelerate Research. New England Journal Of Medicine 2021, 384: e61. PMID: 33761227, DOI: 10.1056/nejmp2034518.
• Medicare’s New Device-Coverage Pathway — Breakthrough or Breakdown?Rathi VK, Johnston JL, Ross JS, Dhruva SS. Medicare’s New Device-Coverage Pathway — Breakthrough or Breakdown? New England Journal Of Medicine 2021, 384: e43. PMID: 33691059, DOI: 10.1056/nejmp2101874.
• U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016Wallach JD, Rhee TG, Edelman EJ, Shah ND, O’Malley S, Ross JS. U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016. Journal Of General Internal Medicine 2021, 37: 495-498. PMID: 33674920, PMCID: PMC8811103, DOI: 10.1007/s11606-021-06668-x.
• Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020Zhang AD, Puthumana J, Egilman AC, Schwartz JL, Ross JS. Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020. Journal Of General Internal Medicine 2021, 37: 700-702. PMID: 33660209, PMCID: PMC7928194, DOI: 10.1007/s11606-021-06670-3.
• Assessment of Concordance and Discordance Among Clinical Studies Posted as Preprints and Subsequently Published in High-Impact JournalsShi X, Ross JS, Amancharla N, Niforatos JD, Krumholz HM, Wallach JD. Assessment of Concordance and Discordance Among Clinical Studies Posted as Preprints and Subsequently Published in High-Impact Journals. JAMA Network Open 2021, 4: e212110. PMID: 33734411, PMCID: PMC7974637, DOI: 10.1001/jamanetworkopen.2021.2110.
• Effects of forced disruption in Medicaid managed care on children with asthmaPiwnica‐Worms K, Staiger B, Ross JS, Rosenthal MS, Ndumele CD. Effects of forced disruption in Medicaid managed care on children with asthma. Health Services Research 2021, 56: 668-676. PMID: 33624290, PMCID: PMC8313960, DOI: 10.1111/1475-6773.13643.
• Age‐Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011–2018Rhee TG, Kumar M, Ross JS, Coll PP. Age‐Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011–2018. Journal Of The American Geriatrics Society 2021, 69: 1272-1282. PMID: 33598936, PMCID: PMC9869399, DOI: 10.1111/jgs.17038.
• Physician variation in the de‐adoption of ineffective statin and fibrate therapyEverhart A, Desai NR, Dowd B, Herrin J, Higuera L, Jeffery MM, Jena AB, Ross JS, Shah ND, Smith LB, Karaca‐Mandic P. Physician variation in the de‐adoption of ineffective statin and fibrate therapy. Health Services Research 2021, 56: 919-931. PMID: 33569804, PMCID: PMC8522575, DOI: 10.1111/1475-6773.13630.
• Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic ShockDhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, Berkowitz AP, Masoudi FA, Messenger JC, Parzynski CS, Ngufor CG, Girotra S, Amin AP, Shah ND, Desai NR. Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA Network Open 2021, 4: e2037748. PMID: 33616664, PMCID: PMC7900859, DOI: 10.1001/jamanetworkopen.2020.37748.
• Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each yearEllingson MK, Shi X, Skydel JJ, Nyhan K, Lehman R, Ross JS, Wallach JD. Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year. BMJ Open 2021, 11: e047107. PMID: 33526505, PMCID: PMC7852964, DOI: 10.1136/bmjopen-2020-047107.
• Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. JAMA Network Open 2021, 4: e2035792. PMID: 33523188, PMCID: PMC7851726, DOI: 10.1001/jamanetworkopen.2020.35792.
• Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019Elliott MH, Skydel JJ, Dhruva SS, Ross JS, Wallach JD. Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019. JAMA Internal Medicine 2021, 181: 282-284. PMID: 33226398, PMCID: PMC7684521, DOI: 10.1001/jamainternmed.2020.4799.
• To Expand the Evidence Base About Harms from Tests and TreatmentsKorenstein D, Harris R, Elshaug AG, Ross JS, Morgan DJ, Cooper RJ, Cho HJ, Segal JB. To Expand the Evidence Base About Harms from Tests and Treatments. Journal Of General Internal Medicine 2021, 36: 2105-2110. PMID: 33479928, PMCID: PMC8298733, DOI: 10.1007/s11606-021-06597-9.
• Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020Liu P, Dhruva SS, Shah ND, Ross JS. Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020. JAMA Network Open 2021, 4: e2035064. PMID: 33481031, PMCID: PMC7823226, DOI: 10.1001/jamanetworkopen.2020.35064.
• Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technologyAkar JG, Hummel JP, Yao X, Sangaralingham L, Dhruva S, Dong J, Ward R, Shah ND, Ross J, Noseworthy PA. Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technology. BMJ Surgery Interventions & Health Technologies 2020, 2: e000058. PMID: 35047796, PMCID: PMC8647613, DOI: 10.1136/bmjsit-2020-000058.
• Reporting of substance use treatment quality in United States adult drug courtsJoudrey PJ, Howell BA, Nyhan K, Moravej A, Doernberg M, Ross JS, Wang EA. Reporting of substance use treatment quality in United States adult drug courts. International Journal Of Drug Policy 2020, 90: 103050. PMID: 33310636, PMCID: PMC8046712, DOI: 10.1016/j.drugpo.2020.103050.
• Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019Johnston JL, Dhruva SS, Ross JS, Rathi VK. Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019. JAMA Internal Medicine 2020, 180: 1701-1703. PMID: 33044513, PMCID: PMC7551221, DOI: 10.1001/jamainternmed.2020.3214.
• Submissions and Downloads of Preprints in the First Year of medRxivKrumholz HM, Bloom T, Sever R, Rawlinson C, Inglis JR, Ross JS. Submissions and Downloads of Preprints in the First Year of medRxiv. JAMA 2020, 324: 1903-1905. PMID: 33170232, PMCID: PMC7656287, DOI: 10.1001/jama.2020.17529.
• Association Between Industry Payments to Physicians and Device Selection in ICD ImplantationAnnapureddy AR, Henien S, Wang Y, Minges KE, Ross JS, Spatz ES, Desai NR, Peterson PN, Masoudi FA, Curtis JP. Association Between Industry Payments to Physicians and Device Selection in ICD Implantation. JAMA 2020, 324: 1755-1764. PMID: 33141208, PMCID: PMC7610190, DOI: 10.1001/jama.2020.17436.
• Mandatory Registration and Results Reporting of Real-World Evidence Studies of FDA-Regulated Medical ProductsDhruva SS, Shah ND, Ross JS. Mandatory Registration and Results Reporting of Real-World Evidence Studies of FDA-Regulated Medical Products. Mayo Clinic Proceedings 2020, 95: 2609-2611. PMID: 33289654, DOI: 10.1016/j.mayocp.2020.04.013.
• Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort studyHwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. The BMJ 2020, 371: m3434. PMID: 33028575, PMCID: PMC7537471, DOI: 10.1136/bmj.m3434.
• Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial FibrillationYao X, Inselman JW, Ross JS, Izem R, Graham DJ, Martin DB, Thompson AM, Ross Southworth M, Siontis KC, Ngufor CG, Nath KA, Desai NR, Nallamothu BK, Saran R, Shah ND, Noseworthy PA. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006515. PMID: 33012172, PMCID: PMC7580213, DOI: 10.1161/circoutcomes.120.006515.
• Transparency and Accountability of Medicaid Section 1115 Waiver Demonstration Programs Under the Affordable Care ActLopez L, Silvestri D, Ross JS. Transparency and Accountability of Medicaid Section 1115 Waiver Demonstration Programs Under the Affordable Care Act. JAMA Network Open 2020, 3: e2022035. PMID: 33104203, PMCID: PMC7588940, DOI: 10.1001/jamanetworkopen.2020.22035.
• Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.govWallach JD, Krystal JH, Ross JS, O’Malley S. Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov. JAMA Psychiatry 2020, 77: 1081-1084. PMID: 32459295, PMCID: PMC7254444, DOI: 10.1001/jamapsychiatry.2020.1167.
• Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin LevelsBrito JP, Ross JS, Sangaralingham L, Dutcher SK, Graham DJ, Wang Z, Wu Y, Yao X, Smallridge RC, Bernet V, Shah ND, Lipska KJ. Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels. JAMA Network Open 2020, 3: e2017645. PMID: 32997127, PMCID: PMC7527873, DOI: 10.1001/jamanetworkopen.2020.17645.
• Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trialsBikdeli B, Caraballo C, Welsh J, Ross JS, Kaul S, Stone GW, Krumholz HM. Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials. Clinical Trials 2020, 17: 723-728. PMID: 32838556, PMCID: PMC8088773, DOI: 10.1177/1740774520949157.
• Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011Rathi VK, Krumholz HM, Masoudi FA, Ross JS. Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011. JAMA Network Open 2020, 3: e2014496. PMID: 32857145, PMCID: PMC7455850, DOI: 10.1001/jamanetworkopen.2020.14496.
• Early experience with the FDA’s Breakthrough Devices programJohnston JL, Dhruva SS, Ross JS, Rathi VK. Early experience with the FDA’s Breakthrough Devices program. Nature Biotechnology 2020, 38: 933-938. PMID: 32704171, DOI: 10.1038/s41587-020-0636-7.
• Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAATalebi R, Redberg RF, Ross JS. Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA. Trials 2020, 21: 675. PMID: 32703252, PMCID: PMC7376878, DOI: 10.1186/s13063-020-04603-9.
• On-Label and Off-Label Clinical Studies of FDA–Approved Ophthalmic TherapeuticsGopal AD, Wallach JD, Shah SA, Regillo C, Ross JS. On-Label and Off-Label Clinical Studies of FDA–Approved Ophthalmic Therapeutics. Ophthalmology 2020, 128: 332-334. PMID: 32682839, PMCID: PMC9900733, DOI: 10.1016/j.ophtha.2020.07.028.
• Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary ConditionsFeder SL, Canavan ME, Wang S, Kent EE, Kapo J, Presley CJ, Ross J, Davidoff AJ. Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. Journal Of Palliative Medicine 2020, 24: 195-204. PMID: 32673139, PMCID: PMC7840305, DOI: 10.1089/jpm.2020.0193.
• The Promise of Big Data and Digital Solutions in Building a Cardiovascular Learning System: Opportunities and Barriers.Mori M, Khera R, Lin Z, Ross JS, Schulz W, Krumholz HM. The Promise of Big Data and Digital Solutions in Building a Cardiovascular Learning System: Opportunities and Barriers. Methodist DeBakey Cardiovascular Journal 2020, 16: 212-219. PMID: 33133357, PMCID: PMC7587314, DOI: 10.14797/mdcj-16-3-212.
• Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015MacGregor A, Zhang AD, Wallach JD, Ross JS, Herder M. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015. JAMA Network Open 2020, 3: e209498. PMID: 32706379, PMCID: PMC7382003, DOI: 10.1001/jamanetworkopen.2020.9498.
• Assessment of Preprint Policies of Top-Ranked Clinical JournalsMassey DS, Opare MA, Wallach JD, Ross JS, Krumholz HM. Assessment of Preprint Policies of Top-Ranked Clinical Journals. JAMA Network Open 2020, 3: e2011127. PMID: 32697320, PMCID: PMC7376388, DOI: 10.1001/jamanetworkopen.2020.11127.
• Assessment of Health Status and Barriers to Employment Among Medicaid Beneficiaries Not Meeting Work Requirements After Accounting for State Medical Frailty ExemptionsSilvestri DM, Gluck AR, Ross JS. Assessment of Health Status and Barriers to Employment Among Medicaid Beneficiaries Not Meeting Work Requirements After Accounting for State Medical Frailty Exemptions. JAMA Internal Medicine 2020, 180: 1008-1010. PMID: 32364563, PMCID: PMC7199172, DOI: 10.1001/jamainternmed.2020.1039.
• Gout Treatment in the USA from 2009 to 2016: A Repeated Cross-sectional AnalysisChock YP, Ross JS, Suter LG, Rhee TG. Gout Treatment in the USA from 2009 to 2016: A Repeated Cross-sectional Analysis. Journal Of General Internal Medicine 2020, 36: 1134-1136. PMID: 32524250, PMCID: PMC8041910, DOI: 10.1007/s11606-020-05942-8.
• 38-OR: Differences in Diabetes Medication Use between Commercial and Medicare Advantage Beneficiaries, 2013-2018MCCOY R, HOUTEN H, ROSS J, KARACA-MANDIC P, MONTORI V, SHAH N. 38-OR: Differences in Diabetes Medication Use between Commercial and Medicare Advantage Beneficiaries, 2013-2018. Diabetes 2020, 69 DOI: 10.2337/db20-38-or.
• 1548-P: Changes in Glucose-Lowering Medication Use in the Era of Cardiovascular Outcomes Trials: Risk/Treatment Paradox PersistsMCCOY R, HOUTEN H, ROSS J, KARACA-MANDIC P, MONTORI V, SHAH N. 1548-P: Changes in Glucose-Lowering Medication Use in the Era of Cardiovascular Outcomes Trials: Risk/Treatment Paradox Persists. Diabetes 2020, 69 DOI: 10.2337/db20-1548-p.
• 1157-P: Out-of-Pocket and Health Plan Spending on Diabetes Drugs, 2006-2018LIPSKA K, MCCOY R, HOUTEN H, YAO X, ROSS J, ALTAN A, SHAH N. 1157-P: Out-of-Pocket and Health Plan Spending on Diabetes Drugs, 2006-2018. Diabetes 2020, 69 DOI: 10.2337/db20-1157-p.
• Medical Crowdfunding for Abortion Services [27I]Solotke M, Ross J, Cron J. Medical Crowdfunding for Abortion Services [27I]. Obstetrics And Gynecology 2020, 135: 98s-99s. DOI: 10.1097/01.aog.0000664196.01993.4e.
• Abstract 345: Non-inferiority Trials With a Primary Surrogate Endpoint: An Increasing Phenotype in Cardiovascular TrialsCaraballo C, Bikdeli B, Welsh J, Ross J, Kaul S, Stone G, Krumholz H. Abstract 345: Non-inferiority Trials With a Primary Surrogate Endpoint: An Increasing Phenotype in Cardiovascular Trials. Circulation Cardiovascular Quality And Outcomes 2020, 13 DOI: 10.1161/hcq.13.suppl_1.345.
• Availability of Telemedicine Services Across Hospitals in the United States in 2018: A Cross-sectional StudyJain S, Khera R, Lin Z, Ross JS, Krumholz HM. Availability of Telemedicine Services Across Hospitals in the United States in 2018: A Cross-sectional Study. Annals Of Internal Medicine 2020, 173: m20-1201. PMID: 32353106, PMCID: PMC7212823, DOI: 10.7326/m20-1201.
• Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harmSmith LB, Desai NR, Dowd B, Everhart A, Herrin J, Higuera L, Jeffery MM, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm. International Journal Of Health Economics And Management 2020, 20: 299-317. PMID: 32350680, PMCID: PMC7725279, DOI: 10.1007/s10754-020-09282-2.
• Aggregating multiple real-world data sources using a patient-centered health-data-sharing platformDhruva SS, Ross JS, Akar JG, Caldwell B, Childers K, Chow W, Ciaccio L, Coplan P, Dong J, Dykhoff HJ, Johnston S, Kellogg T, Long C, Noseworthy PA, Roberts K, Saha A, Yoo A, Shah ND. Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. Npj Digital Medicine 2020, 3: 60. PMID: 32352038, PMCID: PMC7170944, DOI: 10.1038/s41746-020-0265-z.
• Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials—a brave new worldRoss JS, Dhruva SS, Shah ND. Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials—a brave new world. Clinical Trials 2020, 17: 243-246. PMID: 32266836, DOI: 10.1177/1740774520913850.
• Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017Zhang AD, Puthumana J, Downing NS, Shah ND, Krumholz HM, Ross JS. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. JAMA Network Open 2020, 3: e203284. PMID: 32315070, PMCID: PMC7175081, DOI: 10.1001/jamanetworkopen.2020.3284.
• Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender IndividualsSolotke MT, Liu P, Dhruva SS, Gulanski B, Shah ND, Ross JS. Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender Individuals. LGBT Health 2020, 7: 137-145. PMID: 32267818, DOI: 10.1089/lgbt.2019.0306.
• Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017Bartlett VL, Liu P, Dhruva SS, Shah ND, Bollinger KE, Ross JS. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017. Journal Of Managed Care & Specialty Pharmacy 2020, 26: 10.18553/jmcp.2020.26.4.562. PMID: 32223594, PMCID: PMC10391193, DOI: 10.18553/jmcp.2020.26.4.562.
• Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measuresBrandt EJ, Ross JS, Grady JN, Ahmad T, Pawar S, Bernheim SM, Desai NR. Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures. PLOS ONE 2020, 15: e0230734. PMID: 32214363, PMCID: PMC7098556, DOI: 10.1371/journal.pone.0230734.
• Time for NIH to lead on data sharingSim I, Stebbins M, Bierer BE, Butte AJ, Drazen J, Dzau V, Hernandez AF, Krumholz HM, Lo B, Munos B, Perakslis E, Rockhold F, Ross JS, Terry SF, Yamamoto KR, Zarin DA, Li R. Time for NIH to lead on data sharing. Science 2020, 367: 1308-1309. PMID: 32193313, DOI: 10.1126/science.aba4456.
• Conflicts of Interest Among Authors of Published Cannabidiol Articles, 2014-2019.Deary EC, Ross JS, Nyhan K, Wallach JD. Conflicts of Interest Among Authors of Published Cannabidiol Articles, 2014-2019. Annals Of Internal Medicine 2020, 172: 769-771. PMID: 32176891, DOI: 10.7326/m19-3650.
• Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart diseaseWallach JD, Serghiou S, Chu L, Egilman AC, Vasiliou V, Ross JS, Ioannidis JPA. Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease. BMC Medical Research Methodology 2020, 20: 64. PMID: 32171256, PMCID: PMC7071725, DOI: 10.1186/s12874-020-0914-6.
• Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017.Liu P, Dhruva SS, Shah ND, Ross JS. Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017. The American Journal Of Managed Care 2020, 26: 112-117. PMID: 32181626, DOI: 10.37765/ajmc.2020.42635.
• Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic ShockDhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, Berkowitz A, Masoudi FA, Messenger JC, Parzynski CS, Ngufor C, Girotra S, Amin AP, Shah ND, Desai NR. Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA 2020, 323: 734-745. PMID: 32040163, PMCID: PMC7042879, DOI: 10.1001/jama.2020.0254.
• Exploring crowdfunding campaigns for abortion servicesSolotke MT, Brussel Faria N, Karim H, Roy S, Ross JS, Cron J. Exploring crowdfunding campaigns for abortion services. Contraception 2020, 102: 18-22. PMID: 32105655, DOI: 10.1016/j.contraception.2020.02.008.
• Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims DataDhruva SS, Parzynski CS, Gamble GM, Curtis JP, Desai NR, Yeh RW, Masoudi FA, Kuntz R, Shaw RE, Marinac‐Dabic D, Sedrakyan A, Normand S, Krumholz HM, Ross JS. Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. Journal Of The American Heart Association 2020, 9: e013606. PMID: 32063087, PMCID: PMC7070203, DOI: 10.1161/jaha.119.013606.
• Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analysesWallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.
• Clinical Outcomes With Beta-Blocker Use in Patients With Recent History of Myocardial InfarctionJackevicius CA, Krumholz HM, Ross JS, Koh M, Chong A, Austin PC, Stukel TA, Azizi P, Ko DT. Clinical Outcomes With Beta-Blocker Use in Patients With Recent History of Myocardial Infarction. Canadian Journal Of Cardiology 2020, 36: 1633-1640. PMID: 32416066, DOI: 10.1016/j.cjca.2020.01.024.
• Confidentiality Orders and Public Interest in Drug and Medical Device LitigationEgilman AC, Kesselheim AS, Krumholz HM, Ross JS, Kim J, Kapczynski A. Confidentiality Orders and Public Interest in Drug and Medical Device Litigation. JAMA Internal Medicine 2020, 180: 292-299. PMID: 31657836, DOI: 10.1001/jamainternmed.2019.5161.
• Patterns of Opioid Prescribing Among Patients with Pain and Cardiopulmonary Conditions (S763)Feder S, Canavan M, Sheinfeld E, Kapo J, Wang S, Kent E, Presley C, Ross J, Davidoff A. Patterns of Opioid Prescribing Among Patients with Pain and Cardiopulmonary Conditions (S763). Journal Of Pain And Symptom Management 2020, 59: 565. DOI: 10.1016/j.jpainsymman.2019.12.324.
• Vibration of effects in epidemiologic studies of alcohol consumption and breast cancer risk.Chu L, Ioannidis JPA, Egilman AC, Vasiliou V, Ross JS, Wallach JD. Vibration of effects in epidemiologic studies of alcohol consumption and breast cancer risk. International Journal Of Epidemiology 2020, 49: 608-618. PMID: 31967637, PMCID: PMC7266551, DOI: 10.1093/ije/dyz271.
• Impact of US industry payment disclosure laws on payments to surgeons: a natural experimentRhee TG, Stanic T, Ross JS. Impact of US industry payment disclosure laws on payments to surgeons: a natural experiment. Research Integrity And Peer Review 2020, 5: 1. PMID: 31911843, PMCID: PMC6942346, DOI: 10.1186/s41073-019-0087-1.
• The Human Costs of Medicare Fraud and AbuseRoss JS. The Human Costs of Medicare Fraud and Abuse. JAMA Internal Medicine 2020, 180: 69-69. PMID: 31657845, DOI: 10.1001/jamainternmed.2019.5004.
• Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolismBikdeli B, Wang Y, Jimenez D, Ross JS, Gupta A, Desai MM, Parikh SA, Monreal M, Goldhaber SZ, Krumholz HM. Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. Thrombosis Research 2019, 186: 78-79. PMID: 31901644, DOI: 10.1016/j.thromres.2019.12.020.
• Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017Egilman AC, Wallach JD, Morten CJ, Lurie P, Ross JS. Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017. Research Integrity And Peer Review 2019, 4: 26. PMID: 31867126, PMCID: PMC6900838, DOI: 10.1186/s41073-019-0086-2.
• Availability of Grocery Delivery to Food Deserts in States Participating in the Online Purchase PilotBrandt EJ, Silvestri DM, Mande JR, Holland ML, Ross JS. Availability of Grocery Delivery to Food Deserts in States Participating in the Online Purchase Pilot. JAMA Network Open 2019, 2: e1916444. PMID: 31790562, PMCID: PMC6902750, DOI: 10.1001/jamanetworkopen.2019.16444.
• Digital medicine systems: an evergreening strategy or an advance in medication management?Egilman AC, Ross JS. Digital medicine systems: an evergreening strategy or an advance in medication management? BMJ Evidence-Based Medicine 2019, 24: 203. PMID: 31754072, DOI: 10.1136/bmjebm-2019-111265.
• The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.Kent DM, van Klaveren D, Paulus JK, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. Annals Of Internal Medicine 2019, 172: w1-w25. PMID: 31711094, PMCID: PMC7750907, DOI: 10.7326/m18-3668.
• The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement.Kent DM, Paulus JK, van Klaveren D, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. Annals Of Internal Medicine 2019, 172: 35-45. PMID: 31711134, PMCID: PMC7531587, DOI: 10.7326/m18-3667.
• Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviewsLiu P, Ross JS, Ioannidis JP, Dhruva SS, Vasiliou V, Wallach JD. Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews. Clinical Trials 2019, 17: 231-234. PMID: 31709809, DOI: 10.1177/1740774519887148.
• Evidence Supporting US Food and Drug Administration Drug Safety CommunicationsRoss JS. Evidence Supporting US Food and Drug Administration Drug Safety Communications. JAMA Internal Medicine 2019, 179: 1592-1592. PMID: 31479098, DOI: 10.1001/jamainternmed.2019.3065.
• Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.Solotke MT, Ross JS, Shah ND, Karaca-Mandic P, Dhruva SS. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings. Journal Of Managed Care & Specialty Pharmacy 2019, 25: 1201-1217. PMID: 31663461, PMCID: PMC10397710, DOI: 10.18553/jmcp.2019.25.11.1201.
• Accidental drug overdose deaths in Connecticut, 2012–2018: The rise of polysubstance detection?Rhee TG, Ross JS, Rosenheck RA, Grau LE, Fiellin DA, Becker WC. Accidental drug overdose deaths in Connecticut, 2012–2018: The rise of polysubstance detection? Drug And Alcohol Dependence 2019, 205: 107671. PMID: 31706248, DOI: 10.1016/j.drugalcdep.2019.107671.
• Modernizing the FDA’s 510(k) PathwayRathi VK, Ross JS. Modernizing the FDA’s 510(k) Pathway. New England Journal Of Medicine 2019, 381: 1891-1893. PMID: 31644865, DOI: 10.1056/nejmp1908654.
• Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological studyLiu P, Ioannidis JPA, Ross JS, Dhruva SS, Luxkaranayagam AT, Vasiliou V, Wallach JD. Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study. BMC Medicine 2019, 17: 188. PMID: 31639007, PMCID: PMC6805640, DOI: 10.1186/s12916-019-1420-8.
• Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable GenericsVijay A, Gupta R, Liu P, Dhruva SS, Shah ND, Ross JS. Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics. Journal Of General Internal Medicine 2019, 35: 1928-1930. PMID: 31625043, PMCID: PMC7280368, DOI: 10.1007/s11606-019-05432-6.
• Home Health Care After Skilled Nursing Facility Discharge Following Heart Failure HospitalizationWeerahandi H, Bao H, Herrin J, Dharmarajan K, Ross JS, Jones S, Horwitz LI. Home Health Care After Skilled Nursing Facility Discharge Following Heart Failure Hospitalization. Journal Of The American Geriatrics Society 2019, 68: 96-102. PMID: 31603248, PMCID: PMC6964248, DOI: 10.1111/jgs.16179.
• Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort StudyMcCoy R, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, Shah N. Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technology & Therapeutics 2019, 21: 702-712. PMID: 31418588, PMCID: PMC7207017, DOI: 10.1089/dia.2019.0213.
• Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016Kahn PA, Dhruva SS, Rhee TG, Ross JS. Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016. JAMA Network Open 2019, 2: e1913298. PMID: 31617923, PMCID: PMC6806423, DOI: 10.1001/jamanetworkopen.2019.13298.
• Feasibility of Using Real-World Data to Replicate Clinical Trial EvidenceBartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS. Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence. JAMA Network Open 2019, 2: e1912869. PMID: 31596493, PMCID: PMC6802419, DOI: 10.1001/jamanetworkopen.2019.12869.
• Characteristics of Recent Generic Drug Approvals by the US Food and Drug AdministrationJiao K, Gupta R, Fox E, Kesselheim A, Ross JS. Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration. JAMA Network Open 2019, 2: e1913029. PMID: 31603482, PMCID: PMC6804024, DOI: 10.1001/jamanetworkopen.2019.13029.
• Association Between Industry Payments to Physicians and Gabapentinoid PrescribingRhee TG, Ross JS. Association Between Industry Payments to Physicians and Gabapentinoid Prescribing. JAMA Internal Medicine 2019, 179: 1425-1428. PMID: 31282922, PMCID: PMC6618850, DOI: 10.1001/jamainternmed.2019.1082.
• Clinical Trial Evidence for the Real WorldRoss JS, Covinsky K. Clinical Trial Evidence for the Real World. JAMA Internal Medicine 2019, 179: 1333-1334. PMID: 31282933, DOI: 10.1001/jamainternmed.2019.1500.
• Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline UpdatesDayoub EJ, Ross JS, Shah ND, Dhruva SS. Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates. Circulation 2019, 140: 1227-1230. PMID: 31567008, DOI: 10.1161/circulationaha.119.040580.
• Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year AssessmentDuBose‐Briski V, Yao X, Dunlay SM, Dhruva SS, Ross JS, Shah ND, Noseworthy PA. Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year Assessment. Journal Of The American Heart Association 2019, 8: e012065. PMID: 31566106, PMCID: PMC6806052, DOI: 10.1161/jaha.119.012065.
• Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trialsBrennan JM, Wruck L, Pencina MJ, Clare RM, Lopes RD, Alexander JH, O'Brien S, Krucoff M, Rao SV, Wang TY, Curtis LH, Newby LK, Granger CB, Patel M, Mahaffey K, Ross JS, Normand SL, Eloff BC, Caños DA, Lokhnygina YV, Roe MT, Califf RM, Marinac-Dabic D, Peterson ED. Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. American Heart Journal 2019, 218: 110-122. PMID: 31726314, DOI: 10.1016/j.ahj.2019.09.002.
• Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors.Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors. Annals Of Internal Medicine 2019, 171: 521-523. PMID: 31404926, DOI: 10.7326/m19-1085.
• Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016Jeffery MM, Hooten WM, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016. JAMA Network Open 2019, 2: e198325. PMID: 31373650, PMCID: PMC6681551, DOI: 10.1001/jamanetworkopen.2019.8325.
• Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment AgenciesEgilman AC, Wallach JD, Dhruva SS, Gonsalves GS, Ross JS. Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies. Journal Of General Internal Medicine 2019, 34: 2319-2321. PMID: 31313117, PMCID: PMC6848610, DOI: 10.1007/s11606-019-05149-6.
• The Bleeding EdgePendyal A, Ross JS. The Bleeding Edge. JAMA 2019, 322: 190-192. PMID: 31310276, DOI: 10.1001/jama.2019.8147.
• Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008–2015ZHANG AD, SCHWARTZ JL, ROSS JS. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008–2015. Milbank Quarterly 2019, 97: 796-819. PMID: 31304643, PMCID: PMC6739629, DOI: 10.1111/1468-0009.12403.
• Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practicesMiller J, Ross JS, Wilenzick M, Mello MM. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. The BMJ 2019, 366: l4217. PMID: 31292127, PMCID: PMC6614834, DOI: 10.1136/bmj.l4217.
• Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing.Kuntz RE, Antman EM, Califf RM, Ingelfinger JR, Krumholz HM, Ommaya A, Peterson ED, Ross JS, Waldstreicher J, Wang SV, Zarin DA, Whicher DM, Siddiqi SM, Lopez MH. Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing. NAM Perspectives 2019, 2019 PMID: 34532668, PMCID: PMC8406566, DOI: 10.31478/201906b.
• Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysisWallach JD, Luxkaranayagam AT, Dhruva SS, Miller JE, Ross JS. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis. BMC Medicine 2019, 17: 117. PMID: 31203816, PMCID: PMC6572730, DOI: 10.1186/s12916-019-1344-3.
• Noninferiority Designed Cardiovascular Trials in Highest-Impact JournalsBikdeli B, Welsh JW, Akram Y, Punnanithinont N, Lee I, Desai NR, Kaul S, Stone G, Ross JS, Krumholz HM. Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals. Circulation 2019, 140: 379-389. PMID: 31177811, PMCID: PMC8416048, DOI: 10.1161/circulationaha.119.040214.
• Adverse Effects of Pharmacologic Treatments of Major Depression in Older AdultsSobieraj DM, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC, Baker WL. Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults. Journal Of The American Geriatrics Society 2019, 67: 1571-1581. PMID: 31140587, DOI: 10.1111/jgs.15966.
• Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or CommitmentsSkydel JJ, Luxkaranayagam AT, Dhruva SS, Ross JS, Wallach JD. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments. JAMA Network Open 2019, 2: e193410. PMID: 31074812, PMCID: PMC6512282, DOI: 10.1001/jamanetworkopen.2019.3410.
• Association Between Insurance Status and Access to Hospital Care in Emergency Department DispositionVenkatesh AK, Chou SC, Li SX, Choi J, Ross JS, D’Onofrio G, Krumholz HM, Dharmarajan K. Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition. JAMA Internal Medicine 2019, 179: 686-693. PMID: 30933243, PMCID: PMC6503571, DOI: 10.1001/jamainternmed.2019.0037.
• Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority TrialsRoss JS, Wee CC. Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority Trials. JAMA Internal Medicine 2019, 179: 721-722. PMID: 30830205, DOI: 10.1001/jamainternmed.2018.8019.
• Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of OpioidsFleischman W, Agrawal S, Gross CP, Ross JS. Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids. Journal Of General Internal Medicine 2019, 34: 1074-1076. PMID: 31011967, PMCID: PMC6614247, DOI: 10.1007/s11606-019-04897-9.
• Risk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort StudyWeerahandi H, Li L, Bao H, Herrin J, Dharmarajan K, Ross JS, Kim KL, Jones S, Horwitz LI. Risk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort Study. Journal Of The American Medical Directors Association 2019, 20: 432-437. PMID: 30954133, PMCID: PMC6486375, DOI: 10.1016/j.jamda.2019.01.135.
• On the Need for (Only) High-Quality Clinical Practice GuidelinesIncze M, Ross JS. On the Need for (Only) High-Quality Clinical Practice Guidelines. JAMA Internal Medicine 2019, 179: 561-561. PMID: 30776052, DOI: 10.1001/jamainternmed.2018.7471.
• Abstract 216: Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies after Guideline RevisionsDayoub E, Dhruva S, Ross J. Abstract 216: Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies after Guideline Revisions. Circulation Cardiovascular Quality And Outcomes 2019, 12 DOI: 10.1161/hcq.12.suppl_1.216.
• Abstract 11: Comparative Effectiveness and Safety of Oral Anticoagulants across Baseline Kidney FunctionYao X, Inselman J, Shah N, Ross J, Izem R, Graham D, Martin D, Thompson A, Southworth M, Siontis K, Ngufor C, Nath K, Desai N, Nallamothu B, Saran R, Noseworthy P. Abstract 11: Comparative Effectiveness and Safety of Oral Anticoagulants across Baseline Kidney Function. Circulation Cardiovascular Quality And Outcomes 2019, 12 DOI: 10.1161/hcq.12.suppl_1.11.
• Kept in the dark: Scotland rejects “sunshine” legislationRoss JS. Kept in the dark: Scotland rejects “sunshine” legislation. The BMJ 2019, 364: l1379. PMID: 30926587, DOI: 10.1136/bmj.l1379.
• Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluationJackevicius CA, An J, Ko DT, Ross JS, Angraal S, Wallach JD, Koh M, Song J, Krumholz HM. Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation. BMJ Open 2019, 9: e025936. PMID: 30904868, PMCID: PMC6475140, DOI: 10.1136/bmjopen-2018-025936.
• U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015Vijay A, Rhee TG, Ross JS. U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015. Preventive Medicine 2019, 123: 123-129. PMID: 30894321, PMCID: PMC6534435, DOI: 10.1016/j.ypmed.2019.03.022.
• Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl PrescribingFleischman W, Auth D, Shah ND, Agrawal S, Ross JS. Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing. JAMA Network Open 2019, 2: e191340. PMID: 30924899, PMCID: PMC6450314, DOI: 10.1001/jamanetworkopen.2019.1340.
• PULMONARY EMBOLISM HOSPITALIZATIONS AND USE OF INFERIOR VENA CAVAL FILTERS IN OLDER ADULTS: NATIONAL STUDY OF MEDICARE BENEFICIARIESBikdeli B, Wang Y, Jimenez D, Ross J, Desai M, Parikh S, Monreal M, Goldhaber S, Krumholz H. PULMONARY EMBOLISM HOSPITALIZATIONS AND USE OF INFERIOR VENA CAVAL FILTERS IN OLDER ADULTS: NATIONAL STUDY OF MEDICARE BENEFICIARIES. Journal Of The American College Of Cardiology 2019, 73: 2042. DOI: 10.1016/s0735-1097(19)32648-8.
• NON-INFERIORITY TRIALS WITH A PRIMARY SURROGATE ENDPOINT: AN INCREASING PHENOTYPE IN CARDIOVASCULAR TRIALSBikdeli B, Caraballo-Cordovez C, Welsh J, Ross J, Stone G, Krumholz H. NON-INFERIORITY TRIALS WITH A PRIMARY SURROGATE ENDPOINT: AN INCREASING PHENOTYPE IN CARDIOVASCULAR TRIALS. Journal Of The American College Of Cardiology 2019, 73: 1838. DOI: 10.1016/s0735-1097(19)32444-1.
• LINKING THE NCDR CATHPCI REGISTRY WITH ADMINISTRATIVE CLAIMS TO DETERMINE ATTRIBUTION OF REPEAT REVASCULARIZATION FOLLOWING INDEX DRUG-ELUTING STENT IMPLANTATIONDhruva S, Parzynski C, Curtis J, Desai N, Yeh R, Masoudi F, Normand S, Kuntz R, Shaw R, Marinac-Dabic D, Krumholz H, Ross J. LINKING THE NCDR CATHPCI REGISTRY WITH ADMINISTRATIVE CLAIMS TO DETERMINE ATTRIBUTION OF REPEAT REVASCULARIZATION FOLLOWING INDEX DRUG-ELUTING STENT IMPLANTATION. Journal Of The American College Of Cardiology 2019, 73: 1113. DOI: 10.1016/s0735-1097(19)31720-6.
• EVOLUTION OF THE AMERICAN COLLEGE OF CARDIOLOGY AND THE AMERICAN HEART ASSOCIATION CARDIOLOGY CLINICAL PRACTICE GUIDELINES: A 10-YEAR ASSESSMENTDubose-Briski V, Yao X, Dunlay S, Dhruva S, Ross J, Shah N, Noseworthy P. EVOLUTION OF THE AMERICAN COLLEGE OF CARDIOLOGY AND THE AMERICAN HEART ASSOCIATION CARDIOLOGY CLINICAL PRACTICE GUIDELINES: A 10-YEAR ASSESSMENT. Journal Of The American College Of Cardiology 2019, 73: 3028. DOI: 10.1016/s0735-1097(19)33634-4.
• Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary EmbolismBikdeli B, Wang Y, Jimenez D, Ross JS, Monreal M, Goldhaber SZ, Krumholz HM. Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. JAMA Internal Medicine 2019, 179: 263-265. PMID: 30535318, PMCID: PMC6439651, DOI: 10.1001/jamainternmed.2018.5287.
• Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016.Ross JS, Rohde S, Sangaralingham L, Brito JP, Choi L, Dutcher SK, Graham DJ, Jenkins MR, Lipska KJ, Mendoza M, Qiang Y, Wang Z, Wu Y, Yao X, Shah ND. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 2305-2314. PMID: 30690529, DOI: 10.1210/jc.2018-02197.
• Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and OutcomesChui PW, Parzynski CS, Ross JS, Desai NR, Gurm HS, Spertus JA, Seto AH, Ho V, Curtis JP. Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. Journal Of The American Heart Association 2019, 8: e010373. PMID: 30642222, PMCID: PMC6497347, DOI: 10.1161/jaha.118.010373.
• Generic Drugs in the United States: Policies to Address Pricing and CompetitionGupta R, Shah ND, Ross JS. Generic Drugs in the United States: Policies to Address Pricing and Competition. Clinical Pharmacology & Therapeutics 2019, 105: 329-337. PMID: 30471089, PMCID: PMC6355356, DOI: 10.1002/cpt.1314.
• Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017Vijay A, Ross JS, Shah ND, Jeffery MM, Dhruva SS. Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017. Journal Of General Internal Medicine 2019, 34: 518-520. PMID: 30623386, PMCID: PMC6445908, DOI: 10.1007/s11606-018-4752-8.
• Coordinating Clinical Trials to Confirm Drug Safety and Efficacy-Resolving Uncertainty.Ross JS. Coordinating Clinical Trials to Confirm Drug Safety and Efficacy-Resolving Uncertainty. JAMA Internal Medicine 2019, 179: 98. PMID: 30477007, DOI: 10.1001/jamainternmed.2018.6037.
• The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn LitigationMorten CJ, Kesselheim AS, Ross JS. The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation. The Journal Of Law, Medicine & Ethics 2019, 47: 783-787. PMID: 31957583, DOI: 10.1177/1073110519897793.
• Biomarkers as Surrogate Endpoints: Ongoing Opportunities for ValidationZhang AD, Ross JS. Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation. The Journal Of Law, Medicine & Ethics 2019, 47: 393-395. PMID: 31560627, DOI: 10.1177/1073110519876170.
• Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional AnalysisWallach JD, Egilman AC, Ross JS, Woloshin S, Schwartz LM. Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis. Journal Of General Internal Medicine 2018, 34: 492-495. PMID: 30543020, PMCID: PMC6445841, DOI: 10.1007/s11606-018-4779-x.
• Weighing the Harms and Benefits of Using Statins for Primary Prevention: Raising the Risk Threshold.Richman IB, Ross JS. Weighing the Harms and Benefits of Using Statins for Primary Prevention: Raising the Risk Threshold. Annals Of Internal Medicine 2018, 170: 62-63. PMID: 30508426, DOI: 10.7326/m18-3066.
• Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA ApprovalShaw DL, Dhruva SS, Ross JS. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval. Journal Of Managed Care & Specialty Pharmacy 2018, 24: 10.18553/jmcp.2018.24.12.1230. PMID: 30479199, PMCID: PMC10397592, DOI: 10.18553/jmcp.2018.24.12.1230.
• Overview and experience of the YODA Project with clinical trial data sharing after 5 yearsRoss JS, Waldstreicher J, Bamford S, Berlin JA, Childers K, Desai NR, Gamble G, Gross CP, Kuntz R, Lehman R, Lins P, Morris SA, Ritchie JD, Krumholz HM. Overview and experience of the YODA Project with clinical trial data sharing after 5 years. Scientific Data 2018, 5: 180268. PMID: 30480665, PMCID: PMC6257043, DOI: 10.1038/sdata.2018.268.
• Breakthrough Therapy Designation for New Drugs-Reply.Puthumana J, Wallach JD, Ross JS. Breakthrough Therapy Designation for New Drugs-Reply. JAMA 2018, 320: 2042-2043. PMID: 30458490, DOI: 10.1001/jama.2018.15942.
• Clinical Trials-We Get What We Pay For.Ross JS. Clinical Trials-We Get What We Pay For. JAMA Internal Medicine 2018, 178: 1457. PMID: 30264093, DOI: 10.1001/jamainternmed.2018.3930.
• Emergency Department Volume and Outcomes for Patients After Chest Pain AssessmentKo DT, Dattani ND, Austin PC, Schull MJ, Ross JS, Wijeysundera HC, Tu JV, Eberg M, Koh M, Krumholz HM. Emergency Department Volume and Outcomes for Patients After Chest Pain Assessment. Circulation Cardiovascular Quality And Outcomes 2018, 11: e004683. PMID: 30354285, DOI: 10.1161/circoutcomes.118.004683.
• State-Level Population Estimates of Individuals Subject to and Not Meeting Proposed Medicaid Work Requirements.Silvestri DM, Holland ML, Ross JS. State-Level Population Estimates of Individuals Subject to and Not Meeting Proposed Medicaid Work Requirements. JAMA Internal Medicine 2018, 178: 1552-1555. PMID: 30208409, PMCID: PMC6248197, DOI: 10.1001/jamainternmed.2018.4196.
• Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort studyZou CX, Becker JE, Phillips AT, Garritano JM, Krumholz HM, Miller JE, Ross JS. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials 2018, 19: 581. PMID: 30352601, PMCID: PMC6199729, DOI: 10.1186/s13063-018-2957-0.
• Alirocumab’s Price ReductionDhruva SS, Ross JS, Desai NR. Alirocumab’s Price Reduction. Circulation 2018, 138: 1502-1504. PMID: 30354510, DOI: 10.1161/circulationaha.118.036069.
• Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016Roginiel AC, Dhruva SS, Ross JS. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016. Medicine 2018, 97: e12715. PMID: 30290675, PMCID: PMC6200488, DOI: 10.1097/md.0000000000012715.
• Will research preprints improve healthcare for patients?Krumholz HM, Ross JS, Otto CM. Will research preprints improve healthcare for patients? The BMJ 2018, 362: k3628. PMID: 30249719, DOI: 10.1136/bmj.k3628.
• Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and PneumoniaDowning NS, Wang C, Gupta A, Wang Y, Nuti SV, Ross JS, Bernheim SM, Lin Z, Normand ST, Krumholz HM. Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia. JAMA Network Open 2018, 1: e182044. PMID: 30646146, PMCID: PMC6324513, DOI: 10.1001/jamanetworkopen.2018.2044.
• Adherence to the International Committee of Medical Journal Editors’ (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journalsGopal AD, Wallach JD, Aminawung JA, Gonsalves G, Dal-Ré R, Miller JE, Ross JS. Adherence to the International Committee of Medical Journal Editors’ (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals. Trials 2018, 19: 448. PMID: 30134950, PMCID: PMC6106722, DOI: 10.1186/s13063-018-2825-y.
• Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical TrialsO’Connor J, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology 2018, 4: e180798-e180798. PMID: 29800974, PMCID: PMC6143052, DOI: 10.1001/jamaoncol.2018.0798.
• Age of Data at the Time of Publication of Contemporary Clinical TrialsWelsh J, Lu Y, Dhruva SS, Bikdeli B, Desai NR, Benchetrit L, Zimmerman CO, Mu L, Ross JS, Krumholz HM. Age of Data at the Time of Publication of Contemporary Clinical Trials. JAMA Network Open 2018, 1: e181065-e181065. PMID: 30646100, PMCID: PMC6324269, DOI: 10.1001/jamanetworkopen.2018.1065.
• Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort studyJeffery MM, Hooten WM, Henk HJ, Bellolio MF, Hess EP, Meara E, Ross JS, Shah ND. Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study. The BMJ 2018, 362: k2833. PMID: 30068513, PMCID: PMC6066997, DOI: 10.1136/bmj.k2833.
• Real-World Evidence: Promise and Peril For Medical Product Evaluation.Dhruva SS, Ross JS, Desai NR. Real-World Evidence: Promise and Peril For Medical Product Evaluation. P & T : A Peer-reviewed Journal For Formulary Management 2018, 43: 464-472. PMID: 30100687, PMCID: PMC6065494.
• Medicare Beneficiary Out-of-Pocket Costs for Generic Cardiovascular Medications Available Through $4 Generic Drug Discount Programs.Liu P, Dhruva SS, Shah ND, Ross JS. Medicare Beneficiary Out-of-Pocket Costs for Generic Cardiovascular Medications Available Through $4 Generic Drug Discount Programs. Annals Of Internal Medicine 2018, 169: 817-819. PMID: 30039170, DOI: 10.7326/m18-0965.
• Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial populationWarner F, Dhruva SS, Ross JS, Dey P, Murugiah K, Krumholz HM. Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. BMJ Open 2018, 8: e021685. PMID: 30037874, PMCID: PMC6059296, DOI: 10.1136/bmjopen-2018-021685.
• Patterns and predictors of off-label prescription of psychiatric drugsVijay A, Becker JE, Ross JS. Patterns and predictors of off-label prescription of psychiatric drugs. PLOS ONE 2018, 13: e0198363. PMID: 30024873, PMCID: PMC6053129, DOI: 10.1371/journal.pone.0198363.
• Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy DesignationPuthumana J, Wallach JD, Ross JS. Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation. JAMA 2018, 320: 301-303. PMID: 30027239, PMCID: PMC6583484, DOI: 10.1001/jama.2018.7619.
• Off-label Use of Medications—ReplyWallach JD, Ross JS. Off-label Use of Medications—Reply. JAMA 2018, 320: 307-308. PMID: 30027247, DOI: 10.1001/jama.2018.6521.
• Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators.Tannenbaum S, Ross JS, Krumholz HM, Desai NR, Ritchie JD, Lehman R, Gamble GM, Bachand J, Schroter S, Groves T, Gross CP. Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators. Annals Of Internal Medicine 2018, 169: 586-588. PMID: 30014127, DOI: 10.7326/m18-0723.
• Disparities in the Use of Programmed Death 1 Immune Checkpoint InhibitorsO'Connor JM, Seidl‐Rathkopf K, Torres AZ, You P, Carson KR, Ross JS, Gross CP. Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. The Oncologist 2018, 23: 1388-1390. PMID: 30012876, PMCID: PMC6291337, DOI: 10.1634/theoncologist.2017-0673.
• The Early Impact of Medicaid Expansion on Uninsured Patients Undergoing Emergency General SurgeryChiu AS, Jean RA, Ross JS, Pei KY. The Early Impact of Medicaid Expansion on Uninsured Patients Undergoing Emergency General Surgery. Journal Of Surgical Research 2018, 232: 217-226. PMID: 30463721, DOI: 10.1016/j.jss.2018.06.037.
• Publication and Dissemination of Results in Clinical Trials of NeurologySreekrishnan A, Mampre D, Ormseth C, Miyares L, Leasure A, Ross JS, Sheth KN. Publication and Dissemination of Results in Clinical Trials of Neurology. JAMA Neurology 2018, 75: 890-891. PMID: 29710083, PMCID: PMC6145765, DOI: 10.1001/jamaneurol.2018.0674.
• The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH dataWilcox MA, Savitz AJ, Addington AM, Gray GS, Guinan EC, Jackson JW, Lehner T, Normand SL, Ranu H, Senthil G, Spertus J, Valeri L, Ross JS. The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data. Schizophrenia 2018, 4: 14. PMID: 29950580, PMCID: PMC6021398, DOI: 10.1038/s41537-018-0055-7.
• Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillatorsBates J, Parzynski CS, Dhruva SS, Coppi A, Kuntz R, Li S, Marinac‐Dabic D, Masoudi FA, Shaw RE, Warner F, Krumholz HM, Ross JS. Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators. Pharmacoepidemiology And Drug Safety 2018, 27: 848-856. PMID: 29896873, PMCID: PMC6436550, DOI: 10.1002/pds.4565.
• The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvementsWallach JD, Ross JS, Naci H. The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. Clinical Trials 2018, 15: 219-229. PMID: 29871509, DOI: 10.1177/1740774518770648.
• The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generationWallach JD, Ross JS, Naci H. The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation. Clinical Trials 2018, 15: 243-246. PMID: 29871507, DOI: 10.1177/1740774518770657.
• Fulfilling the Promise of Unique Device Identifiers.Dhruva SS, Ross JS, Schulz WL, Krumholz HM. Fulfilling the Promise of Unique Device Identifiers. Annals Of Internal Medicine 2018, 169: 183-185. PMID: 29868760, DOI: 10.7326/m18-0526.
• Network Optimization And The Continuity Of Physicians In Medicaid Managed CareNdumele CD, Staiger B, Ross JS, Schlesinger MJ. Network Optimization And The Continuity Of Physicians In Medicaid Managed Care. Health Affairs 2018, 37: 929-935. PMID: 29863934, DOI: 10.1377/hlthaff.2017.1410.
• Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use ProgramsPuthumana J, Miller JE, Kim J, Ross JS. Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use Programs. JAMA Network Open 2018, 1: e180283-e180283. PMID: 30646072, PMCID: PMC6324420, DOI: 10.1001/jamanetworkopen.2018.0283.
• 2492 Risk of readmission after discharge from skilled nursing facilities following heart failure hospitalizationWeerahandi H, Li L, Herrin J, Dharmarajan K, Kim L, Ross J, Jones S, Horwitz L. 2492 Risk of readmission after discharge from skilled nursing facilities following heart failure hospitalization. Journal Of Clinical And Translational Science 2018, 2: 87-87. PMCID: PMC6799699, DOI: 10.1017/cts.2018.303.
• Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysisWallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. The BMJ 2018, 361: k2031. PMID: 29794072, PMCID: PMC5967364, DOI: 10.1136/bmj.k2031.
• Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012Crossley JR, Tan TP, Smith KH, Ross JS, Merenstein DJ. Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012. Journal Of General Internal Medicine 2018, 33: 1431-1432. PMID: 29777429, PMCID: PMC6108986, DOI: 10.1007/s11606-018-4486-7.
• The Impact of Off-Patent Drug Acquisitions on PricesGupta R, Henkel A, Forman HP, Ross JS. The Impact of Off-Patent Drug Acquisitions on Prices. Journal Of General Internal Medicine 2018, 33: 1007-1009. PMID: 29687433, PMCID: PMC6025665, DOI: 10.1007/s11606-018-4372-3.
• Abstract 279: Eligibility and Cost Estimates for Anti-inflammatory Therapy for Atherosclerotic Disease: Implications of the CANTOS Trial for the US Adult PopulationKhera R, Saxena A, Hong J, Arrieta A, Ross J, Krumholz H, Nasir K. Abstract 279: Eligibility and Cost Estimates for Anti-inflammatory Therapy for Atherosclerotic Disease: Implications of the CANTOS Trial for the US Adult Population. Circulation Cardiovascular Quality And Outcomes 2018, 11 DOI: 10.1161/circoutcomes.11.suppl_1.279.
• Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015Egilman AC, Wallach JD, Ross JS, Dhruva SS. Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015. JAMA Internal Medicine 2018, 178: 567-569. PMID: 29340562, PMCID: PMC5876838, DOI: 10.1001/jamainternmed.2017.8016.
• Older drugs with infantile evidence: the illustrative example of loop diureticsBikdeli B, Testani JM, Ross JS, Krumholz HM. Older drugs with infantile evidence: the illustrative example of loop diuretics. European Heart Journal - Quality Of Care And Clinical Outcomes 2018, 4: 232-234. PMID: 29617967, PMCID: PMC6030914, DOI: 10.1093/ehjqcco/qcy012.
• National Prescribing Trends for High‐Risk Anticholinergic Medications in Older AdultsRhee TG, Choi YC, Ouellet GM, Ross JS. National Prescribing Trends for High‐Risk Anticholinergic Medications in Older Adults. Journal Of The American Geriatrics Society 2018, 66: 1382-1387. PMID: 29582410, PMCID: PMC6097908, DOI: 10.1111/jgs.15357.
• Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological studyWallach JD, Ciani O, Pease AM, Gonsalves GS, Krumholz HM, Taylor RS, Ross JS. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study. BMC Medicine 2018, 16: 45. PMID: 29562926, PMCID: PMC5863466, DOI: 10.1186/s12916-018-1023-9.
• Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational studyGupta R, Bollyky TJ, Cohen M, Ross JS, Kesselheim AS. Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study. The BMJ 2018, 360: k831. PMID: 29555641, PMCID: PMC5858606, DOI: 10.1136/bmj.k831.
• Statewide Inferior Vena Cava Filter Placement, Complications, and RetrievalsCharalel RA, Durack JC, Mao J, Ross JS, Meltzer AJ, Sedrakyan A. Statewide Inferior Vena Cava Filter Placement, Complications, and Retrievals. Medical Care 2018, 56: 260-265. PMID: 29356721, DOI: 10.1097/mlr.0000000000000867.
• Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation EffortsWallach JD, Ross JS. Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts. JAMA 2018, 319: 776-778. PMID: 29486013, DOI: 10.1001/jama.2017.21897.
• Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA GuidelinesKlara K, Kim J, Ross JS. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. Journal Of General Internal Medicine 2018, 33: 651-658. PMID: 29484575, PMCID: PMC5910340, DOI: 10.1007/s11606-017-4274-9.
• Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable AnalysisZeitoun J, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P. Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis. Clinical Pharmacology & Therapeutics 2018, 104: 1000-1007. PMID: 29377075, DOI: 10.1002/cpt.1038.
• Defining Multiple Chronic Conditions for Quality MeasurementDrye EE, Altaf FK, Lipska KJ, Spatz ES, Montague JA, Bao H, Parzynski CS, Ross JS, Bernheim SM, Krumholz HM, Lin Z. Defining Multiple Chronic Conditions for Quality Measurement. Medical Care 2018, 56: 193-201. PMID: 29271820, DOI: 10.1097/mlr.0000000000000853.
• Bringing Vioxx back to marketRoss JS, Krumholz HM. Bringing Vioxx back to market. The BMJ 2018, 360: k242. PMID: 29371221, DOI: 10.1136/bmj.k242.
• For transparency and accountability more is betterKrumholz H, Ross J. For transparency and accountability more is better. Nature Human Behaviour 2018, 2: 96-96. DOI: 10.1038/s41562-018-0300-0.
• Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiencesWallach JD, Egilman AC, Gopal AD, Swami N, Krumholz HM, Ross JS. Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences. Research Integrity And Peer Review 2018, 3: 1. PMID: 29451557, PMCID: PMC5803634, DOI: 10.1186/s41073-017-0045-8.
• Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia OutcomesLindenauer PK, Strait KM, Grady JN, Ngo CK, Parisi ML, Metersky M, Ross JS, Bernheim SM, Dorsey K. Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes. Annals Of The American Thoracic Society 2018, 15: 562-569. PMID: 29298090, DOI: 10.1513/annalsats.201709-728oc.
• Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHSKim J, Ross JS, Kapczynski A. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS. JAMA 2018, 319: 21-22. PMID: 29117365, DOI: 10.1001/jama.2017.16477.
• Physician Denial of Inappropriate Patient Requests—What If I Say No??Ross JS. Physician Denial of Inappropriate Patient Requests—What If I Say No?? JAMA Internal Medicine 2018, 178: 92. PMID: 29181540, DOI: 10.1001/jamainternmed.2017.7367.
• Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional studyZeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study. BMJ Open 2017, 7: e018587. PMID: 29273664, PMCID: PMC5778291, DOI: 10.1136/bmjopen-2017-018587.
• New and incremental FDA black box warnings from 2008 to 2015Solotke MT, Dhruva SS, Downing NS, Shah ND, Ross JS. New and incremental FDA black box warnings from 2008 to 2015. Expert Opinion On Drug Safety 2017, 17: 117-123. PMID: 29215916, PMCID: PMC6013049, DOI: 10.1080/14740338.2018.1415323.
• High Costs of FDA Approval for Formerly Unapproved Marketed DrugsHakim A, Gupta R, Ross JS. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs. JAMA 2017, 318: 2181-2182. PMID: 29131905, DOI: 10.1001/jama.2017.16481.
• Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companiesMiller JE, Wilenzick M, Ritcey N, Ross JS, Mello MM. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open 2017, 7: e017917. PMID: 29208616, PMCID: PMC5728266, DOI: 10.1136/bmjopen-2017-017917.
• Data Sharing and Cardiology Platforms and PossibilitiesDey P, Ross JS, Ritchie JD, Desai NR, Bhavnani SP, Krumholz HM. Data Sharing and Cardiology Platforms and Possibilities. Journal Of The American College Of Cardiology 2017, 70: 3018-3025. PMID: 29241491, DOI: 10.1016/j.jacc.2017.10.037.
• Research, regulatory, and clinical decision-making: the importance of scientific integrityWallach JD, Gonsalves GS, Ross JS. Research, regulatory, and clinical decision-making: the importance of scientific integrity. Journal Of Clinical Epidemiology 2017, 93: 88-93. PMID: 29042327, DOI: 10.1016/j.jclinepi.2017.08.021.
• Post‐marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross‐sectional studyZeitoun J, Baron G, Vivot A, Atal I, Downing NS, Ross JS, Ravaud P. Post‐marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross‐sectional study. International Journal Of Cancer 2017, 142: 414-423. PMID: 28929484, DOI: 10.1002/ijc.31061.
• Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015.Samuels EA, Ross JS, Dhruva SS. Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015. Annals Of Internal Medicine 2017, 167: 895-896. PMID: 29052693, DOI: 10.7326/m17-1823.
• The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.Gupta R, Dhruva SS, Fox ER, Ross JS. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States. Journal Of Managed Care & Specialty Pharmacy 2017, 23: 1066-1076. PMID: 28944731, PMCID: PMC10397719, DOI: 10.18553/jmcp.2017.23.10.1066.
• Quality of Care in the United States Territories, 1999–2012Nuti SV, Wang Y, Masoudi FA, Nunez-Smith M, Normand ST, Murugiah K, Rodríguez-Vilá O, Ross JS, Krumholz HM. Quality of Care in the United States Territories, 1999–2012. Medical Care 2017, 55: 886-892. PMID: 28906314, PMCID: PMC6482857, DOI: 10.1097/mlr.0000000000000797.
• Merits of Data Sharing The Digitalis Investigation Group TrialAngraal S, Ross JS, Dhruva SS, Desai NR, Welsh JW, Krumholz HM. Merits of Data Sharing The Digitalis Investigation Group Trial. Journal Of The American College Of Cardiology 2017, 70: 1825-1827. PMID: 28958337, DOI: 10.1016/j.jacc.2017.07.786.
• Challenges to Biosimilar Substitution—ReplyHakim A, Ross JS. Challenges to Biosimilar Substitution—Reply. JAMA 2017, 318: 1186-1187. PMID: 28973611, DOI: 10.1001/jama.2017.11937.
• Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term UseJeffery MM, Hooten WM, Hess EP, Meara ER, Ross JS, Henk HJ, Borgundvaag B, Shah ND, Bellolio MF. Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use. Annals Of Emergency Medicine 2017, 71: 326-336.e19. PMID: 28967517, PMCID: PMC6295192, DOI: 10.1016/j.annemergmed.2017.08.042.
• Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling.Dharmarajan K, McNamara RL, Wang Y, Masoudi FA, Ross JS, Spatz EE, Desai NR, de Lemos JA, Fonarow GC, Heidenreich PA, Bhatt DL, Bernheim SM, Slattery LE, Khan YM, Curtis JP. Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. Annals Of Internal Medicine 2017, 167: 555-564. PMID: 28973634, PMCID: PMC9359429, DOI: 10.7326/m16-2871.
• Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient SelectionJeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection. The Journal Of Allergy And Clinical Immunology In Practice 2017, 6: 1568-1577.e4. PMID: 28958746, DOI: 10.1016/j.jaip.2017.07.034.
• Characteristics of Novel Therapeutics and Postmarket Safety Events—ReplyDowning NS, Shah ND, Ross JS. Characteristics of Novel Therapeutics and Postmarket Safety Events—Reply. JAMA 2017, 318: 1067-1068. PMID: 28975302, DOI: 10.1001/jama.2017.11517.
• Hospital-Readmission Risk — Isolating Hospital Effects from Patient EffectsKrumholz HM, Wang K, Lin Z, Dharmarajan K, Horwitz LI, Ross JS, Drye EE, Bernheim SM, Normand ST. Hospital-Readmission Risk — Isolating Hospital Effects from Patient Effects. New England Journal Of Medicine 2017, 377: 1055-1064. PMID: 28902587, PMCID: PMC5671772, DOI: 10.1056/nejmsa1702321.
• The Importance of Independent EvaluationJohnson KA, Ross JS. The Importance of Independent Evaluation. JAMA Internal Medicine 2017, 177: 1343. PMID: 28759680, DOI: 10.1001/jamainternmed.2017.3044.
• Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical DevicesDhruva SS, Mazure CM, Ross JS, Redberg RF. Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices. JAMA Internal Medicine 2017, 177: 1390-1391. PMID: 28738116, PMCID: PMC5818834, DOI: 10.1001/jamainternmed.2017.3148.
• Association between FDA black box warnings and Medicare formulary coverage changes.Dhruva SS, Karaca-Mandic P, Shah ND, Shaw DL, Ross JS. Association between FDA black box warnings and Medicare formulary coverage changes. The American Journal Of Managed Care 2017, 23: e310-e315. PMID: 29087169.
• US Food and Drug Administration Clearance of Moderate‐Risk Otolaryngologic Devices via the 510(k) Process, 1997‐2016Rathi VK, Gadkaree SK, Ross JS, Kozin ED, Sethi RK, Naunheim MR, Puram SV, Gray ST. US Food and Drug Administration Clearance of Moderate‐Risk Otolaryngologic Devices via the 510(k) Process, 1997‐2016. Otolaryngology 2017, 157: 608-617. PMID: 28786317, DOI: 10.1177/0194599817721689.
• Facts Concerning Duexis Prescribing Habits Related to Combination Therapies—ReplyHakim A, Ross JS. Facts Concerning Duexis Prescribing Habits Related to Combination Therapies—Reply. JAMA Internal Medicine 2017, 177: 1228-1228. PMID: 28783837, DOI: 10.1001/jamainternmed.2017.2460.
• Can machine learning complement traditional medical device surveillance? A case-study of dual-chamber implantable cardioverter–defibrillatorsRoss JS, Bates J, Parzynski CS, Akar JG, Curtis JP, Desai NR, Freeman JV, Gamble GM, Kuntz R, Li SX, Marinac-Dabic D, Masoudi FA, Normand ST, Ranasinghe I, Shaw RE, Krumholz HM. Can machine learning complement traditional medical device surveillance? A case-study of dual-chamber implantable cardioverter–defibrillators. Medical Devices Evidence And Research 2017, 10: 165-188. PMID: 28860874, PMCID: PMC5566316, DOI: 10.2147/mder.s138158.
• Characterizing expanded access and compassionate use programs for experimental drugsMiller JE, Ross JS, Moch KI, Caplan AL. Characterizing expanded access and compassionate use programs for experimental drugs. BMC Research Notes 2017, 10: 350. PMID: 28754150, PMCID: PMC5534121, DOI: 10.1186/s13104-017-2687-5.
• Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital DischargeDharmarajan K, Wang Y, Lin Z, Normand ST, Ross JS, Horwitz LI, Desai NR, Suter LG, Drye EE, Bernheim SM, Krumholz HM. Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge. JAMA 2017, 318: 270-278. PMID: 28719692, PMCID: PMC5817448, DOI: 10.1001/jama.2017.8444.
• Association of the FDA Amendment Act with trial registration, publication, and outcome reportingPhillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials 2017, 18: 333. PMID: 28720112, PMCID: PMC5516301, DOI: 10.1186/s13063-017-2068-3.
• Trends in readmission rates for safety net hospitals and non-safety net hospitals in the era of the US Hospital Readmission Reduction Program: a retrospective time series analysis using Medicare administrative claims data from 2008 to 2015Salerno AM, Horwitz LI, Kwon JY, Herrin J, Grady JN, Lin Z, Ross JS, Bernheim SM. Trends in readmission rates for safety net hospitals and non-safety net hospitals in the era of the US Hospital Readmission Reduction Program: a retrospective time series analysis using Medicare administrative claims data from 2008 to 2015. BMJ Open 2017, 7: e016149. PMID: 28710221, PMCID: PMC5541519, DOI: 10.1136/bmjopen-2017-016149.
• The Need to Test Strategies Based on Common SenseKhoong EC, Ross JS. The Need to Test Strategies Based on Common Sense. JAMA Internal Medicine 2017, 177: 929. PMID: 28600912, DOI: 10.1001/jamainternmed.2017.1251.
• Regulatory Review of New Therapeutic AgentsDowning NS, Zhang AD, Ross JS. Regulatory Review of New Therapeutic Agents. New England Journal Of Medicine 2017, 376: 2598-2598. PMID: 28657868, DOI: 10.1056/nejmc1705868.
• Obstacles to the Adoption of Biosimilars for Chronic DiseasesHakim A, Ross JS. Obstacles to the Adoption of Biosimilars for Chronic Diseases. JAMA 2017, 317: 2163-2164. PMID: 28459924, DOI: 10.1001/jama.2017.5202.
• Having Their Cake and Eating It Too: Physician Skepticism of the Open Payments ProgramRoss JS. Having Their Cake and Eating It Too: Physician Skepticism of the Open Payments Program. The American Journal Of Bioethics 2017, 17: 19-22. PMID: 28537822, DOI: 10.1080/15265161.2017.1313340.
• Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors.O'Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres A, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: e14583-e14583. DOI: 10.1200/jco.2017.35.15_suppl.e14583.
• Racial disparities in the use of programmed death-1 checkpoint inhibitors.O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.
• Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979–2015Gopal AD, Rathi VK, Teng CC, Del Priore L, Ross JS. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979–2015. Ophthalmology 2017, 124: 1237-1246. PMID: 28501378, DOI: 10.1016/j.ophtha.2017.03.040.
• Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. JAMA 2017, 317: 1854-1863. PMID: 28492899, PMCID: PMC5815036, DOI: 10.1001/jama.2017.5150.
• Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic reviewPease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. The BMJ 2017, 357: j1680. PMID: 28468750, PMCID: PMC5421452, DOI: 10.1136/bmj.j1680.
• US drug marketing: how does promotion correspond with health value?Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value? The BMJ 2017, 357: j1855. PMID: 28465309, DOI: 10.1136/bmj.j1855.
• Hospital Characteristics Associated With Risk-standardized Readmission RatesHorwitz LI, Bernheim SM, Ross JS, Herrin J, Grady JN, Krumholz HM, Drye EE, Lin Z. Hospital Characteristics Associated With Risk-standardized Readmission Rates. Medical Care 2017, 55: 528-534. PMID: 28319580, PMCID: PMC5426655, DOI: 10.1097/mlr.0000000000000713.
• Regulatory Review of New Therapeutic Agents — FDA versus EMA, 2011–2015Downing NS, Zhang AD, Ross JS. Regulatory Review of New Therapeutic Agents — FDA versus EMA, 2011–2015. New England Journal Of Medicine 2017, 376: 1386-1387. PMID: 28379798, DOI: 10.1056/nejmc1700103.
• Factors Associated with Refugee Acute Healthcare Utilization in Southern ConnecticutSemere W, Agrawal P, Yun K, Di Bartolo I, Annamalai A, Ross JS. Factors Associated with Refugee Acute Healthcare Utilization in Southern Connecticut. Journal Of Immigrant And Minority Health 2017, 20: 327-333. PMID: 28382427, DOI: 10.1007/s10903-017-0574-8.
• Health and Health Care Use Among Individuals at Risk to Lose Health Insurance With Repeal of the Affordable Care ActKaraca-Mandic P, Jena AB, Ross JS. Health and Health Care Use Among Individuals at Risk to Lose Health Insurance With Repeal of the Affordable Care Act. JAMA Internal Medicine 2017, 177: 590-593. PMID: 28114528, PMCID: PMC5470386, DOI: 10.1001/jamainternmed.2016.9541.
• Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011Bikdeli B, Punnanithinont N, Akram Y, Lee I, Desai NR, Ross JS, Krumholz HM. Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011. Journal Of The American Heart Association 2017, 6: e005285. PMID: 28325713, PMCID: PMC5524035, DOI: 10.1161/jaha.116.005285.
• Abstract 136: The Relationship of Changing Hospital Readmission Rates and Mortality Rates After Hospitalization for Heart Failure, Acute Myocardial Infarction, and PneumoniaDharmarajan K, Wang Y, Bernheim S, Lin Z, Horwitz L, Ross J, Desai N, Suter L, Drye E, Normand S, Krumholz H. Abstract 136: The Relationship of Changing Hospital Readmission Rates and Mortality Rates After Hospitalization for Heart Failure, Acute Myocardial Infarction, and Pneumonia. Circulation Cardiovascular Quality And Outcomes 2017, 10 DOI: 10.1161/circoutcomes.10.suppl_3.136.
• Abstract 041: Trends in Publication and Methodological Quality of Major Non-inferiority Cardiovascular Trials From 1990-2016: a Systematic ReviewWelsh J, Bikdeli B, Akram Y, Lee I, Desai N, Stone G, Ross J, Krumholz H. Abstract 041: Trends in Publication and Methodological Quality of Major Non-inferiority Cardiovascular Trials From 1990-2016: a Systematic Review. Circulation Cardiovascular Quality And Outcomes 2017, 10 DOI: 10.1161/circoutcomes.10.suppl_3.041.
• High Prices for Drugs With Generic Alternatives: The Curious Case of DuexisHakim A, Ross JS. High Prices for Drugs With Generic Alternatives: The Curious Case of Duexis. JAMA Internal Medicine 2017, 177: 305-306. PMID: 28114637, DOI: 10.1001/jamainternmed.2016.8423.
• Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic ProjectLow J, Ross JS, Ritchie JD, Gross CP, Lehman R, Lin H, Fu R, Stewart LA, Krumholz HM. Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic Project. Systematic Reviews 2017, 6: 28. PMID: 28196521, PMCID: PMC5310069, DOI: 10.1186/s13643-017-0422-x.
• Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort studyLarochelle M, Downing NS, Ross JS, David FS. Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study. BMJ Open 2017, 7: e014582. PMID: 28179418, PMCID: PMC5306516, DOI: 10.1136/bmjopen-2016-014582.
• Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005‐2014Rathi VK, Wang B, Ross JS, Downing NS, Kesselheim AS, Gray ST. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005‐2014. Otolaryngology 2017, 156: 683-692. PMID: 28116974, DOI: 10.1177/0194599816689666.
• Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High‐Risk Otolaryngologic Devices, 2000‐2014Rathi VK, Wang B, Ross JS, Downing NS, Kesselheim AS, Gray ST. Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High‐Risk Otolaryngologic Devices, 2000‐2014. Otolaryngology 2017, 156: 285-288. PMID: 28093943, DOI: 10.1177/0194599816684094.
• Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical ProductsSharfstein J, Miller J, Davis A, Ross J, McCarthy M, Smith B, Chaudhry A, Alexander G, Kesselheim A. Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products. The Journal Of Law, Medicine & Ethics 2017, 45: 7-23. DOI: 10.1177/1073110517750615.
• Data Desert for Inferior Vena Caval Filters: Limited Evidence, Supervision, and ResearchBikdeli B, Ross JS, Krumholz HM. Data Desert for Inferior Vena Caval Filters: Limited Evidence, Supervision, and Research. JAMA Cardiology 2017, 2: 3-4. PMID: 27806161, DOI: 10.1001/jamacardio.2016.3764.
• Prioritization of Generic Drug Review—ReplyGupta R, Kesselheim AS, Ross JS. Prioritization of Generic Drug Review—Reply. JAMA Internal Medicine 2017, 177: 141-142. PMID: 28030736, DOI: 10.1001/jamainternmed.2016.7817.
• Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol GuidelineDhruva SS, Desai NR, Karaca-Mandic P, Shah ND, Ross JS. Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline. Journal Of The American College Of Cardiology 2017, 69: 244-246. PMID: 28081832, DOI: 10.1016/j.jacc.2016.10.053.
• Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget ConditionsDesai NR, Ross JS, Kwon JY, Herrin J, Dharmarajan K, Bernheim SM, Krumholz HM, Horwitz LI. Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. JAMA 2016, 316: 2647-2656. PMID: 28027367, PMCID: PMC5599851, DOI: 10.1001/jama.2016.18533.
• The Rising Price of Naloxone — Risks to Efforts to Stem Overdose DeathsGupta R, Shah ND, Ross JS. The Rising Price of Naloxone — Risks to Efforts to Stem Overdose Deaths. New England Journal Of Medicine 2016, 375: 2213-2215. PMID: 27959694, DOI: 10.1056/nejmp1609578.
• Hospital Use of Observation StaysVenkatesh AK, Wang C, Ross JS, Altaf FK, Suter LG, Vellanky S, Grady JN, Bernheim SM. Hospital Use of Observation Stays. Medical Care 2016, 54: 1070-1077. PMID: 27579906, PMCID: PMC5850934, DOI: 10.1097/mlr.0000000000000601.
• Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage PatientsParikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology 2016, 124: 352-358. PMID: 27890437, DOI: 10.1016/j.ophtha.2016.10.036.
• Frequency and Importance of Incomplete Screening Fetal Anatomic Sonography in PregnancySilvestri MT, Pettker CM, Raney JH, Xu X, Ross JS. Frequency and Importance of Incomplete Screening Fetal Anatomic Sonography in Pregnancy. Journal Of Ultrasound In Medicine 2016, 35: 2665-2673. PMID: 27821652, DOI: 10.7863/ultra.16.01084.
• Unplanned Hospital Admissions after Same-Day SurgeryBongiovanni T, Ross J, Krumholz H, Ranasinghe I, Lin Z. Unplanned Hospital Admissions after Same-Day Surgery. Journal Of The American College Of Surgeons 2016, 223: s121. DOI: 10.1016/j.jamcollsurg.2016.06.251.
• Authors’ reply to RamachandranFleischman W, Ross JS, Agrawal S. Authors’ reply to Ramachandran. The BMJ 2016, 354: i5255. PMID: 27687513, DOI: 10.1136/bmj.i5255.
• Commentary: Diagnostic devices in clinical trials have high stakes for patient careRathi VK, Krumholz HM, Ross JS. Commentary: Diagnostic devices in clinical trials have high stakes for patient care. The BMJ 2016, 354: i5197. PMID: 27681285, DOI: 10.1136/bmj.i5197.
• Data sharing through an NIH central database repository: a cross-sectional survey of BioLINCC usersRoss JS, Ritchie JD, Finn E, Desai NR, Lehman RL, Krumholz HM, Gross CP. Data sharing through an NIH central database repository: a cross-sectional survey of BioLINCC users. BMJ Open 2016, 6: e012769. PMID: 27670522, PMCID: PMC5051517, DOI: 10.1136/bmjopen-2016-012769.
• Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care 2016, 40: 468-475. PMID: 27659408, PMCID: PMC5360291, DOI: 10.2337/dc16-0985.
• Clinical research data sharing: what an open science world means for researchers involved in evidence synthesisRoss JS. Clinical research data sharing: what an open science world means for researchers involved in evidence synthesis. Systematic Reviews 2016, 5: 159. PMID: 27649796, PMCID: PMC5029013, DOI: 10.1186/s13643-016-0334-1.
• A Nationwide Assessment of the Association of Smoking Bans and Cigarette Taxes With Hospitalizations for Acute Myocardial Infarction, Heart Failure, and PneumoniaHo V, Ross JS, Steiner CA, Mandawat A, Short M, Ku-Goto MH, Krumholz HM. A Nationwide Assessment of the Association of Smoking Bans and Cigarette Taxes With Hospitalizations for Acute Myocardial Infarction, Heart Failure, and Pneumonia. Medical Care Research And Review 2016, 74: 687-704. PMID: 27624634, PMCID: PMC5665160, DOI: 10.1177/1077558716668646.
• Industry support of physician education in the USAFleischman W, Ross JS. Industry support of physician education in the USA. Journal Of Epidemiology & Community Health 2016, 71: 213. PMID: 27612981, DOI: 10.1136/jech-2015-206592.
• Generic Drug Approvals Since the 1984 Hatch-Waxman ActGupta R, Kesselheim AS, Downing N, Greene J, Ross JS. Generic Drug Approvals Since the 1984 Hatch-Waxman Act. JAMA Internal Medicine 2016, 176: 1391-3. PMID: 27428055, DOI: 10.1001/jamainternmed.2016.3411.
• Why the Open Payments Program Is Likely to Provide Systematic and Transparent Data on Financial Relationships with IndustryFleischman W, Ross JS. Why the Open Payments Program Is Likely to Provide Systematic and Transparent Data on Financial Relationships with Industry. The American Journal Of Medicine 2016, 129: e193. PMID: 27554954, DOI: 10.1016/j.amjmed.2016.01.051.
• Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological studyFleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. The BMJ 2016, 354: i4189. PMID: 27540015, PMCID: PMC4989280, DOI: 10.1136/bmj.i4189.
• The updated AMSA scorecard of conflict-of-interest policies: a survey of U.S. medical schoolsCarlat DJ, Fagrelius T, Ramachandran R, Ross JS, Bergh S. The updated AMSA scorecard of conflict-of-interest policies: a survey of U.S. medical schools. BMC Medical Education 2016, 16: 202. PMID: 27519253, PMCID: PMC4983088, DOI: 10.1186/s12909-016-0725-y.
• Open Access Platforms for Sharing Clinical Trial DataRoss JS, Krumholz HM. Open Access Platforms for Sharing Clinical Trial Data. JAMA 2016, 316: 666-666. PMID: 27532929, DOI: 10.1001/jama.2016.8794.
• Accounting For Patients’ Socioeconomic Status Does Not Change Hospital Readmission RatesBernheim SM, Parzynski CS, Horwitz L, Lin Z, Araas MJ, Ross JS, Drye EE, Suter LG, Normand SL, Krumholz HM. Accounting For Patients’ Socioeconomic Status Does Not Change Hospital Readmission Rates. Health Affairs 2016, 35: 1461-1470. PMID: 27503972, PMCID: PMC7664840, DOI: 10.1377/hlthaff.2015.0394.
• Population Of US Practicing Psychiatrists Declined, 2003–13, Which May Help Explain Poor Access To Mental Health CareBishop TF, Seirup JK, Pincus HA, Ross JS. Population Of US Practicing Psychiatrists Declined, 2003–13, Which May Help Explain Poor Access To Mental Health Care. Health Affairs 2016, 35: 1271-1277. PMID: 27385244, DOI: 10.1377/hlthaff.2015.1643.
• Declining Admission Rates And Thirty-Day Readmission Rates Positively Associated Even Though Patients Grew Sicker Over TimeDharmarajan K, Qin L, Lin Z, Horwitz LI, Ross JS, Drye EE, Keshawarz A, Altaf F, Normand SL, Krumholz HM, Bernheim SM. Declining Admission Rates And Thirty-Day Readmission Rates Positively Associated Even Though Patients Grew Sicker Over Time. Health Affairs 2016, 35: 1294-1302. PMID: 27385247, DOI: 10.1377/hlthaff.2015.1614.
• Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 DiabetesMcCoy RG, Lipska KJ, Yao X, Ross JS, Montori VM, Shah ND. Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Internal Medicine 2016, 176: 969-78. PMID: 27273792, PMCID: PMC5380118, DOI: 10.1001/jamainternmed.2016.2275.
• Therapeutic Substitution—Should It Be Systematic or Automatic?Ross JS. Therapeutic Substitution—Should It Be Systematic or Automatic? JAMA Internal Medicine 2016, 176: 776. PMID: 27158769, DOI: 10.1001/jamainternmed.2016.2271.
• Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014.Yao X, Sangaralingham LR, Ross JS, Shah ND, Talwalkar JA. Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014. The American Journal Of Managed Care 2016, 22: e224-32. PMID: 27355910.
• Triage, Copayments, and Emergency Department VisitsRoss JS. Triage, Copayments, and Emergency Department Visits. JAMA Internal Medicine 2016, 176: 854. PMID: 27089246, DOI: 10.1001/jamainternmed.2016.0882.
• Impact of Hospitalization for Acute Myocardial Infarction on Adherence to Statins Among Older AdultsKronish IM, Ross JS, Zhao H, Muntner P. Impact of Hospitalization for Acute Myocardial Infarction on Adherence to Statins Among Older Adults. Circulation Cardiovascular Quality And Outcomes 2016, 9: 364-371. PMID: 27220368, PMCID: PMC4956547, DOI: 10.1161/circoutcomes.115.002418.
• Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study.Ranasinghe I, Parzynski CS, Freeman JV, Dreyer RP, Ross JS, Akar JG, Krumholz HM, Curtis JP. Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study. Annals Of Internal Medicine 2016, 165: 20-29. PMID: 27135392, DOI: 10.7326/m15-2732.
• The US Food and Drug Administration 515 Program Initiative: Addressing the Evidence Gap for Widely Used, High-Risk Cardiovascular Devices?Rathi VK, Kesselheim AS, Ross JS. The US Food and Drug Administration 515 Program Initiative: Addressing the Evidence Gap for Widely Used, High-Risk Cardiovascular Devices? JAMA Cardiology 2016, 1: 117. PMID: 27437879, DOI: 10.1001/jamacardio.2016.0002.
• Despite Federal Legislation, Shortages Of Drugs Used In Acute Care Settings Remain Persistent And ProlongedChen SI, Fox ER, Hall MK, Ross JS, Bucholz EM, Krumholz HM, Venkatesh AK. Despite Federal Legislation, Shortages Of Drugs Used In Acute Care Settings Remain Persistent And Prolonged. Health Affairs 2016, 35: 798-804. PMID: 27140985, PMCID: PMC6712565, DOI: 10.1377/hlthaff.2015.1157.
• Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care OrganizationsSpatz ES, Lipska KJ, Dai Y, Bao H, Lin Z, Parzynski CS, Altaf FK, Joyce EK, Montague JA, Ross JS, Bernheim SM, Krumholz HM, Drye EE. Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care Organizations. Medical Care 2016, 54: 528-537. PMID: 26918404, PMCID: PMC5356461, DOI: 10.1097/mlr.0000000000000518.
• Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvalsDowning NS, Shah ND, Neiman JH, Aminawung JA, Krumholz HM, Ross JS. Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals. Trials 2016, 17: 199. PMID: 27079511, PMCID: PMC4832528, DOI: 10.1186/s13063-016-1322-4.
• Availability of Clinical Trial Data From Industry‐Sponsored Cardiovascular TrialsMurugiah K, Ritchie JD, Desai NR, Ross JS, Krumholz HM. Availability of Clinical Trial Data From Industry‐Sponsored Cardiovascular Trials. Journal Of The American Heart Association 2016, 5: e003307. PMID: 27098969, PMCID: PMC4859296, DOI: 10.1161/jaha.116.003307.
• Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary SyndromeJackevicius CA, Tu JV, Krumholz HM, Austin PC, Ross JS, Stukel TA, Koh M, Chong A, Ko DT. Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome. Journal Of The American Heart Association 2016, 5: e003350. PMID: 27098970, PMCID: PMC4859299, DOI: 10.1161/jaha.116.003350.
• Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional StudyPhillips AT, Rathi VK, Ross JS. Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional Study. JAMA Internal Medicine 2016, 176: 551. PMID: 26902933, DOI: 10.1001/jamainternmed.2015.8590.
• Making Electronic Health Records Work Better for Patient CareRoss JS. Making Electronic Health Records Work Better for Patient Care. JAMA Internal Medicine 2016, 176: 560. PMID: 26974253, DOI: 10.1001/jamainternmed.2016.0219.
• Impact of laboratory cost display on resident attitudes and knowledge about costsLong T, Bongiovanni T, Dashevsky M, Halim A, Ross JS, Fogerty RL, Silvestri MT. Impact of laboratory cost display on resident attitudes and knowledge about costs. Postgraduate Medical Journal 2016, 92: 592-596. PMID: 27033861, DOI: 10.1136/postgradmedj-2015-133851.
• ReplyRanasinghe I, Parzynski CS, Searfoss R, Montague J, Lin Z, Allen J, Vender R, Bhat K, Ross JS, Bernheim S, Krumholz HM, Drye E. Reply. Gastroenterology 2016, 150: 1249-1251. PMID: 27025674, DOI: 10.1053/j.gastro.2016.03.031.
• Financial Ties Between Emergency Physicians and Industry: Insights From Open Payments DataFleischman W, Ross JS, Melnick ER, Newman DH, Venkatesh AK. Financial Ties Between Emergency Physicians and Industry: Insights From Open Payments Data. Annals Of Emergency Medicine 2016, 68: 153-158.e4. PMID: 26973175, DOI: 10.1016/j.annemergmed.2016.01.014.
• High-Deductible Health Plans and Higher-Value Decisions: A Mirage or Are We Just Not There Yet?Ross JS. High-Deductible Health Plans and Higher-Value Decisions: A Mirage or Are We Just Not There Yet? JAMA Internal Medicine 2016, 176: 1-1. PMID: 26784353, DOI: 10.1001/jamainternmed.2015.7559.
• Preventive Care Quality of Medicare Accountable Care OrganizationsAlbright BB, Lewis VA, Ross JS, Colla CH. Preventive Care Quality of Medicare Accountable Care Organizations. Medical Care 2016, 54: 326-335. PMID: 26759974, PMCID: PMC4752877, DOI: 10.1097/mlr.0000000000000477.
• Publication and reporting of clinical trial results: cross sectional analysis across academic medical centersChen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, Murugiah K, Lu DY, Mittal A, Krumholz HM. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. The BMJ 2016, 352: i637. PMID: 26888209, PMCID: PMC4768882, DOI: 10.1136/bmj.i637.
• Association of Admission to Veterans Affairs Hospitals vs Non–Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or PneumoniaNuti SV, Qin L, Rumsfeld JS, Ross JS, Masoudi FA, Normand SL, Murugiah K, Bernheim SM, Suter LG, Krumholz HM. Association of Admission to Veterans Affairs Hospitals vs Non–Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. JAMA 2016, 315: 582-592. PMID: 26864412, PMCID: PMC5459395, DOI: 10.1001/jama.2016.0278.
• Revisiting Essure—Toward Safe and Effective SterilizationDhruva S, Ross J, Gariepy A. Revisiting Essure—Toward Safe and Effective Sterilization. Obstetrical & Gynecological Survey 2016, 71: 86-87. DOI: 10.1097/01.ogx.0000479905.52201.55.
• Making Data Submitted to the Food and Drug Administration More VisibleRoss JS. Making Data Submitted to the Food and Drug Administration More Visible. JAMA Internal Medicine 2016, 176: 1-1. PMID: 26752009, DOI: 10.1001/jamainternmed.2015.6773.
• Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reportingDal-Ré R, Ross JS, Marušić A. Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. Journal Of Clinical Epidemiology 2016, 75: 100-107. PMID: 26820559, DOI: 10.1016/j.jclinepi.2016.01.017.
• Characterisation of trials where marketing purposes have been influential in study design: a descriptive studyBarbour V, Burch D, Godlee F, Heneghan C, Lehman R, Perera R, Ross JS, Schroter S. Characterisation of trials where marketing purposes have been influential in study design: a descriptive study. Trials 2016, 17: 31. PMID: 26792624, PMCID: PMC4720997, DOI: 10.1186/s13063-015-1107-1.
• Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI studyLi J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L, Group F. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. European Heart Journal Acute Cardiovascular Care 2016, 6: 232-243. PMID: 26787648, DOI: 10.1177/2048872615626656.
• Response to Letter Regarding Article, “Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007Ranasinghe I, Shojaee A, Bikdeli B, Gupta A, Chen R, Ross JS, Masoudi FA, Spertus JA, Nallamothu BK, Krumholz HM. Response to Letter Regarding Article, “Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007. Circulation 2016, 133: e23-e24. PMID: 27028443, DOI: 10.1161/circulationaha.115.018777.
• Identifying Sociodemographic Characteristics Associated With Burden Among Caregivers of the Urban HomeboundWajnberg A, Soones TN, Smith KL, Russell D, Ross JS, Federman A. Identifying Sociodemographic Characteristics Associated With Burden Among Caregivers of the Urban Homebound. Gerontology And Geriatric Medicine 2016, 2: 2333721416667878. PMID: 28913372, PMCID: PMC5590692, DOI: 10.1177/2333721416667878.
• HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based studyMcCoy RG, Van Houten HK, Ross JS, Montori VM, Shah ND. HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study. The BMJ 2015, 351: h6138. PMID: 26646052, PMCID: PMC4673101, DOI: 10.1136/bmj.h6138.
• No Time to WaitRoss JS, Katz MH. No Time to Wait. JAMA Internal Medicine 2015, 175: 1-1. PMID: 26437319, DOI: 10.1001/jamainternmed.2015.5393.
• US Federal Government Efforts to Improve Clinical Trial Transparency with Expanded Trial Registries and Open Data SharingShaw DL, Ross JS. US Federal Government Efforts to Improve Clinical Trial Transparency with Expanded Trial Registries and Open Data Sharing. The AMA Journal Of Ethic 2015, 17: 1152. PMID: 26698589, DOI: 10.1001/journalofethics.2015.17.12.pfor1-1512.
• How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?Samuel AM, Rathi VK, Grauer JN, Ross JS. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval? Clinical Orthopaedics And Related Research® 2015, 474: 1053-1068. PMID: 26584802, PMCID: PMC4773325, DOI: 10.1007/s11999-015-4634-x.
• Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012Miller JE, Korn D, Ross JS. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ Open 2015, 5: e009758. PMID: 26563214, PMCID: PMC4654354, DOI: 10.1136/bmjopen-2015-009758.
• Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional studyZeitoun JD, Lefèvre JH, Downing NS, Bergeron H, Ross JS. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional study. Pharmacoepidemiology And Drug Safety 2015, 25: 687-694. PMID: 26554874, DOI: 10.1002/pds.3910.
• Abstract 18805: Association of State Certificate of Need Regulations With the Appropriateness of PCI ProceduresChui P, Parzynski C, Ross J, Ho V, Spertus J, Gurm H, Curtis J. Abstract 18805: Association of State Certificate of Need Regulations With the Appropriateness of PCI Procedures. Circulation 2015, 132 DOI: 10.1161/circ.132.suppl_3.18805.
• Abstract 19637: Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990- 2011Bikdeli B, Punnanithinont N, Akram Y, Lee I, Desai N, Ross J, Krumholz H. Abstract 19637: Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990- 2011. Circulation 2015, 132 DOI: 10.1161/circ.132.suppl_3.19637.
• Would a Breakthrough Therapy by Any Other Name Be as Promising?Ross JS, Redberg RF. Would a Breakthrough Therapy by Any Other Name Be as Promising? JAMA Internal Medicine 2015, 175: 1858-1859. PMID: 26390064, DOI: 10.1001/jamainternmed.2015.5311.
• Global Drug Safety Insights From TaiwanRoss JS. Global Drug Safety Insights From Taiwan. JAMA Internal Medicine 2015, 175: 1847-1847. PMID: 26437202, DOI: 10.1001/jamainternmed.2015.5402.
• Hospital-Based Acute Care After Total Hip and Knee Arthroplasty: Implications for Quality MeasurementTrimba R, Laughlin RT, Krishnamurthy A, Ross JS, Fox JP. Hospital-Based Acute Care After Total Hip and Knee Arthroplasty: Implications for Quality Measurement. The Journal Of Arthroplasty 2015, 31: 573-578.e2. PMID: 26689614, DOI: 10.1016/j.arth.2015.10.019.
• Predictors and outcomes of unplanned readmission to a different hospitalKim H, Hung WW, Paik MC, Ross JS, Zhao Z, Kim GS, Boockvar K. Predictors and outcomes of unplanned readmission to a different hospital. International Journal For Quality In Health Care 2015, 27: 513-519. PMID: 26472739, PMCID: PMC4665363, DOI: 10.1093/intqhc/mzv082.
• Characterizing the US FDA's approach to promoting transformative innovationDowning NS, Krumholz HM, Ross JS, Shah ND. Characterizing the US FDA's approach to promoting transformative innovation. Nature Reviews Drug Discovery 2015, 14: 740-741. PMID: 26435528, DOI: 10.1038/nrd4734.
• 162 EMF Characterizing Hospital-Level Variation in Emergency Department Visitation After Hospital Discharge for Medicare BeneficiariesVenkatesh A, Wang C, Ross J, Suter L, Vellanky S, Grady J, Atlaf F, Han L, Bernheim S. 162 EMF Characterizing Hospital-Level Variation in Emergency Department Visitation After Hospital Discharge for Medicare Beneficiaries. Annals Of Emergency Medicine 2015, 66: s57-s58. DOI: 10.1016/j.annemergmed.2015.07.194.
• 180 National Shortages of Drugs Used in the Emergency Department, 2002-2014Chen S, Fox E, Hall M, Ross J, Krumholz H, Venkatesh A. 180 National Shortages of Drugs Used in the Emergency Department, 2002-2014. Annals Of Emergency Medicine 2015, 66: s64. DOI: 10.1016/j.annemergmed.2015.07.212.
• Differences in Colonoscopy Quality Among Facilities: Development of a Post-Colonoscopy Risk-Standardized Rate of Unplanned Hospital VisitsRanasinghe I, Parzynski CS, Searfoss R, Montague J, Lin Z, Allen J, Vender R, Bhat K, Ross JS, Bernheim S, Krumholz HM, Drye EE. Differences in Colonoscopy Quality Among Facilities: Development of a Post-Colonoscopy Risk-Standardized Rate of Unplanned Hospital Visits. Gastroenterology 2015, 150: 103-113. PMID: 26404952, DOI: 10.1053/j.gastro.2015.09.009.
• Revisiting Essure — Toward Safe and Effective SterilizationDhruva SS, Ross JS, Gariepy AM. Revisiting Essure — Toward Safe and Effective Sterilization. New England Journal Of Medicine 2015, 373: e17. PMID: 26397951, DOI: 10.1056/nejmp1510514.
• FDA Policy and Cardiovascular MedicineRoss JS, Kesselheim AS. FDA Policy and Cardiovascular Medicine. Circulation 2015, 132: 1136-1145. PMID: 26391294, PMCID: PMC4586041, DOI: 10.1161/circulationaha.114.010295.
• Informed Consent and Communicating Risk and Benefits of Research on Higher-Risk MedicationsRoss JS. Informed Consent and Communicating Risk and Benefits of Research on Higher-Risk Medications. JAMA Internal Medicine 2015, 175: 1568-1569. PMID: 26214751, DOI: 10.1001/jamainternmed.2015.3555.
• Promoting Evidence-Based High-Value Health CareRoss JS. Promoting Evidence-Based High-Value Health Care. JAMA Internal Medicine 2015, 175: 1564-1564. PMID: 26192635, DOI: 10.1001/jamainternmed.2015.3543.
• Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011Rathi VK, Krumholz HM, Masoudi FA, Ross JS. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. JAMA 2015, 314: 604-612. PMID: 26262798, DOI: 10.1001/jama.2015.8761.
• Physician and other healthcare personnel responses to hospital stroke quality of care performance feedback: a qualitative studyRoss JS, Williams L, Damush TM, Matthias M. Physician and other healthcare personnel responses to hospital stroke quality of care performance feedback: a qualitative study. BMJ Quality & Safety 2015, 25: 441. PMID: 26253122, DOI: 10.1136/bmjqs-2015-004197.
• Strengthening Medical Device Postmarket Safety SurveillanceRoss JS. Strengthening Medical Device Postmarket Safety Surveillance. JAMA Internal Medicine 2015, 175: 1350-1351. PMID: 26099118, DOI: 10.1001/jamainternmed.2015.2650.
• Development and Validation of an Algorithm to Identify Planned Readmissions From Claims DataHorwitz LI, Grady JN, Cohen DB, Lin Z, Volpe M, Ngo CK, Masica AL, Long T, Wang J, Keenan M, Montague J, Suter LG, Ross JS, Drye EE, Krumholz HM, Bernheim SM. Development and Validation of an Algorithm to Identify Planned Readmissions From Claims Data. Journal Of Hospital Medicine 2015, 10: 670-677. PMID: 26149225, PMCID: PMC5459369, DOI: 10.1002/jhm.2416.
• On Chlorofluorocarbon Bans and Inhaled Albuterol PricesRoss JS, Redberg RF. On Chlorofluorocarbon Bans and Inhaled Albuterol Prices. JAMA Internal Medicine 2015, 175: 1179-1179. PMID: 25962127, DOI: 10.1001/jamainternmed.2015.1696.
• National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011Guan W, Murugiah K, Downing N, Li J, Wang Q, Ross JS, Desai NR, Masoudi FA, Spertus JA, Li X, Krumholz HM, Jiang L, Group T. National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011. Journal Of The American Heart Association 2015, 4: e001718. PMID: 26071031, PMCID: PMC4599529, DOI: 10.1161/jaha.114.001718.
• Postmarket Modifications of High‐Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug AdministrationRathi VK, Ross JS, Samuel AM, Mehra S. Postmarket Modifications of High‐Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration. Otolaryngology 2015, 153: 400-408. PMID: 26044785, DOI: 10.1177/0194599815587508.
• High-Risk Medical Devices: Why Do We Not Better Understand Effectiveness and Safety?Ross JS. High-Risk Medical Devices: Why Do We Not Better Understand Effectiveness and Safety? JAMA Internal Medicine 2015, 175: 939-940. PMID: 25822990, DOI: 10.1001/jamainternmed.2015.0578.
• Regulatory review time and post‐market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional studyZeitoun JD, Lefèvre JH, Downing NS, Bergeron H, Ross JS. Regulatory review time and post‐market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional study. British Journal Of Clinical Pharmacology 2015, 80: 716-726. PMID: 25808713, PMCID: PMC4594708, DOI: 10.1111/bcp.12643.
• National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)–Retrospective AMI StudyZhang H, Masoudi FA, Li J, Wang Q, Li X, Spertus JA, Ross JS, Desai NR, Krumholz HM, Jiang L, Group C. National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)–Retrospective AMI Study. American Heart Journal 2015, 170: 506-515.e1. PMID: 26385034, PMCID: PMC5459420, DOI: 10.1016/j.ahj.2015.05.012.
• Trial-Results Reporting and Academic Medical CentersZarin DA, Tse T, Ross JS. Trial-Results Reporting and Academic Medical Centers. New England Journal Of Medicine 2015, 372: 2371-2372. PMID: 25992618, DOI: 10.1056/nejmc1505965.
• On Ghosts and Other Unwelcome GuestsRoss JS. On Ghosts and Other Unwelcome Guests. Journal Of General Internal Medicine 2015, 30: 1389-1391. PMID: 25986141, PMCID: PMC4579201, DOI: 10.1007/s11606-015-3400-9.
• Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely CampaignMakarov DV, Soulos PR, Gold HT, Yu JB, Sen S, Ross JS, Gross CP. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign. JAMA Oncology 2015, 1: 185-194. PMID: 26181021, PMCID: PMC4707944, DOI: 10.1001/jamaoncol.2015.37.
• Post-market clinical research conducted by medical device manufacturers: a cross-sectional surveyRoss JS, Blount KL, Ritchie JD, Hodshon B, Krumholz HM. Post-market clinical research conducted by medical device manufacturers: a cross-sectional survey. Medical Devices Evidence And Research 2015, Volume 8: 241-249. PMID: 26060416, PMCID: PMC4454210, DOI: 10.2147/mder.s82964.
• A Better Pain PlanRoss JS. A Better Pain Plan. JAMA Internal Medicine 2015, 175: 690-690. PMID: 25751165, DOI: 10.1001/jamainternmed.2015.102.
• Efficacy And Safety Concerns Are Important Reasons Why The FDA Requires Multiple Reviews Before Approval Of New DrugsRoss JS, Dzara K, Downing NS. Efficacy And Safety Concerns Are Important Reasons Why The FDA Requires Multiple Reviews Before Approval Of New Drugs. Health Affairs 2015, 34: 681-688. PMID: 25847652, DOI: 10.1377/hlthaff.2014.1160.
• Observation encounters and subsequent nursing facility stays.Vashi AA, Cafardi SG, Powers CA, Ross JS, Shrank WH. Observation encounters and subsequent nursing facility stays. The American Journal Of Managed Care 2015, 21: e276-81. PMID: 26244791.
• Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time PeriodsFeinstein AJ, Long J, Soulos PR, Ma X, Herrin J, Frick KD, Chagpar AB, Krumholz HM, Yu JB, Ross JS, Gross CP. Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Affairs 2015, 34: 592-600. PMID: 25847641, DOI: 10.1377/hlthaff.2014.1119.
• Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007Ranasinghe I, Shojaee A, Bikdeli B, Gupta A, Chen R, Ross JS, Masoudi FA, Spertus JA, Nallamothu BK, Krumholz HM. Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007. Circulation 2015, 131: 1755-1762. PMID: 25812573, PMCID: PMC4560203, DOI: 10.1161/circulationaha.114.015080.
• Reporting of Noninferiority Trials in ClinicalTrials.gov and Corresponding PublicationsGopal AD, Desai NR, Tse T, Ross JS. Reporting of Noninferiority Trials in ClinicalTrials.gov and Corresponding Publications. JAMA 2015, 313: 1163-1165. PMID: 25781447, PMCID: PMC5897692, DOI: 10.1001/jama.2015.1697.
• ACUTE ADMISSION RATES FOR PATIENTS WITH HEART FAILURE CARED FOR BY ACCOUNTABLE CARE ORGANIZATIONSSpatz E, Lipska K, Dai Y, Altaf F, Joyce E, Montague J, Bao H, Sutton L, Parzynski C, Herrin J, Zhang V, Ross J, Lin Z, Bernheim S, Krumholz H, Drye E. ACUTE ADMISSION RATES FOR PATIENTS WITH HEART FAILURE CARED FOR BY ACCOUNTABLE CARE ORGANIZATIONS. Journal Of The American College Of Cardiology 2015, 65: a782. DOI: 10.1016/s0735-1097(15)60782-3.
• Variation in US Hospital Emergency Department Admission Rates by Clinical ConditionVenkatesh AK, Dai Y, Ross JS, Schuur JD, Capp R, Krumholz HM. Variation in US Hospital Emergency Department Admission Rates by Clinical Condition. Medical Care 2015, 53: 237-244. PMID: 25397965, PMCID: PMC4858175, DOI: 10.1097/mlr.0000000000000261.
• Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic ControlLipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control. JAMA Internal Medicine 2015, 175: 356-362. PMID: 25581565, PMCID: PMC4426991, DOI: 10.1001/jamainternmed.2014.7345.
• Association of hospital volume with readmission rates: a retrospective cross-sectional studyHorwitz LI, Lin Z, Herrin J, Bernheim S, Drye EE, Krumholz HM, Hines HJ, Ross JS. Association of hospital volume with readmission rates: a retrospective cross-sectional study. The BMJ 2015, 350: h447. PMID: 25665806, PMCID: PMC4353286, DOI: 10.1136/bmj.h447.
• Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort studyDharmarajan K, Hsieh AF, Kulkarni VT, Lin Z, Ross JS, Horwitz LI, Kim N, Suter LG, Lin H, Normand SL, Krumholz HM. Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. The BMJ 2015, 350: h411. PMID: 25656852, PMCID: PMC4353309, DOI: 10.1136/bmj.h411.
• Confronting BiasRoss JS. Confronting Bias. JAMA Internal Medicine 2015, 175: 307-307. PMID: 25545247, DOI: 10.1001/jamainternmed.2014.6933.
• We Can See the (Risks of UV) LightRoss JS. We Can See the (Risks of UV) Light. JAMA Internal Medicine 2015, 175: 311-312. PMID: 25506708, DOI: 10.1001/jamainternmed.2014.6703.
• Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI StudyLiu J, Masoudi FA, Spertus JA, Wang Q, Murugiah K, Spatz ES, Li J, Li X, Ross JS, Krumholz HM, Jiang L, Group C. Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study. Journal Of The American Heart Association 2015, 4: e001343. PMID: 25713293, PMCID: PMC4345866, DOI: 10.1161/jaha.114.001343.
• Decision-making and cancer screening: A qualitative study of older adults with multiple chronic conditionsGross CP, Fried TR, Tinetti ME, Ross JS, Genao I, Hossain S, Wolf E, Lewis CL. Decision-making and cancer screening: A qualitative study of older adults with multiple chronic conditions. Journal Of Geriatric Oncology 2014, 6: 93-100. PMID: 25544380, DOI: 10.1016/j.jgo.2014.12.001.
• The Shape of Things to Come: 3D Printing in MedicineMichalski MH, Ross JS. The Shape of Things to Come: 3D Printing in Medicine. JAMA 2014, 312: 2213-2214. PMID: 25461994, DOI: 10.1001/jama.2014.9542.
• Attitudes of Hospital Leaders Toward Publicly Reported Measures of Health Care QualityLindenauer PK, Lagu T, Ross JS, Pekow PS, Shatz A, Hannon N, Rothberg MB, Benjamin EM. Attitudes of Hospital Leaders Toward Publicly Reported Measures of Health Care Quality. JAMA Internal Medicine 2014, 174: 1904-1911. PMID: 25286316, PMCID: PMC4250277, DOI: 10.1001/jamainternmed.2014.5161.
• Abstract 20158: Long-Term Device-Related Adverse Events After Implantable Cardioverter-Defibrillator TherapyRanasinghe I, Parzynski C, Freeman J, Dreyer R, Ross J, Akar J, Krumholz H, Curtis J. Abstract 20158: Long-Term Device-Related Adverse Events After Implantable Cardioverter-Defibrillator Therapy. Circulation 2014, 130 DOI: 10.1161/circ.130.suppl_2.20158.
• Reporting discrepancies between the clinicaltrials.gov results database and peer-reviewed publications.Becker JE, Ross JS. Reporting discrepancies between the clinicaltrials.gov results database and peer-reviewed publications. Annals Of Internal Medicine 2014, 161: 760. PMID: 25402518, DOI: 10.7326/l14-5022.
• Development and use of an administrative claims measure for profiling hospital-wide performance on 30-day unplanned readmission.Horwitz LI, Partovian C, Lin Z, Grady JN, Herrin J, Conover M, Montague J, Dillaway C, Bartczak K, Suter LG, Ross JS, Bernheim SM, Krumholz HM, Drye EE. Development and use of an administrative claims measure for profiling hospital-wide performance on 30-day unplanned readmission. Annals Of Internal Medicine 2014, 161: s66-75. PMID: 25402406, PMCID: PMC4235629, DOI: 10.7326/m13-3000.
• Marketing to Physicians in a Digital WorldManz C, Ross JS, Grande D. Marketing to Physicians in a Digital World. New England Journal Of Medicine 2014, 371: 1857-1859. PMID: 25390738, DOI: 10.1056/nejmp1408974.
• Payments for Acute Myocardial Infarction Episodes-of-Care Initiated at Hospitals With and Without Interventional CapabilitiesBen-Josef G, Ott LS, Spivack SB, Wang C, Ross JS, Shah SJ, Curtis JP, Kim N, Krumholz HM, Bernheim SM. Payments for Acute Myocardial Infarction Episodes-of-Care Initiated at Hospitals With and Without Interventional Capabilities. Circulation Cardiovascular Quality And Outcomes 2014, 7: 882-888. PMID: 25387777, DOI: 10.1161/circoutcomes.114.000927.
• Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literatureStockmann C, Ross JS, Sherwin CMT, Reilly CA, McDowell B, Fassl B, Nkoy F, Maloney CG, Spigarelli MG. Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature. Journal Of Allergy And Clinical Immunology 2014, 134: 1443-1446. PMID: 25441299, PMCID: PMC4261054, DOI: 10.1016/j.jaci.2014.09.019.
• Inconsistencies among European Union Pharmaceutical Regulator Safety Communications: A Cross-Country ComparisonZeitoun JD, Lefèvre JH, Downing N, Bergeron H, Ross JS. Inconsistencies among European Union Pharmaceutical Regulator Safety Communications: A Cross-Country Comparison. PLOS ONE 2014, 9: e109100. PMID: 25333986, PMCID: PMC4204813, DOI: 10.1371/journal.pone.0109100.
• Pediatric screening urinalysis: a difference-in-differences analysis of how a 2007 change in guidelines impacted useFilice CE, Green JC, Rosenthal MS, Ross JS. Pediatric screening urinalysis: a difference-in-differences analysis of how a 2007 change in guidelines impacted use. BMC Pediatrics 2014, 14: 260. PMID: 25303836, PMCID: PMC4287447, DOI: 10.1186/1471-2431-14-260.
• Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional surveyRathi VK, Strait KM, Gross CP, Hrynaszkiewicz I, Joffe S, Krumholz HM, Dzara K, Ross JS. Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey. Trials 2014, 15: 384. PMID: 25277128, PMCID: PMC4192345, DOI: 10.1186/1745-6215-15-384.
• Randomized Clinical Trials and Observational Studies Are More Often Alike Than UnlikeRoss JS. Randomized Clinical Trials and Observational Studies Are More Often Alike Than Unlike. JAMA Internal Medicine 2014, 174: 1557-1557. PMID: 25111371, DOI: 10.1001/jamainternmed.2014.3366.
• It’s Not Just About the Money, Money, Money…Ross JS. It’s Not Just About the Money, Money, Money…. JAMA Internal Medicine 2014, 174: 1696-1696. PMID: 25157893, DOI: 10.1001/jamainternmed.2014.3374.
• Publication of Pivotal Efficacy Trials for Novel Therapeutic Agents Approved Between 2005 and 2011: A Cross-sectional StudySmithy JW, Downing NS, Ross JS. Publication of Pivotal Efficacy Trials for Novel Therapeutic Agents Approved Between 2005 and 2011: A Cross-sectional Study. JAMA Internal Medicine 2014, 174: 1518-1520. PMID: 25070357, PMCID: PMC4221247, DOI: 10.1001/jamainternmed.2014.3438.
• Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010Ross JS, Frazee SG, Garavaglia SB, Levin R, Novshadian H, Jackevicius CA, Stettin G, Krumholz HM. Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010. JAMA Internal Medicine 2014, 174: 1486-1493. PMID: 25070672, PMCID: PMC4208827, DOI: 10.1001/jamainternmed.2014.3404.
• Restricting Interactions With Industry to Promote Evidence-Based PrescribingRoss JS. Restricting Interactions With Industry to Promote Evidence-Based Prescribing. JAMA Internal Medicine 2014, 174: 1290-1290. PMID: 24912054, DOI: 10.1001/jamainternmed.2014.1862.
• Place of Residence and Outcomes of Patients With Heart FailureBikdeli B, Wayda B, Bao H, Ross JS, Xu X, Chaudhry SI, Spertus JA, Bernheim SM, Lindenauer PK, Krumholz HM. Place of Residence and Outcomes of Patients With Heart Failure. Circulation Cardiovascular Quality And Outcomes 2014, 7: 749-756. PMID: 25074375, PMCID: PMC5323058, DOI: 10.1161/circoutcomes.113.000911.
• Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic ImplicationsKillelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications. Journal Of The National Cancer Institute 2014, 106 PMID: 25031307, PMCID: PMC4155428, DOI: 10.1093/jnci/dju159.
• Abstract 26: Comparison of Medicare Claims with Clinical Trial Outcomes for Follow-up of Older Individuals with Acute Coronary SyndromeBrennan J, O'Brien S, Milford-Beland S, Marinac-Dabic D, Rao S, Krucoff M, Normand S, Tsai T, Ross J, Nelson C, Canos D, Eloff B, Sansing V, Torosyan Y, Xian Y, Englum B, Ko L, Graham F, Peterson E. Abstract 26: Comparison of Medicare Claims with Clinical Trial Outcomes for Follow-up of Older Individuals with Acute Coronary Syndrome. Circulation Cardiovascular Quality And Outcomes 2014, 7 DOI: 10.1161/circoutcomes.7.suppl_1.26.
• Abstract 22: Impact Of Drug Policy On Regional Trends In Ezetimibe UseLu L, Krumholz H, Tu J, Ko D, Ross J, Jackevicius C. Abstract 22: Impact Of Drug Policy On Regional Trends In Ezetimibe Use. Circulation Cardiovascular Quality And Outcomes 2014, 7 DOI: 10.1161/circoutcomes.7.suppl_1.22.
• Sea Change in Open Science and Data SharingKrumholz HM, Gross CP, Blount KL, Ritchie JD, Hodshon B, Lehman R, Ross JS. Sea Change in Open Science and Data Sharing. Circulation Cardiovascular Quality And Outcomes 2014, 7: 499-504. PMID: 24891590, PMCID: PMC4146622, DOI: 10.1161/circoutcomes.114.001166.
• National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ, Huang ES, Desai MM, Gill TM, Krumholz HM. National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011. JAMA Internal Medicine 2014, 174: 1116-1124. PMID: 24838229, PMCID: PMC4152370, DOI: 10.1001/jamainternmed.2014.1824.
• Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature: A Cross-Sectional AnalysisDowning NS, Cheng T, Krumholz HM, Shah ND, Ross JS. Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature: A Cross-Sectional Analysis. JAMA Internal Medicine 2014, 174: 1176-1182. PMID: 24796406, PMCID: PMC4124903, DOI: 10.1001/jamainternmed.2014.1371.
• Withdrawal of Personal Genome Service—ReplyDowning NS, Ross JS. Withdrawal of Personal Genome Service—Reply. JAMA 2014, 311: 2441-2442. PMID: 24938574, DOI: 10.1001/jama.2014.5584.
• National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010Wang Y, Lichtman JH, Dharmarajan K, Masoudi FA, Ross JS, Dodson JA, Chen J, Spertus JA, Chaudhry SI, Nallamothu BK, Krumholz HM. National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010. American Heart Journal 2014, 169: 78-85.e4. PMID: 25497251, PMCID: PMC4824179, DOI: 10.1016/j.ahj.2014.06.011.
• Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010Lipska KJ, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND. Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010. JAMA 2014, 311: 2331-2333. PMID: 24915266, PMCID: PMC4133975, DOI: 10.1001/jama.2014.6316.
• Impact of Drug Policy on Regional Trends in Ezetimibe UseLu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of Drug Policy on Regional Trends in Ezetimibe Use. Circulation Cardiovascular Quality And Outcomes 2014, 7: 589-596. PMID: 24895451, PMCID: PMC4222175, DOI: 10.1161/circoutcomes.114.001023.
• Ensuring Correct Interpretation of Diagnostic Test ResultsRoss JS. Ensuring Correct Interpretation of Diagnostic Test Results. JAMA Internal Medicine 2014, 174: 993-993. PMID: 24756330, DOI: 10.1001/jamainternmed.2014.165.
• Trial Evidence and Approval of Therapeutic Agents—ReplyDowning NS, Ross JS. Trial Evidence and Approval of Therapeutic Agents—Reply. JAMA 2014, 311: 2129-2129. PMID: 24867021, DOI: 10.1001/jama.2014.3420.
• Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer.Han L, Shah N, Gross C, Ross J, Nguyen P, Smaldone M, Tilburt J, Yu J, Trinh Q, Karnes R, Ranasinghe W, Sun M, Kim S. Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer. Journal Of Clinical Oncology 2014, 32: e16085-e16085. DOI: 10.1200/jco.2014.32.15_suppl.e16085.
• Doctors and healthcare reform: a duty to understand?Long T, Ross JS. Doctors and healthcare reform: a duty to understand? Postgraduate Medical Journal 2014, 90: 303-304. PMID: 24835534, DOI: 10.1136/postgradmedj-2014-132689.
• High Incarceration Rates Among Black Men Enrolled In Clinical Studies May Compromise Ability To Identify DisparitiesWang EA, Aminawung JA, Wildeman C, Ross JS, Krumholz HM. High Incarceration Rates Among Black Men Enrolled In Clinical Studies May Compromise Ability To Identify Disparities. Health Affairs 2014, 33: 848-855. PMID: 24799583, PMCID: PMC4065793, DOI: 10.1377/hlthaff.2013.1325.
• Physician clinical management strategies and reasoning: a cross-sectional survey using clinical vignettes of eight common medical admissionsSmith KL, Ashburn S, Aminawung JA, Mann M, Ross JS. Physician clinical management strategies and reasoning: a cross-sectional survey using clinical vignettes of eight common medical admissions. BMC Health Services Research 2014, 14: 176. PMID: 24742131, PMCID: PMC4021187, DOI: 10.1186/1472-6963-14-176.
• FIBRINOLYTIC THERAPY IN HOSPITALS WITHOUT PERCUTANEOUS CORONARY INTERVENTION CAPABILITIES IN CHINA FROM 2001 TO 2011Li J, Wang Q, Masoudi F, Spertus J, Desai N, Ross J, Krumholz H, Jiang L, Collaborative P. FIBRINOLYTIC THERAPY IN HOSPITALS WITHOUT PERCUTANEOUS CORONARY INTERVENTION CAPABILITIES IN CHINA FROM 2001 TO 2011. Journal Of The American College Of Cardiology 2014, 63: a134. DOI: 10.1016/s0735-1097(14)60134-0.
• MP11-06 REGIONAL-LEVEL INAPPROPRIATE IMAGING RATES FOR PROSTATE AND BREAST CANCERS ARE CORRELATED: POTENTIAL LESSONS FOR THE CHOOSING WISELY CAMPAIGNMakarov D, Sen S, Soulos P, Gold H, Yu J, Ross J, Gross C. MP11-06 REGIONAL-LEVEL INAPPROPRIATE IMAGING RATES FOR PROSTATE AND BREAST CANCERS ARE CORRELATED: POTENTIAL LESSONS FOR THE CHOOSING WISELY CAMPAIGN. Journal Of Urology 2014, 191: e97. DOI: 10.1016/j.juro.2014.02.421.
• Moving Forward From rhBMP-2Low JB, Ross JS, Krumholz HM. Moving Forward From rhBMP-2. Spine 2014, 39: 531-532. PMID: 24503690, PMCID: PMC3981828, DOI: 10.1097/brs.0000000000000256.
• Hospital variation in risk-standardized hospital admission rates from US EDs among adultsCapp R, Ross JS, Fox JP, Wang Y, Desai MM, Venkatesh AK, Krumholz HM. Hospital variation in risk-standardized hospital admission rates from US EDs among adults. The American Journal Of Emergency Medicine 2014, 32: 837-843. PMID: 24881514, DOI: 10.1016/j.ajem.2014.03.033.
• Reporting of Results in ClinicalTrials.gov and High-Impact JournalsBecker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of Results in ClinicalTrials.gov and High-Impact Journals. JAMA 2014, 311: 1063-1065. PMID: 24618969, PMCID: PMC3979514, DOI: 10.1001/jama.2013.285634.
• Innovation, Risk, and Patient Empowerment: The FDA-Mandated Withdrawal of 23andMe’s Personal Genome ServiceDowning NS, Ross JS. Innovation, Risk, and Patient Empowerment: The FDA-Mandated Withdrawal of 23andMe’s Personal Genome Service. JAMA 2014, 311: 793-794. PMID: 24474248, DOI: 10.1001/jama.2014.148.
• Impact of the ENHANCE Trial on the use of ezetimibe in the United States and CanadaLu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. American Heart Journal 2014, 167: 683-689. PMID: 24766978, PMCID: PMC4215424, DOI: 10.1016/j.ahj.2014.01.014.
• Usual Source of Care and Outcomes Following Acute Myocardial InfarctionSpatz ES, Sheth SD, Gosch KL, Desai MM, Spertus JA, Krumholz HM, Ross JS. Usual Source of Care and Outcomes Following Acute Myocardial Infarction. Journal Of General Internal Medicine 2014, 29: 862-869. PMID: 24553957, PMCID: PMC4026492, DOI: 10.1007/s11606-014-2794-0.
• Association of Physician Specialty and Medical Therapy for Benign Prostatic HyperplasiaHan LC, Kim SP, Gross CP, Ross JS, Van Houten HK, Smaldone MC, Krambeck AE, Shah ND. Association of Physician Specialty and Medical Therapy for Benign Prostatic Hyperplasia. Medical Care 2014, 52: 128-136. PMID: 24423810, DOI: 10.1097/mlr.0000000000000078.
• Transfer Rates From Nonprocedure Hospitals After Initial Admission and Outcomes Among Elderly Patients With Acute Myocardial InfarctionBarreto-Filho JA, Wang Y, Rathore SS, Spatz ES, Ross JS, Curtis JP, Nallamothu BK, Normand SL, Krumholz HM. Transfer Rates From Nonprocedure Hospitals After Initial Admission and Outcomes Among Elderly Patients With Acute Myocardial Infarction. JAMA Internal Medicine 2014, 174: 213-222. PMID: 24296747, DOI: 10.1001/jamainternmed.2013.11944.
• Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012. JAMA 2014, 311: 368-377. PMID: 24449315, PMCID: PMC4144867, DOI: 10.1001/jama.2013.282034.
• Abstract P6-07-05: Regional variation in Medicare expenditures for older women with localized breast cancerXu X, Soulos P, Herrin J, Ross J, Saraf A, Roberts K, Killelea B, Wang S, Long J, Wang R, Ma X, Gross C. Abstract P6-07-05: Regional variation in Medicare expenditures for older women with localized breast cancer. Cancer Research 2013, 73: p6-07-05-p6-07-05. DOI: 10.1158/0008-5472.sabcs13-p6-07-05.
• For-profit hospital ownership status and use of brachytherapy after breast-conserving surgerySen S, Soulos PR, Herrin J, Roberts KB, Yu JB, Lesnikoski BA, Ross JS, Krumholz HM, Gross CP. For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Surgery 2013, 155: 776-788. PMID: 24787104, PMCID: PMC4008843, DOI: 10.1016/j.surg.2013.12.009.
• Hospital-based, acute care after ambulatory surgery center dischargeFox JP, Vashi AA, Ross JS, Gross CP. Hospital-based, acute care after ambulatory surgery center discharge. Surgery 2013, 155: 743-753. PMID: 24787100, PMCID: PMC4114736, DOI: 10.1016/j.surg.2013.12.008.
• Hospital Discharge and the Transition Home for Poor Patients: “I Knew I Couldn’t Do What They Were Asking Me”Bernheim SM, Ross JS. Hospital Discharge and the Transition Home for Poor Patients: “I Knew I Couldn’t Do What They Were Asking Me”. Journal Of General Internal Medicine 2013, 29: 269-270. PMID: 24327310, PMCID: PMC3912274, DOI: 10.1007/s11606-013-2698-4.
• Hospital readmission performance and patterns of readmission: retrospective cohort study of Medicare admissionsDharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto-Filho JA, Kim N, Suter LG, Bernheim SM, Drye EE, Krumholz HM. Hospital readmission performance and patterns of readmission: retrospective cohort study of Medicare admissions. The BMJ 2013, 347: f6571. PMID: 24259033, PMCID: PMC3898430, DOI: 10.1136/bmj.f6571.
• The cost implications of prostate cancer screening in the Medicare populationMa X, Wang R, Long JB, Ross JS, Soulos PR, Yu JB, Makarov DV, Gold HT, Gross CP. The cost implications of prostate cancer screening in the Medicare population. Cancer 2013, 120: 96-102. PMID: 24122801, PMCID: PMC3867600, DOI: 10.1002/cncr.28373.
• Prescription-Drug Coupons — No Such Thing as a Free LunchRoss JS, Kesselheim AS. Prescription-Drug Coupons — No Such Thing as a Free Lunch. New England Journal Of Medicine 2013, 369: 1188-1189. PMID: 23984672, DOI: 10.1056/nejmp1301993.
• Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancerKillelea BK, Long JB, Chagpar AB, Ma X, Soulos PR, Ross JS, Gross CP. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. Breast Cancer Research And Treatment 2013, 141: 155-163. PMID: 23942872, PMCID: PMC3893026, DOI: 10.1007/s10549-013-2656-1.
• The Case for Generic Statins: Not If They Don’t Work So Well—ReplyGreen JB, Ross JS, Krumholz HM. The Case for Generic Statins: Not If They Don’t Work So Well—Reply. JAMA Internal Medicine 2013, 173: 1474-1474. PMID: 23939523, DOI: 10.1001/jamainternmed.2013.7781.
• Age-based and Sex-based Disparities in Screening Colonoscopy Use Among Medicare BeneficiariesGancayco J, Soulos PR, Khiani V, Cramer LD, Ross JS, Genao I, Tinetti M, Gross CP. Age-based and Sex-based Disparities in Screening Colonoscopy Use Among Medicare Beneficiaries. Journal Of Clinical Gastroenterology 2013, 47: 630-636. PMID: 23619827, DOI: 10.1097/mcg.0b013e31828345c8.
• A historic moment for open science: the Yale University Open Data Access project and medtronic.Krumholz HM, Ross JS, Gross CP, Emanuel EJ, Hodshon B, Ritchie JD, Low JB, Lehman R. A historic moment for open science: the Yale University Open Data Access project and medtronic. Annals Of Internal Medicine 2013, 158: 910-1. PMID: 23778908, PMCID: PMC5459387, DOI: 10.7326/0003-4819-158-12-201306180-00009.
• Evaluation of the Mobile Acute Care of the Elderly (MACE) ServiceHung WW, Ross JS, Farber J, Siu AL. Evaluation of the Mobile Acute Care of the Elderly (MACE) Service. JAMA Internal Medicine 2013, 173: 990-996. PMID: 23608775, PMCID: PMC3691362, DOI: 10.1001/jamainternmed.2013.478.
• Hospital-Based, Acute Care Use Among Patients Within 30 Days of Discharge After Coronary Artery Bypass SurgeryFox JP, Suter LG, Wang K, Wang Y, Krumholz HM, Ross JS. Hospital-Based, Acute Care Use Among Patients Within 30 Days of Discharge After Coronary Artery Bypass Surgery. The Annals Of Thoracic Surgery 2013, 96: 96-104. PMID: 23702228, PMCID: PMC3758868, DOI: 10.1016/j.athoracsur.2013.03.091.
• The cost implications of prostate cancer screening in the Medicare population.Ma X, Wang R, Long J, Ross J, Soulos P, Yu J, Makarov D, Gold H, Gross C. The cost implications of prostate cancer screening in the Medicare population. Journal Of Clinical Oncology 2013, 31: 6549-6549. DOI: 10.1200/jco.2013.31.15_suppl.6549.
• For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery.Sen S, Soulos P, Herrin J, Roberts K, Yu J, Lesnikoski B, Ross J, Krumholz H, Gross C. For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Journal Of Clinical Oncology 2013, 31: 6511-6511. DOI: 10.1200/jco.2013.31.15_suppl.6511.
• Regional Density of Cardiologists and Rates of Mortality for Acute Myocardial Infarction and Heart FailureKulkarni VT, Ross JS, Wang Y, Nallamothu BK, Spertus JA, Normand SL, Masoudi FA, Krumholz HM. Regional Density of Cardiologists and Rates of Mortality for Acute Myocardial Infarction and Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6: 352-359. PMID: 23680965, PMCID: PMC5323047, DOI: 10.1161/circoutcomes.113.000214.
• Time to Publication Among Completed Clinical TrialsRoss JS, Mocanu M, Lampropulos JF, Tse T, Krumholz HM. Time to Publication Among Completed Clinical Trials. JAMA Internal Medicine 2013, 173: 825-828. PMID: 23460252, PMCID: PMC3691813, DOI: 10.1001/jamainternmed.2013.136.
• Abstract 153: Impact Of The Enhance Trial On The Use Of Ezetimibe In The Us And CanadaLu L, Krumholz H, Tu J, Ross J, Ko D, Jackevicius C. Abstract 153: Impact Of The Enhance Trial On The Use Of Ezetimibe In The Us And Canada. Circulation Cardiovascular Quality And Outcomes 2013, 6 DOI: 10.1161/circoutcomes.6.suppl_1.a153.
• Abstract 13: Risks of Death and Hospital Readmission by Time Following Hospitalization for Heart Failure and Acute Myocardial InfarctionDharmarajan K, Hsieh A, Lin Z, Kim N, Ross J, Horwitz L, Kulkarni V, Suter L, Bernheim S, Drye E, Normand S, Krumholz H. Abstract 13: Risks of Death and Hospital Readmission by Time Following Hospitalization for Heart Failure and Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2013, 6 DOI: 10.1161/circoutcomes.6.suppl_1.a13.
• Abstract 14: Regional Cardiologist Density and 30-Day and 1-Year Mortality in Acute Myocardial Infarction and Heart FailureKulkarni V, Ross J, Wang Y, Nallamothu B, Spertus J, Normand S, Masoudi F, Krumholz H. Abstract 14: Regional Cardiologist Density and 30-Day and 1-Year Mortality in Acute Myocardial Infarction and Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6 DOI: 10.1161/circoutcomes.6.suppl_1.a14.
• Ushering in a New Era of Open Science Through Data Sharing: The Wall Must Come DownRoss JS, Krumholz HM. Ushering in a New Era of Open Science Through Data Sharing: The Wall Must Come Down. JAMA 2013, 309: 1355-1356. PMID: 23508736, DOI: 10.1001/jama.2013.1299.
• Direct-to-Consumer Television Advertising: Time to Turn Off the Tube?Ross JS, Kravitz RL. Direct-to-Consumer Television Advertising: Time to Turn Off the Tube? Journal Of General Internal Medicine 2013, 28: 862-864. PMID: 23539285, PMCID: PMC3682047, DOI: 10.1007/s11606-013-2424-2.
• Implications of clinical trial data sharing for medical writersRoss J, Krumholz H. Implications of clinical trial data sharing for medical writers. Medical Writing 2013, 22: 45-48. DOI: 10.1179/2047480612z.00000000085.
• MAJOR CARDIOVASCULAR TRIALS WITH PRIMARY SURROGATE ENDPOINTS: 2006 TO 2011Bikdeli B, Punnanithinont N, Shi R, Ross J, Krumholz H. MAJOR CARDIOVASCULAR TRIALS WITH PRIMARY SURROGATE ENDPOINTS: 2006 TO 2011. Journal Of The American College Of Cardiology 2013, 61: e1585. DOI: 10.1016/s0735-1097(13)61585-5.
• PLACE OF RESIDENCE AND OUTCOMES OF PATIENTS WITH HEART FAILURE: AN ANALYSIS FROM THE TELE-HF TRIAL PARTICIPANTSBikdeli B, Wayda B, Bao H, Ross J, Xu X, Chaudhry S, Spertus J, Krumholz H. PLACE OF RESIDENCE AND OUTCOMES OF PATIENTS WITH HEART FAILURE: AN ANALYSIS FROM THE TELE-HF TRIAL PARTICIPANTS. Journal Of The American College Of Cardiology 2013, 61: e783. DOI: 10.1016/s0735-1097(13)60783-4.
• A SYSTEMATIC REVIEW OF MAJOR NON-INFERIORITY CARDIOVASCULAR TRIALS FROM 2006-2011Bikdeli B, Shi R, Punnanithinont N, Ross J, Krumholz H. A SYSTEMATIC REVIEW OF MAJOR NON-INFERIORITY CARDIOVASCULAR TRIALS FROM 2006-2011. Journal Of The American College Of Cardiology 2013, 61: e1583. DOI: 10.1016/s0735-1097(13)61583-1.
• USE OF NIACIN IN THE UNITED STATES AND CANADAJackevicius C, Tu J, Ross J, Ko D, de Leon N, Krumholz H. USE OF NIACIN IN THE UNITED STATES AND CANADA. Journal Of The American College Of Cardiology 2013, 61: e1549. DOI: 10.1016/s0735-1097(13)61549-1.
• Relationship Between Hospital Readmission and Mortality Rates for Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, or PneumoniaKrumholz HM, Lin Z, Keenan PS, Chen J, Ross JS, Drye EE, Bernheim SM, Wang Y, Bradley EH, Han LF, Normand SL. Relationship Between Hospital Readmission and Mortality Rates for Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. JAMA 2013, 309: 587-593. PMID: 23403683, PMCID: PMC3621028, DOI: 10.1001/jama.2013.333.
• The Cost of Breast Cancer Screening in the Medicare PopulationGross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X. The Cost of Breast Cancer Screening in the Medicare Population. JAMA Internal Medicine 2013, 173: 220-226. PMID: 23303200, PMCID: PMC3638736, DOI: 10.1001/jamainternmed.2013.1397.
• When Choosing Statin Therapy: The Case for GenericsGreen JB, Ross JS, Jackevicius CA, Shah ND, Krumholz HM. When Choosing Statin Therapy: The Case for Generics. JAMA Internal Medicine 2013, 173: 229-232. PMID: 23303273, DOI: 10.1001/jamainternmed.2013.1529.
• Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysisKing M, Essick C, Bearman P, Ross JS. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. The BMJ 2013, 346: f264. PMID: 23372175, PMCID: PMC3623604, DOI: 10.1136/bmj.f264.
• Tamiflu: 14 flu seasons and still questionsKrumholz HM, Jackevicius CA, Ross JS. Tamiflu: 14 flu seasons and still questions. The BMJ 2013, 346: f547. PMID: 23355545, DOI: 10.1136/bmj.f547.
• Use of Hospital-Based Acute Care Among Patients Recently Discharged From the HospitalVashi AA, Fox JP, Carr BG, D’Onofrio G, Pines JM, Ross JS, Gross CP. Use of Hospital-Based Acute Care Among Patients Recently Discharged From the Hospital. JAMA 2013, 309: 364-371. PMID: 23340638, PMCID: PMC3598620, DOI: 10.1001/jama.2012.216219.
• Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or PneumoniaDharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto-Filho JA, Kim N, Bernheim SM, Suter LG, Drye EE, Krumholz HM. Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia. JAMA 2013, 309: 355-363. PMID: 23340637, PMCID: PMC3688083, DOI: 10.1001/jama.2012.216476.
• A Measure of Care Coordination?Bynum JP, Ross JS. A Measure of Care Coordination? Journal Of General Internal Medicine 2012, 28: 336-338. PMID: 23179970, PMCID: PMC3579982, DOI: 10.1007/s11606-012-2269-0.
• Sharing of clinical trial data among trialists: a cross sectional surveyRathi V, Dzara K, Gross CP, Hrynaszkiewicz I, Joffe S, Krumholz HM, Strait KM, Ross JS. Sharing of clinical trial data among trialists: a cross sectional survey. The BMJ 2012, 345: e7570. PMID: 23169870, PMCID: PMC3502744, DOI: 10.1136/bmj.e7570.
• Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare BeneficiariesRoss JS, Wang R, Long JB, Gross CP, Ma X. Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare Beneficiaries. JAMA Internal Medicine 2012, 172: 1601-1603. PMID: 22987029, PMCID: PMC3597450, DOI: 10.1001/archinternmed.2012.3726.
• Discharge disposition disagreements and re-admission risk among older adults: a retrospective cohort studyDinescu A, Korc-Grodzicki B, Farber J, Ross JS. Discharge disposition disagreements and re-admission risk among older adults: a retrospective cohort study. BMJ Open 2012, 2: e001646. PMID: 23117568, PMCID: PMC3547317, DOI: 10.1136/bmjopen-2012-001646.
• Financial Stress and Outcomes after Acute Myocardial InfarctionShah SJ, Krumholz HM, Reid KJ, Rathore SS, Mandawat A, Spertus JA, Ross JS. Financial Stress and Outcomes after Acute Myocardial Infarction. PLOS ONE 2012, 7: e47420. PMID: 23112814, PMCID: PMC3480393, DOI: 10.1371/journal.pone.0047420.
• Generic Competition in a Flawed System: Pill Them, Bill Them—ReplyDowning NS, Ross JS, Krumholz HM. Generic Competition in a Flawed System: Pill Them, Bill Them—Reply. JAMA Internal Medicine 2012, 172: 1522-1523. PMID: 23752463, DOI: 10.1001/2013.jamainternmed.806.
• Visits for Primary Care Services to Primary Care and Specialty Care Physicians, 1999 and 2007Kale MS, Federman AD, Ross JS. Visits for Primary Care Services to Primary Care and Specialty Care Physicians, 1999 and 2007. JAMA Internal Medicine 2012, 172: 1421-1423. PMID: 22911398, PMCID: PMC3561474, DOI: 10.1001/archinternmed.2012.3207.
• Based On Key Measures, Care Quality For Medicare Enrollees At Safety-Net And Non-Safety-Net Hospitals Was Almost EqualRoss JS, Bernheim SM, Lin Z, Drye EE, Chen J, Normand SL, Krumholz HM. Based On Key Measures, Care Quality For Medicare Enrollees At Safety-Net And Non-Safety-Net Hospitals Was Almost Equal. Health Affairs 2012, 31: 1739-1748. PMID: 22869652, PMCID: PMC3527010, DOI: 10.1377/hlthaff.2011.1028.
• Through the looking glass: evaluating the dissemination of research in cardiologyRoss JS, Nallamothu BK. Through the looking glass: evaluating the dissemination of research in cardiology. European Heart Journal 2012, 33: 3002-3004. PMID: 22669849, DOI: 10.1093/eurheartj/ehs160.
• Association of Chronic Diseases and Impairments With Disability in Older AdultsHung WW, Ross JS, Boockvar KS, Siu AL. Association of Chronic Diseases and Impairments With Disability in Older Adults. Medical Care 2012, 50: 501-507. PMID: 22584885, PMCID: PMC3353149, DOI: 10.1097/mlr.0b013e318245a0e0.
• The evolution of breast cancer screening in the Medicare population: Clinical and economic implications.Killelea B, Long J, Ma X, Wang R, Chagpar A, Ross J, Gross C. The evolution of breast cancer screening in the Medicare population: Clinical and economic implications. Journal Of Clinical Oncology 2012, 30: 1595-1595. DOI: 10.1200/jco.2012.30.15_suppl.1595.
• Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory AgenciesDowning NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies. New England Journal Of Medicine 2012, 366: 2284-2293. PMID: 22591257, PMCID: PMC3504361, DOI: 10.1056/nejmsa1200223.
• Avoidance of Generic Competition by Abbott Laboratories' Fenofibrate FranchiseDowning NS, Ross JS, Jackevicius CA, Krumholz HM. Avoidance of Generic Competition by Abbott Laboratories' Fenofibrate Franchise. JAMA Internal Medicine 2012, 172: 724-730. PMID: 22493409, PMCID: PMC3636774, DOI: 10.1001/archinternmed.2012.187.
• Abstract 148: The Timing of 30-Day Readmissions after Hospitalization for Heart Failure and Acute Myocardial InfarctionDharmarajan K, Hsieh F, Lin Z, Ross J, Kim N, Barreto-Filho J, Bueno H, Bernheim S, Drye E, Krumholz H. Abstract 148: The Timing of 30-Day Readmissions after Hospitalization for Heart Failure and Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2012, 5 DOI: 10.1161/circoutcomes.5.suppl_1.a148.
• Association between physician quality improvement incentives and ambulatory quality measures.Bishop TF, Federman AD, Ross JS. Association between physician quality improvement incentives and ambulatory quality measures. The American Journal Of Managed Care 2012, 18: e126-34. PMID: 22554038, PMCID: PMC3537503.
• Coronary Artery Bypass GraftHu S, Zheng Z, Yuan X, Wang Y, Normand SL, Ross JS, Krumholz HM. Coronary Artery Bypass Graft. Circulation Cardiovascular Quality And Outcomes 2012, 5: 214-221. PMID: 22396587, PMCID: PMC3509783, DOI: 10.1161/circoutcomes.111.962365.
• HOSPITAL PERCUTANEOUS CORONARY INTERVENTION CAPABILITY IS NOT ASSOCIATED WITH HIGHER PAYMENTS FOR ACUTE MYOCARDIAL INFARCTION PATIENTSBen-Josef G, Bernheim S, Wang C, Ross J, Shah S, Kim N, Krumholz H. HOSPITAL PERCUTANEOUS CORONARY INTERVENTION CAPABILITY IS NOT ASSOCIATED WITH HIGHER PAYMENTS FOR ACUTE MYOCARDIAL INFARCTION PATIENTS. Journal Of The American College Of Cardiology 2012, 59: e1884. DOI: 10.1016/s0735-1097(12)61885-3.
• HOSPITAL PERFORMANCE IS NOT ASSOCIATED WITH THE TIMING OR CAUSES OF 30-DAY READMISSION AFTER HOSPITALIZATION FOR HEART FAILURE OR ACUTE MYOCARDIAL INFARCTIONDharmarajan K, Hsieh F, Lin Z, Kim N, Bernheim S, Bueno H, Ross J, Horwitz L, Barreto-Filho J, Drye E, Krumholz H. HOSPITAL PERFORMANCE IS NOT ASSOCIATED WITH THE TIMING OR CAUSES OF 30-DAY READMISSION AFTER HOSPITALIZATION FOR HEART FAILURE OR ACUTE MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2012, 59: e1887. DOI: 10.1016/s0735-1097(12)61888-9.
• Impact of State Laws That Extend Eligibility for Parents’ Health Insurance Coverage to Young AdultsBlum AB, Kleinman LC, Starfield B, Ross JS. Impact of State Laws That Extend Eligibility for Parents’ Health Insurance Coverage to Young Adults. Pediatrics 2012, 129: 426-432. PMID: 22331339, PMCID: PMC3356137, DOI: 10.1542/peds.2011-1505.
• The Importance of Clinical Trial Data SharingRoss JS, Lehman R, Gross CP. The Importance of Clinical Trial Data Sharing. Circulation Cardiovascular Quality And Outcomes 2012, 5: 238-240. PMID: 22438465, PMCID: PMC3318983, DOI: 10.1161/circoutcomes.112.965798.
• “Transparency Reports” on Industry Payments to Physicians and Teaching HospitalsSteinbrook R, Ross JS. “Transparency Reports” on Industry Payments to Physicians and Teaching Hospitals. JAMA 2012, 307: 1029-1030. PMID: 22336624, DOI: 10.1001/jama.2012.211.
• Ghostwriting: Research Misconduct, Plagiarism, or Fool's Gold?Bosch X, Ross JS. Ghostwriting: Research Misconduct, Plagiarism, or Fool's Gold? The American Journal Of Medicine 2012, 125: 324-326. PMID: 22305580, DOI: 10.1016/j.amjmed.2011.07.015.
• State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone WarningRoss JS, Jackevicius C, Krumholz HM, Ridgeway J, Montori VM, Alexander GC, Zerzan J, Fan J, Shah ND. State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning. Health Affairs 2012, 31: 188-198. PMID: 22232110, PMCID: PMC3319744, DOI: 10.1377/hlthaff.2011.1068.
• Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysisRoss JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. The BMJ 2012, 344: d7292. PMID: 22214755, PMCID: PMC3623605, DOI: 10.1136/bmj.d7292.
• Comparison of hospital risk-standardized mortality rates calculated by using in-hospital and 30-day models: an observational study with implications for hospital profiling.Drye EE, Normand SL, Wang Y, Ross JS, Schreiner GC, Han L, Rapp M, Krumholz HM. Comparison of hospital risk-standardized mortality rates calculated by using in-hospital and 30-day models: an observational study with implications for hospital profiling. Annals Of Internal Medicine 2012, 156: 19-26. PMID: 22213491, PMCID: PMC3319769, DOI: 10.7326/0003-4819-156-1-201201030-00004.
• The Use and Misuse of Thrombolytic Therapy Within the Veterans Health AdministrationKeyhani S, Arling G, Williams LS, Ross JS, Ordin DL, Myers J, Tyndall G, Vogel B, Bravata DM. The Use and Misuse of Thrombolytic Therapy Within the Veterans Health Administration. Medical Care 2012, 50: 66-73. PMID: 22182924, DOI: 10.1097/mlr.0b013e3182294092.
• Skilled Nursing Facility Referral and Hospital Readmission Rates after Heart Failure or Myocardial InfarctionChen J, Ross JS, Carlson MD, Lin Z, Normand SL, Bernheim SM, Drye EE, Ling SM, Han LF, Rapp MT, Krumholz HM. Skilled Nursing Facility Referral and Hospital Readmission Rates after Heart Failure or Myocardial Infarction. The American Journal Of Medicine 2012, 125: 100.e1-100.e9. PMID: 22195535, PMCID: PMC3246370, DOI: 10.1016/j.amjmed.2011.06.011.
• Generic Atorvastatin and Health Care CostsJackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic Atorvastatin and Health Care Costs. New England Journal Of Medicine 2011, 366: 201-204. PMID: 22149736, PMCID: PMC3319770, DOI: 10.1056/nejmp1113112.
• Estimating and Reporting on the Quality of Inpatient Stroke Care by Veterans Health Administration Medical CentersArling G, Reeves M, Ross J, Williams LS, Keyhani S, Chumbler N, Phipps MS, Roumie C, Myers LJ, Salanitro AH, Ordin DL, Myers J, Bravata DM. Estimating and Reporting on the Quality of Inpatient Stroke Care by Veterans Health Administration Medical Centers. Circulation Cardiovascular Quality And Outcomes 2011, 5: 44-51. PMID: 22147888, PMCID: PMC3261327, DOI: 10.1161/circoutcomes.111.961474.
• US Cardiologist Workforce From 1995 To 2007: Modest Growth, Lasting Geographic Maldistribution Especially In Rural AreasAneja S, Ross JS, Wang Y, Matsumoto M, Rodgers GP, Bernheim SM, Rathore SS, Krumholz HM. US Cardiologist Workforce From 1995 To 2007: Modest Growth, Lasting Geographic Maldistribution Especially In Rural Areas. Health Affairs 2011, 30: 2301-2309. PMID: 22147857, PMCID: PMC3332098, DOI: 10.1377/hlthaff.2011.0255.
• Promoting transparency in pharmaceutical industry-sponsored research.Ross JS, Gross CP, Krumholz HM. Promoting transparency in pharmaceutical industry-sponsored research. American Journal Of Public Health 2011, 102: 72-80. PMID: 22095335, PMCID: PMC3319748, DOI: 10.2105/ajph.2011.300187.
• Abstract P141: Health Care Insurance, Financial Concerns in Accessing Care, and Nonelective Readmissions Following Acute Myocardial InfarctionSmolderen K, Spertus J, Nallamothu B, Krumholz H, Tang F, Xiang Y, Wang T, Ross J, Ting H, Rathore S, Chan P. Abstract P141: Health Care Insurance, Financial Concerns in Accessing Care, and Nonelective Readmissions Following Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2011, 4 DOI: 10.1161/circoutcomes.4.suppl_2.ap141.
• Abstract 4: The Association Between Admission Rate and 30-Day Risk Standardized Readmission Rate for Heart Failure and Acute Myocardial InfarctionShah S, Ross J, Lin Z, Normand S, Krumholz H. Abstract 4: The Association Between Admission Rate and 30-Day Risk Standardized Readmission Rate for Heart Failure and Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2011, 4 DOI: 10.1161/circoutcomes.4.suppl_2.a4.
• Abstract P46: Correlation Between Inpatient and Outpatient Measures of Stroke Care Quality Within Veterans Health Administration HospitalsRoss J, Arling G, Ofner S, Roumie C, Keyhani S, Ordin D, Williams L, Bravata D. Abstract P46: Correlation Between Inpatient and Outpatient Measures of Stroke Care Quality Within Veterans Health Administration Hospitals. Circulation Cardiovascular Quality And Outcomes 2011, 4 DOI: 10.1161/circoutcomes.4.suppl_1.ap46.
• Abstract P41: Predictive Models of Mortality After Stroke: A Systematic ReviewBernheim S, Bhat K, Savage S, Phipps M, Drye E, Ross J, Desai M, Krumholz H, Lichtman J. Abstract P41: Predictive Models of Mortality After Stroke: A Systematic Review. Circulation Cardiovascular Quality And Outcomes 2011, 4 DOI: 10.1161/circoutcomes.4.suppl_1.ap41.
• Abstract P255: Should Models of Hospital Outcomes Include Race as a Covariate?Hebert P, Ross J, Goldstein N, Howell E. Abstract P255: Should Models of Hospital Outcomes Include Race as a Covariate? Circulation Cardiovascular Quality And Outcomes 2011, 4 DOI: 10.1161/circoutcomes.4.suppl_1.ap255.
• A Model for Dissemination and Independent Analysis of Industry DataKrumholz HM, Ross JS. A Model for Dissemination and Independent Analysis of Industry Data. JAMA 2011, 306: 1593-1594. PMID: 21990302, PMCID: PMC3688082, DOI: 10.1001/jama.2011.1459.
• Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional studyNeuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. The BMJ 2011, 343: d5621. PMID: 21990257, PMCID: PMC3191201, DOI: 10.1136/bmj.d5621.
• Recent trends in chronic disease, impairment and disability among older adults in the United StatesHung WW, Ross JS, Boockvar KS, Siu AL. Recent trends in chronic disease, impairment and disability among older adults in the United States. BMC Geriatrics 2011, 11: 47. PMID: 21851629, PMCID: PMC3170191, DOI: 10.1186/1471-2318-11-47.
• Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe PrescribingKorenstein D, Keyhani S, Mendelson A, Ross JS. Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe Prescribing. PLOS ONE 2011, 6: e23336. PMID: 21858076, PMCID: PMC3157354, DOI: 10.1371/journal.pone.0023336.
• Assessing the Impact of Screening Colonoscopy on Mortality in the Medicare PopulationGross CP, Soulos PR, Ross JS, Cramer LD, Guerrero C, Tinetti ME, Braithwaite RS. Assessing the Impact of Screening Colonoscopy on Mortality in the Medicare Population. Journal Of General Internal Medicine 2011, 26: 1441-1449. PMID: 21842323, PMCID: PMC3235614, DOI: 10.1007/s11606-011-1816-4.
• Correlation of Inpatient and Outpatient Measures of Stroke Care Quality Within Veterans Health Administration HospitalsRoss JS, Arling G, Ofner S, Roumie CL, Keyhani S, Williams LS, Ordin DL, Bravata DM. Correlation of Inpatient and Outpatient Measures of Stroke Care Quality Within Veterans Health Administration Hospitals. Stroke 2011, 42: 2269-2275. PMID: 21719771, PMCID: PMC3144276, DOI: 10.1161/strokeaha.110.611913.
• Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial: A Narrative Account of a Gabapentin Seeding TrialKrumholz SD, Egilman DS, Ross JS. Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial: A Narrative Account of a Gabapentin Seeding Trial. JAMA Internal Medicine 2011, 171: 1100-1107. PMID: 21709111, PMCID: PMC3319750, DOI: 10.1001/archinternmed.2011.241.
• Prevalence of Inadequate Blood Pressure Control Among Veterans After Acute Ischemic Stroke HospitalizationRoumie CL, Ofner S, Ross JS, Arling G, Williams LS, Ordin DL, Bravata DM. Prevalence of Inadequate Blood Pressure Control Among Veterans After Acute Ischemic Stroke Hospitalization. Circulation Cardiovascular Quality And Outcomes 2011, 4: 399-407. PMID: 21693725, PMCID: PMC3140571, DOI: 10.1161/circoutcomes.110.959809.
• Do Imaging Studies Performed in Physician Offices Increase Downstream Utilization? An Empiric Analysis of Cardiac Stress Testing With ImagingChen J, Fazel R, Ross JS, McNamara RL, Einstein AJ, Al-Mallah M, Krumholz HM, Nallamothu BK. Do Imaging Studies Performed in Physician Offices Increase Downstream Utilization? An Empiric Analysis of Cardiac Stress Testing With Imaging. JACC Cardiovascular Imaging 2011, 4: 630-637. PMID: 21679898, PMCID: PMC3319749, DOI: 10.1016/j.jcmg.2011.04.003.
• Advanced Access Scheduling Outcomes: A Systematic ReviewRose KD, Ross JS, Horwitz LI. Advanced Access Scheduling Outcomes: A Systematic Review. JAMA Internal Medicine 2011, 171: 1150-1159. PMID: 21518935, PMCID: PMC3154021, DOI: 10.1001/archinternmed.2011.168.
• TRENDS IN THE GEOGRAPHIC DISTRIBUTION OF THE CARDIOVASCULAR WORKFORCEAneja S, Ross J, Rodgers G, Matsumoto M, Wang Y, Bernheim S, Krumholz H. TRENDS IN THE GEOGRAPHIC DISTRIBUTION OF THE CARDIOVASCULAR WORKFORCE. Journal Of The American College Of Cardiology 2011, 57: e1284. DOI: 10.1016/s0735-1097(11)61284-9.
• Use of Fibrates in the United States and CanadaJackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.
• Switching From Rosiglitazone: Thinking Outside the ClassLipska KJ, Ross JS. Switching From Rosiglitazone: Thinking Outside the Class. JAMA 2011, 305: 820-821. PMID: 21304068, DOI: 10.1001/jama.2011.193.
• Reporting Hospital Quality: The Authors ReplyRoss J, Sheth S, Krumholz H. Reporting Hospital Quality: The Authors Reply. Health Affairs 2011, 30: 367-367. DOI: 10.1377/hlthaff.2011.0101.
• Audit and feedback: An intervention to improve discharge summary completionDinescu A, Fernandez H, Ross JS, Karani R. Audit and feedback: An intervention to improve discharge summary completion. Journal Of Hospital Medicine 2011, 6: 28-32. PMID: 21241038, PMCID: PMC3102562, DOI: 10.1002/jhm.831.
• Expanding the Frontier of Outcomes Measurement for Public ReportingRoss JS, Bernheim SM, Drye ED. Expanding the Frontier of Outcomes Measurement for Public Reporting. Circulation Cardiovascular Quality And Outcomes 2011, 4: 11-13. PMID: 21245460, PMCID: PMC3046632, DOI: 10.1161/circoutcomes.110.959908.
• Persistence of Cardiovascular Risk After Rofecoxib DiscontinuationRoss JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM. Persistence of Cardiovascular Risk After Rofecoxib Discontinuation. JAMA Internal Medicine 2010, 170: 2035-2036. PMID: 21149763, PMCID: PMC3024905, DOI: 10.1001/archinternmed.2010.461.
• State-Sponsored Public Reporting Of Hospital Quality: Results Are Hard To Find And Lack UniformityRoss JS, Sheth S, Krumholz HM. State-Sponsored Public Reporting Of Hospital Quality: Results Are Hard To Find And Lack Uniformity. Health Affairs 2010, 29: 2317-2322. PMID: 21134936, PMCID: PMC3020979, DOI: 10.1377/hlthaff.2010.0564.
• Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measuresBernheim SM, Wang Y, Bradley EH, Masoudi FA, Rathore SS, Ross JS, Drye E, Krumholz HM. Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measures. American Heart Journal 2010, 160: 943-950.e5. PMID: 21095284, PMCID: PMC3319386, DOI: 10.1016/j.ahj.2010.06.046.
• Scheduled and unscheduled hospital readmissions among patients with diabetes.Kim H, Ross JS, Melkus GD, Zhao Z, Boockvar K. Scheduled and unscheduled hospital readmissions among patients with diabetes. The American Journal Of Managed Care 2010, 16: 760-7. PMID: 20964472, PMCID: PMC3024140.
• National Patterns of Risk-Standardized Mortality and Readmission for Acute Myocardial Infarction and Heart FailureBernheim SM, Grady JN, Lin Z, Wang Y, Wang Y, Savage SV, Bhat KR, Ross JS, Desai MM, Merrill AR, Han LF, Rapp MT, Drye EE, Normand SL, Krumholz HM. National Patterns of Risk-Standardized Mortality and Readmission for Acute Myocardial Infarction and Heart Failure. Circulation Cardiovascular Quality And Outcomes 2010, 3: 459-467. PMID: 20736442, PMCID: PMC3027304, DOI: 10.1161/circoutcomes.110.957613.
• Cumulative Exposure to Ionizing Radiation From Diagnostic and Therapeutic Cardiac Imaging Procedures A Population-Based AnalysisChen J, Einstein AJ, Fazel R, Krumholz HM, Wang Y, Ross JS, Ting HH, Shah ND, Nasir K, Nallamothu BK. Cumulative Exposure to Ionizing Radiation From Diagnostic and Therapeutic Cardiac Imaging Procedures A Population-Based Analysis. Journal Of The American College Of Cardiology 2010, 56: 702-711. PMID: 20619569, PMCID: PMC2952402, DOI: 10.1016/j.jacc.2010.05.014.
• Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination SurveySpatz ES, Ross JS, Desai MM, Canavan ME, Krumholz HM. Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. American Heart Journal 2010, 160: 115-121. PMID: 20598981, PMCID: PMC3025407, DOI: 10.1016/j.ahj.2010.04.013.
• Use of Administrative Claims Models to Assess 30-Day Mortality Among Veterans Health Administration HospitalsRoss JS, Maynard C, Krumholz HM, Sun H, Rumsfeld JS, Normand SL, Wang Y, Fihn SD. Use of Administrative Claims Models to Assess 30-Day Mortality Among Veterans Health Administration Hospitals. Medical Care 2010, 48: 652-658. PMID: 20548253, PMCID: PMC3020977, DOI: 10.1097/mlr.0b013e3181dbe35d.
• Laboratory Test Ordering at Physician Offices with and without On-Site LaboratoriesBishop TF, Federman AD, Ross JS. Laboratory Test Ordering at Physician Offices with and without On-Site Laboratories. Journal Of General Internal Medicine 2010, 25: 1057-1063. PMID: 20532656, PMCID: PMC2955467, DOI: 10.1007/s11606-010-1409-7.
• Trends in Length of Stay and Short-term Outcomes Among Medicare Patients Hospitalized for Heart Failure, 1993-2006Bueno H, Ross JS, Wang Y, Chen J, Vidán MT, Normand SL, Curtis JP, Drye EE, Lichtman JH, Keenan PS, Kosiborod M, Krumholz HM. Trends in Length of Stay and Short-term Outcomes Among Medicare Patients Hospitalized for Heart Failure, 1993-2006. JAMA 2010, 303: 2141-2147. PMID: 20516414, PMCID: PMC3020983, DOI: 10.1001/jama.2010.748.
• Physician Attitudes Toward Industry: A View Across the SpecialtiesKorenstein D, Keyhani S, Ross JS. Physician Attitudes Toward Industry: A View Across the Specialties. JAMA Surgery 2010, 145: 570-577. PMID: 20566978, PMCID: PMC2891545, DOI: 10.1001/archsurg.2010.75.
• A Random Effects Multinomial Logit Analysis of Using Medicare and VA Healthcare Among Veterans With DementiaZhu CW, Livote EE, Ross JS, Penrod JD. A Random Effects Multinomial Logit Analysis of Using Medicare and VA Healthcare Among Veterans With Dementia. Home Health Care Services Quarterly 2010, 29: 91-104. PMID: 20635273, PMCID: PMC3233994, DOI: 10.1080/01621424.2010.493771.
• Response to Letter Regarding Article, “Recent National Trends in Readmission Rates After Heart Failure Hospitalization”Ross J, Krumholz H. Response to Letter Regarding Article, “Recent National Trends in Readmission Rates After Heart Failure Hospitalization”. Circulation Heart Failure 2010, 3: e17. DOI: 10.1161/circheartfailure.110.952895.
• S1147 Effect of Gender, Age, and Life Expectancy on Receipt of Screening Colonoscopy in the Medicare PopulationGancayco J, Khiani V, Soulos P, Cramer L, Ross J, Braithwaite S, Genao I, Tinetti M, Gross C. S1147 Effect of Gender, Age, and Life Expectancy on Receipt of Screening Colonoscopy in the Medicare Population. Gastroenterology 2010, 138: s-190. DOI: 10.1016/s0016-5085(10)60863-3.
• Health Care Insurance, Financial Concerns in Accessing Care, and Delays to Hospital Presentation in Acute Myocardial InfarctionSmolderen KG, Spertus JA, Nallamothu BK, Krumholz HM, Tang F, Ross JS, Ting HH, Alexander KP, Rathore SS, Chan PS. Health Care Insurance, Financial Concerns in Accessing Care, and Delays to Hospital Presentation in Acute Myocardial Infarction. JAMA 2010, 303: 1392-1400. PMID: 20388895, PMCID: PMC3020978, DOI: 10.1001/jama.2010.409.
• Hospital Volume and 30-Day Mortality for Three Common Medical ConditionsRoss JS, Normand SL, Wang Y, Ko DT, Chen J, Drye EE, Keenan PS, Lichtman JH, Bueno H, Schreiner GC, Krumholz HM. Hospital Volume and 30-Day Mortality for Three Common Medical Conditions. New England Journal Of Medicine 2010, 362: 1110-1118. PMID: 20335587, PMCID: PMC2880468, DOI: 10.1056/nejmsa0907130.
• THE PHYSICAL ACTIVITY CONTRACT—TAILORED TO PROMOTE PHYSICAL ACTIVITY IN A GERIATRIC OUTPATIENT SETTING: A PILOT STUDYGerber JB, Bloom PA, Ross JS. THE PHYSICAL ACTIVITY CONTRACT—TAILORED TO PROMOTE PHYSICAL ACTIVITY IN A GERIATRIC OUTPATIENT SETTING: A PILOT STUDY. Journal Of The American Geriatrics Society 2010, 58: 604-606. PMID: 20398129, PMCID: PMC2947346, DOI: 10.1111/j.1532-5415.2010.02751.x.
• Differences in Patient Survival After Acute Myocardial Infarction by Hospital Capability of Performing Percutaneous Coronary Intervention: Implications for RegionalizationChen J, Krumholz HM, Wang Y, Curtis JP, Rathore SS, Ross JS, Normand SL, Schreiner GC, Mulvey G, Nallamothu BK. Differences in Patient Survival After Acute Myocardial Infarction by Hospital Capability of Performing Percutaneous Coronary Intervention: Implications for Regionalization. JAMA Internal Medicine 2010, 170: 433-439. PMID: 20212179, PMCID: PMC2900156, DOI: 10.1001/archinternmed.2009.538.
• CUMULATIVE EXPOSURE TO IONIZING RADIATION FROM CARDIAC IMAGING PROCEDURESChen J, Krumholz H, Wang Y, Ross J, Fazel R, Ting H, Shah N, Brink J, Nasir K, Einstein A, Nallamouthu B. CUMULATIVE EXPOSURE TO IONIZING RADIATION FROM CARDIAC IMAGING PROCEDURES. Journal Of The American College Of Cardiology 2010, 55: a139.e1302. DOI: 10.1016/s0735-1097(10)61303-4.
• THE IMPACT OF CONFLICTS OF INTEREST ON ADJUDICATION AND OUTCOMES IN CARDIOVASCULAR CLINICAL TRIALSEsquitin R, Aneja A, Shah K, Razzouk L, Mann D, Ross J, Iyengar R, Wali I, Mathew V, Farkouh M. THE IMPACT OF CONFLICTS OF INTEREST ON ADJUDICATION AND OUTCOMES IN CARDIOVASCULAR CLINICAL TRIALS. Journal Of The American College Of Cardiology 2010, 55: a132.e1237. DOI: 10.1016/s0735-1097(10)61238-7.
• PREVALENCE, CORRELATES AND INTER-HOSPITAL VARIATION OF EARLY OUTPATIENT FOLLOW-UP AFTER ACUTE MYOCARDIAL INFARCTIONSalisbury A, Kennedy K, Spertus J, Daugherty S, Masoudi F, Ross J, Alexander K, Krumholz H. PREVALENCE, CORRELATES AND INTER-HOSPITAL VARIATION OF EARLY OUTPATIENT FOLLOW-UP AFTER ACUTE MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2010, 55: a143.e1347. DOI: 10.1016/s0735-1097(10)61348-4.
• FINANCIAL BARRIERS TO CARE AND OUTCOMES AFTER ACUTE MYOCARDIAL INFARCTION: DOES AGE MATTER?Ross J, Spatz E, Reid K, Chan P, Bernheim S, Lichtman J, Spertus J, Krumholz H. FINANCIAL BARRIERS TO CARE AND OUTCOMES AFTER ACUTE MYOCARDIAL INFARCTION: DOES AGE MATTER? Journal Of The American College Of Cardiology 2010, 55: a144.e1353. DOI: 10.1016/s0735-1097(10)61354-x.
• USUAL SOURCE OF CARE AND OUTCOMES AFTER ACUTE MYOCARDIAL INFARCTION: DATA FROM THE PROSPECTIVE REGISTRY EVALUATING MYOCARDIAL INFARCTION: EVENT AND RECOVERY (PREMIER)Spatz E, Desai M, Riley K, Ross J, Sheth S, Spertus J, Krumholz H. USUAL SOURCE OF CARE AND OUTCOMES AFTER ACUTE MYOCARDIAL INFARCTION: DATA FROM THE PROSPECTIVE REGISTRY EVALUATING MYOCARDIAL INFARCTION: EVENT AND RECOVERY (PREMIER). Journal Of The American College Of Cardiology 2010, 55: a136.e1277. DOI: 10.1016/s0735-1097(10)61278-8.
• MONEY LEFT OVER AT THE END OF THE MONTH AND OUTCOMES AFTER MYOCARDIAL INFARCTIONMandawat A, Rathore S, Shah S, Bucholz E, Reid K, Wang O, Ross J, Spertus J, Krumholz H. MONEY LEFT OVER AT THE END OF THE MONTH AND OUTCOMES AFTER MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2010, 55: a133.e1244. DOI: 10.1016/s0735-1097(10)61245-4.
• Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–4Ross JS, Krumholz HM. Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–4. Mayo Clinic Proceedings 2010, 85: 199-200. PMID: 20118400, PMCID: PMC2813835, DOI: 10.4065/mcp.2009.0744.
• The relationship between systolic blood pressure on admission and mortality in older patients with heart failureVidán MT, Bueno H, Wang Y, Schreiner G, Ross JS, Chen J, Krumholz HM. The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. European Journal Of Heart Failure 2010, 12: 148-155. PMID: 20083624, PMCID: PMC2807767, DOI: 10.1093/eurjhf/hfp195.
• Self-Reported and Actual Beta-Blocker Prescribing for Heart Failure Patients: Physician PredictorsSinha S, Schwartz MD, Qin A, Ross JS. Self-Reported and Actual Beta-Blocker Prescribing for Heart Failure Patients: Physician Predictors. PLOS ONE 2009, 4: e8522. PMID: 20046824, PMCID: PMC2796176, DOI: 10.1371/journal.pone.0008522.
• Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial InfarctionKo DT, Ross JS, Wang Y, Krumholz HM. Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2009, 3: 54-62. PMID: 20123672, PMCID: PMC3024143, DOI: 10.1161/circoutcomes.109.858456.
• Economic Evaluation of a Comprehensive Teenage Pregnancy Prevention Program Pilot ProgramRosenthal MS, Ross JS, Bilodeau R, Richter RS, Palley JE, Bradley EH. Economic Evaluation of a Comprehensive Teenage Pregnancy Prevention Program Pilot Program. American Journal Of Preventive Medicine 2009, 37: s280-s287. PMID: 19896030, PMCID: PMC3020976, DOI: 10.1016/j.amepre.2009.08.014.
• Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety SurveillanceRoss JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.
• Recent National Trends in Readmission Rates After Heart Failure HospitalizationRoss JS, Chen J, Lin Z, Bueno H, Curtis JP, Keenan PS, Normand SL, Schreiner G, Spertus JA, Vidán MT, Wang Y, Wang Y, Krumholz HM. Recent National Trends in Readmission Rates After Heart Failure Hospitalization. Circulation Heart Failure 2009, 3: 97-103. PMID: 19903931, PMCID: PMC2830811, DOI: 10.1161/circheartfailure.109.885210.
• Health Care Choices and Decisions in the United States and CanadaRoss JS, Detsky AS. Health Care Choices and Decisions in the United States and Canada. JAMA 2009, 302: 1803-1804. PMID: 19861673, PMCID: PMC2835156, DOI: 10.1001/jama.2009.1566.
• Appropriateness of Collaborations between Industry and the Medical Profession: Physicians' PerceptionsRoss JS, Keyhani S, Korenstein D. Appropriateness of Collaborations between Industry and the Medical Profession: Physicians' Perceptions. The American Journal Of Medicine 2009, 122: 955-960. PMID: 19786162, PMCID: PMC3020980, DOI: 10.1016/j.amjmed.2009.04.013.
• Mis-SHAPEing Public Health PolicySpatz ES, Ross JS. Mis-SHAPEing Public Health Policy. Circulation Cardiovascular Quality And Outcomes 2009, 2: 681-683. PMID: 20031909, PMCID: PMC2835162, DOI: 10.1161/circoutcomes.109.890715.
• Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional AnalysisRoss JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis. PLOS Medicine 2009, 6: e1000144. PMID: 19901971, PMCID: PMC2728480, DOI: 10.1371/journal.pmed.1000144.
• Exposure to Low-Dose Ionizing Radiation from Medical Imaging ProceduresFazel R, Krumholz HM, Wang Y, Ross JS, Chen J, Ting HH, Shah ND, Nasir K, Einstein AJ, Nallamothu BK. Exposure to Low-Dose Ionizing Radiation from Medical Imaging Procedures. New England Journal Of Medicine 2009, 361: 849-857. PMID: 19710483, PMCID: PMC3707303, DOI: 10.1056/nejmoa0901249.
• Reduction in Acute Myocardial Infarction Mortality in the United States: Risk-Standardized Mortality Rates From 1995-2006Krumholz HM, Wang Y, Chen J, Drye EE, Spertus JA, Ross JS, Curtis JP, Nallamothu BK, Lichtman JH, Havranek EP, Masoudi FA, Radford MJ, Han LF, Rapp MT, Straube BM, Normand SL. Reduction in Acute Myocardial Infarction Mortality in the United States: Risk-Standardized Mortality Rates From 1995-2006. JAMA 2009, 302: 767-773. PMID: 19690309, PMCID: PMC3349070, DOI: 10.1001/jama.2009.1178.
• Use of Medicare and Department of Veterans Affairs Health Care by Veterans with Dementia: A Longitudinal AnalysisZhu CW, Penrod JD, Ross JS, Dellenbaugh C, Sano M. Use of Medicare and Department of Veterans Affairs Health Care by Veterans with Dementia: A Longitudinal Analysis. Journal Of The American Geriatrics Society 2009, 57: 1908-1914. PMID: 19682132, PMCID: PMC3233990, DOI: 10.1111/j.1532-5415.2009.02405.x.
• Cognitive Decline among Patients with Chronic Obstructive Pulmonary DiseaseHung WW, Wisnivesky JP, Siu AL, Ross JS. Cognitive Decline among Patients with Chronic Obstructive Pulmonary Disease. American Journal Of Respiratory And Critical Care Medicine 2009, 180: 134-137. PMID: 19423714, DOI: 10.1164/rccm.200902-0276oc.
• Use of Stroke Secondary Prevention ServicesRoss JS, Halm EA, Bravata DM. Use of Stroke Secondary Prevention Services. Stroke 2009, 40: 1811-1819. PMID: 19265044, PMCID: PMC2768116, DOI: 10.1161/strokeaha.108.539619.
• Policy ResearchRoss JS, Gross CP. Policy Research. Circulation 2009, 119: 891-898. PMID: 19221232, DOI: 10.1161/circulationaha.107.729855.
• Relationships with the drug industry: More regulation, greater transparencyKrumholz HM, Ross JS. Relationships with the drug industry: More regulation, greater transparency. The BMJ 2009, 338: b211. PMID: 19193612, DOI: 10.1136/bmj.b211.
• Editorial CommentRoss J. Editorial Comment. Journal Of Urology 2009, 181: 583. DOI: 10.1016/j.juro.2008.10.185.
• Electronic Health Record Components and the Quality of CareKeyhani S, Hebert PL, Ross JS, Federman A, Zhu CW, Siu AL. Electronic Health Record Components and the Quality of Care. Medical Care 2008, 46: 1267-1272. PMID: 19300317, DOI: 10.1097/mlr.0b013e31817e18ae.
• Appropriate proton pump inhibitor use among older adults: A retrospective chart reviewGeorge CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: A retrospective chart review. The American Journal Of Geriatric Pharmacotherapy 2008, 6: 249-254. PMID: 19161927, DOI: 10.1016/j.amjopharm.2008.12.001.
• Updated Estimates of Pharmaceutical Company Payments to Physicians in VermontRoss JS, Nazem AG, Lurie P, Lackner JE, Krumholz HM. Updated Estimates of Pharmaceutical Company Payments to Physicians in Vermont. JAMA 2008, 300: 1998-2000. PMID: 18984886, DOI: 10.1001/jama.2008.560.
• Hospital Remoteness And Thirty-Day Mortality From Three Serious ConditionsRoss JS, Normand SL, Wang Y, Nallamothu BK, Lichtman JH, Krumholz HM. Hospital Remoteness And Thirty-Day Mortality From Three Serious Conditions. Health Affairs 2008, 27: 1707-1717. PMID: 18997230, DOI: 10.1377/hlthaff.27.6.1707.
• Racial and ethnic differences in personal cervical cancer screening amongst post-graduate physicians: Results from a cross-sectional surveyRoss JS, Nuñez-Smith M, Forsyth BA, Rosenbaum JR. Racial and ethnic differences in personal cervical cancer screening amongst post-graduate physicians: Results from a cross-sectional survey. BMC Public Health 2008, 8: 378. PMID: 18973674, PMCID: PMC2590615, DOI: 10.1186/1471-2458-8-378.
• Comparison of the US and Canadian Health Care Systems: A Tale of 2 Mount Sinai’sRoss JS, Detsky AS. Comparison of the US and Canadian Health Care Systems: A Tale of 2 Mount Sinai’s. JAMA 2008, 300: 1934-1936. PMID: 18940983, DOI: 10.1001/jama.300.16.1934.
• Pharmaceutical Industry Marketing: Understanding Its Impact on Women’s HealthSufrin CB, Ross JS. Pharmaceutical Industry Marketing: Understanding Its Impact on Women’s Health. Obstetrical & Gynecological Survey 2008, 63: 585-596. PMID: 18713478, DOI: 10.1097/ogx.0b013e31817f1585.
• An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart FailureKeenan PS, Normand SL, Lin Z, Drye EE, Bhat KR, Ross JS, Schuur JD, Stauffer BD, Bernheim SM, Epstein AJ, Wang Y, Herrin J, Chen J, Federer JJ, Mattera JA, Wang Y, Krumholz HM. An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure. Circulation Cardiovascular Quality And Outcomes 2008, 1: 29-37. PMID: 20031785, DOI: 10.1161/circoutcomes.108.802686.
• Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—ReplyRoss J, Egilman D, Krumholz H. Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—Reply. JAMA 2008, 300: 900-906. DOI: 10.1001/jama.300.8.904-c.
• The ADVANTAGE seeding trial: a review of internal documents.Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals Of Internal Medicine 2008, 149: 251-8. PMID: 18711155, DOI: 10.7326/0003-4819-149-4-200808190-00006.
• Statistical Models and Patient Predictors of Readmission for Heart Failure: A Systematic ReviewRoss JS, Mulvey GK, Stauffer B, Patlolla V, Bernheim SM, Keenan PS, Krumholz HM. Statistical Models and Patient Predictors of Readmission for Heart Failure: A Systematic Review. JAMA Internal Medicine 2008, 168: 1371-1386. PMID: 18625917, DOI: 10.1001/archinte.168.13.1371.
• Use of Recommended Ambulatory Care Services: Is the Veterans Affairs Quality Gap Narrowing?Ross JS, Keyhani S, Keenan PS, Bernheim SM, Penrod JD, Boockvar KS, Federman AD, Krumholz HM, Siu AL. Use of Recommended Ambulatory Care Services: Is the Veterans Affairs Quality Gap Narrowing? JAMA Internal Medicine 2008, 168: 950-958. PMID: 18474759, DOI: 10.1001/archinte.168.9.950.
• Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib LitigationRoss JS, Hill KP, Egilman DS, Krumholz HM. Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA 2008, 299: 1800-1812. PMID: 18413874, DOI: 10.1001/jama.299.15.1800.
• Use of Ezetimibe in the United States and CanadaJackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of Ezetimibe in the United States and Canada. New England Journal Of Medicine 2008, 358: 1819-1828. PMID: 18375999, DOI: 10.1056/nejmsa0801461.
• Dual Use of Veterans Affairs Services and Use of Recommended Ambulatory CareRoss JS, Keyhani S, Keenan PS, Bernheim SM, Penrod JD, Boockvar KS, Krumholz HM, Siu AL. Dual Use of Veterans Affairs Services and Use of Recommended Ambulatory Care. Medical Care 2008, 46: 309-316. PMID: 18388846, DOI: 10.1097/mlr.0b013e31815b9db3.
• Regional Variation in Cardiac Catheterization Appropriateness and Baseline Risk After Acute Myocardial InfarctionKo DT, Wang Y, Alter DA, Curtis JP, Rathore SS, Stukel TA, Masoudi FA, Ross JS, Foody JM, Krumholz HM. Regional Variation in Cardiac Catheterization Appropriateness and Baseline Risk After Acute Myocardial Infarction. Journal Of The American College Of Cardiology 2008, 51: 716-723. PMID: 18279735, DOI: 10.1016/j.jacc.2007.10.039.
• Influence of Patients’ Socioeconomic Status on Clinical Management Decisions: A Qualitative StudyBernheim SM, Ross JS, Krumholz HM, Bradley EH. Influence of Patients’ Socioeconomic Status on Clinical Management Decisions: A Qualitative Study. The Annals Of Family Medicine 2008, 6: 53-59. PMID: 18195315, PMCID: PMC2203396, DOI: 10.1370/afm.749.
• What Is Different About the Market for Health Care?Wells DA, Ross JS, Detsky AS. What Is Different About the Market for Health Care? JAMA 2007, 298: 2785-2787. PMID: 18165673, DOI: 10.1001/jama.298.23.2785.
• The cost of pharmaceutical innovation to patientsKeyhani S, Ross JS. The cost of pharmaceutical innovation to patients. Expert Opinion On Drug Discovery 2007, 2: 1431-1434. PMID: 23484595, DOI: 10.1517/17460441.2.11.1431.
• Use of preventive care by elderly male veterans receiving care through the Veterans Health Administration, Medicare fee-for-service, and Medicare HMO plans.Keyhani S, Ross JS, Hebert P, Dellenbaugh C, Penrod JD, Siu AL. Use of preventive care by elderly male veterans receiving care through the Veterans Health Administration, Medicare fee-for-service, and Medicare HMO plans. American Journal Of Public Health 2007, 97: 2179-85. PMID: 17971544, PMCID: PMC2089117, DOI: 10.2105/ajph.2007.114934.
• Acute Myocardial Infarction and Congestive Heart Failure Outcomes at Specialty Cardiac HospitalsNallamothu BK, Wang Y, Cram P, Birkmeyer JD, Ross JS, Normand SL, Krumholz HM. Acute Myocardial Infarction and Congestive Heart Failure Outcomes at Specialty Cardiac Hospitals. Circulation 2007, 116: 2280-2287. PMID: 17967975, DOI: 10.1161/circulationaha.107.709220.
• Is P4P Really FFS?Wodchis WP, Ross JS, Detsky AS. Is P4P Really FFS? JAMA 2007, 298: 1797-1799. PMID: 17940237, DOI: 10.1001/jama.298.15.1797.
• Cardiac Certificate of Need regulations and the availability and use of revascularization servicesHo V, Ross JS, Nallamothu BK, Krumholz HM. Cardiac Certificate of Need regulations and the availability and use of revascularization services. American Heart Journal 2007, 154: 767-775. PMID: 17893007, PMCID: PMC2084214, DOI: 10.1016/j.ahj.2007.06.031.
• Insurance coverage and care of patients with non ST-segment elevation acute coronary syndromes.Ross JS. Insurance coverage and care of patients with non ST-segment elevation acute coronary syndromes. Annals Of Internal Medicine 2007, 147: 212; author reply 212. PMID: 17679711, DOI: 10.7326/0003-4819-147-3-200708070-00014.
• Pharmaceutical Company Payments to Physicians: Early Experiences With Disclosure Laws in Vermont and MinnesotaRoss JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical Company Payments to Physicians: Early Experiences With Disclosure Laws in Vermont and Minnesota. JAMA 2007, 297: 1216-1223. PMID: 17374816, DOI: 10.1001/jama.297.11.1216.
• Certificate of Need Regulation and Cardiac Catheterization Appropriateness After Acute Myocardial InfarctionRoss JS, Ho V, Wang Y, Cha SS, Epstein AJ, Masoudi FA, Nallamothu BK, Krumholz HM. Certificate of Need Regulation and Cardiac Catheterization Appropriateness After Acute Myocardial Infarction. Circulation 2007, 115: 1012-1019. PMID: 17283258, DOI: 10.1161/circulationaha.106.658377.
• The Importance of Population‐Based Performance MeasuresRoss JS, Siu AL. The Importance of Population‐Based Performance Measures. Health Services Research 2007, 42: 1-6. PMID: 17355578, PMCID: PMC1955236, DOI: 10.1111/j.1475-6773.2006.00693.x.
• What have we learnt from Vioxx?Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? The BMJ 2007, 334: 120. PMID: 17235089, PMCID: PMC1779871, DOI: 10.1136/bmj.39024.487720.68.
• Quality Of Care For Acute Myocardial Infarction At Urban Safety-Net HospitalsRoss JS, Cha SS, Epstein AJ, Wang Y, Bradley EH, Herrin J, Lichtman JH, Normand SL, Masoudi FA, Krumholz HM. Quality Of Care For Acute Myocardial Infarction At Urban Safety-Net Hospitals. Health Affairs 2007, 26: 238-248. PMID: 17211034, DOI: 10.1377/hlthaff.26.1.238.
• Use of preventive care by the working poor in the United StatesRoss JS, Bernheim SM, Bradley EH, Teng HM, Gallo WT. Use of preventive care by the working poor in the United States. Preventive Medicine 2006, 44: 254-259. PMID: 17196642, PMCID: PMC1810564, DOI: 10.1016/j.ypmed.2006.11.006.
• Refusal of Care by PatientsBernheim SM, Ross JS, Bradley EH. Refusal of Care by Patients. JAMA 2006, 296: 2921-2923. PMID: 17190887, DOI: 10.1001/jama.296.24.2921-a.
• Abstract Acceptance and Blinded Peer Review—ReplyRoss J, Krumholz H. Abstract Acceptance and Blinded Peer Review—Reply. JAMA 2006, 296: 1230-1231. DOI: 10.1001/jama.296.10.1230-c.
• Description of a Research‐Based Health Activism Curriculum for Medical StudentsCha SS, Ross JS, Lurie P, Sacajiu G. Description of a Research‐Based Health Activism Curriculum for Medical Students. Journal Of General Internal Medicine 2006, 21: 1325-1328. PMID: 16961754, PMCID: PMC1924746, DOI: 10.1111/j.1525-1497.2006.00608.x.
• Use of Health Care Services by Lower-Income and Higher-Income Uninsured AdultsRoss JS, Bradley EH, Busch SH. Use of Health Care Services by Lower-Income and Higher-Income Uninsured Adults. JAMA 2006, 295: 2027-2036. PMID: 16670411, DOI: 10.1001/jama.295.17.2027.
• Book ReviewRoss J. Book Review. New England Journal Of Medicine 2006, 354: 1859-1861. DOI: 10.1056/nejmbkrev39462.
• Effect of Blinded Peer Review on Abstract AcceptanceRoss JS, Gross CP, Desai MM, Hong Y, Grant AO, Daniels SR, Hachinski VC, Gibbons RJ, Gardner TJ, Krumholz HM. Effect of Blinded Peer Review on Abstract Acceptance. JAMA 2006, 295: 1675-1680. PMID: 16609089, DOI: 10.1001/jama.295.14.1675.
• BRIEF REPORT: Housestaff Adherence to Cervical Cancer Screening RecommendationsRoss JS, Forsyth BA, Rosenbaum JR. BRIEF REPORT: Housestaff Adherence to Cervical Cancer Screening Recommendations. Journal Of General Internal Medicine 2005, 21: 68-70. PMID: 16423127, PMCID: PMC1484609, DOI: 10.1111/j.1525-1497.2005.0279.x.
• Mismeasurement and the Resonance of Strong Confounders: Correlated ErrorsMarshall J, Hastrup J, Ross J. Mismeasurement and the Resonance of Strong Confounders: Correlated Errors. American Journal Of Epidemiology 1999, 150: 88-96. PMID: 10400558, DOI: 10.1093/oxfordjournals.aje.a009922.